ANALYSIS OF NEURONAL DIFFERENTIATION IN  GENETIC FORMS OF PARKINSON’S DISEASE REVEALS  A NEURODEVELOPMENTAL CONTRIBUTION by Walter, Jonas
  
 
PhD- FSTC-2017-50 
The Faculty of Sciences, Technology and Communication 
 
DISSERTATION 
 
Defence held on 15/09/2017 in Belvaux (Luxembourg)  
 
to obtain the degree of 
 
 
DOCTEUR DE L’UNIVERSITÉ DU LUXEMBOURG 
 
EN BIOLOGIE 
 
by 
 
Jonas WALTER 
Born on 6. April 1985 in Warburg, (Germany) 
 
ANALYSIS OF NEURONAL DIFFERENTIATION IN 
GENETIC FORMS OF PARKINSON’S DISEASE REVEALS 
A NEURODEVELOPMENTAL CONTRIBUTION 
 
 
Dissertation defence committee 
 
Dr Jens C. Schwamborn, dissertation supervisor 
Professor, Université du Luxembourg 
 
Dr Rudi Balling, Chairman 
Professor, Université du Luxembourg 
 
Dr Alexander Skupin, Vice Chairman 
Professor, Université du Luxembourg 
 
Dr Demetrios K. Vassilatis 
Professor, Biomedical Research Foundation Academy of Athens (BRFAA) 
 
Dr M. Adele Rüger 
Priv.-Doz., Universitätsklinikum Köln 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
      Google (C), 2012 
                                                                                                                        Table of Contents 
 
                                                                                                                                                    I 
Table of Contents 
Table of Contents ................................................................................................................. I 
Summary ............................................................................................................................. III 
1. Introduction ...................................................................................................................... 1 
1.1. Parkinson’s disease .................................................................................................... 1 
1.1.1. Clinical manifestation and treatments of PD ......................................................... 3 
1.1.2. Histo-/neuropathological hallmarks of PD ............................................................. 5 
1.1.3. Genetics of PD: Sporadic, idiopathic, and familial/genetic PD .............................. 7 
1.1.4. Genetic forms of PD ............................................................................................. 7 
1.1.4.1. LRRK2 (PARK8) ............................................................................................................ 9 
1.1.4.2. LRRK2 p.G2019S ........................................................................................................ 10 
1.1.5. Non-genetic impacts / idiopathic PD ................................................................... 11 
1.2. Parkinson’s disease cellular/molecular mechanisms ................................................. 12 
1.2.1. LRRK2-G2019S associated cellular/molecular mechanisms .............................. 12 
1.2.2. Mitochondria and mitochondrial biogenesis ........................................................ 14 
1.2.2.1. Mitochondrial dysfunction in aging and Parkinson ...................................................... 17 
1.2.3. Cellular (and mitochondrial) clearance mechanisms ........................................... 18 
1.3. Neurodevelopment and PD ....................................................................................... 20 
1.3.1. Early embryonic neurodevelopment ................................................................... 21 
1.3.2. Embryonic midbrain specification ....................................................................... 23 
1.3.3. Development of midbrain dopaminergic neurons ................................................ 24 
1.4. Modeling Parkinson’s disease ................................................................................... 25 
1.4.1. Patient derived iPSC .......................................................................................... 27 
1.4.2. Genome editing .................................................................................................. 28 
1.4.3. In vitro neural stem cells ..................................................................................... 31 
1.4.4. In vitro midbrain patterning and dopaminergic neurons derivation ...................... 33 
2. Motivation and aims ...................................................................................................... 34 
2.1. Aims: ......................................................................................................................... 35 
3. Results ............................................................................................................................ 36 
3.1. Manuscript I .............................................................................................................. 37 
3.1.1. Preface ............................................................................................................... 38 
3.1.2. Manuscript.......................................................................................................... 39 
3.2. Manuscript II ........................................................................................................... 112 
3.2.1. Preface ............................................................................................................. 113 
3.2.2. Manuscript........................................................................................................ 114 
3.3. Manuscript III .......................................................................................................... 166 
3.3.1 Preface .............................................................................................................. 167 
                                                                                                                        Table of Contents 
 
                                                                                                                                                    II 
3.3.2. Manuscript........................................................................................................ 168 
3.4. Manuscript IV .......................................................................................................... 210 
3.4.1 Preface .............................................................................................................. 211 
3.4.2. Manuscript........................................................................................................ 212 
4. Discussion and perspectives ...................................................................................... 254 
4.1. NSC and neurodevelopment in PD ......................................................................... 255 
4.2. Modeling age-related disorders using embryonic cells? .......................................... 256 
4.3. Autophagosomal-lysosomal alterations underlying PD ............................................ 257 
4.4. Mitochondriogenesis ............................................................................................... 259 
4.5. Susceptibility factors of PD ...................................................................................... 261 
4.6. PD beyond nigral degeneration ............................................................................... 262 
4.7. Hypothetical in vivo translation and vision of PD ..................................................... 263 
4.8. Conclusions ............................................................................................................ 265 
4.8.1. Major achievements ......................................................................................... 266 
4.8.2. Future directions .............................................................................................. 266 
5. Appendix ......................................................................................................................... IX 
5.1. Abbreviations ............................................................................................................. IX 
5.3. Index of Figures and Tables ....................................................................................... XI 
5.3.1. Figures ................................................................................................................ XI 
5.3.2. Tables ................................................................................................................. XI 
5.4. Bibliography .............................................................................................................. XII 
Acknowledgement ......................................................................................................... XLIX 
Affidavit ................................................................................................................................ L 
 
 
 
 
 
 
 
                                                                                                                                       Abstract 
 
                                                                                                                                                    III 
Summary 
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease after 
Alzheimer’s disease. The growing number of cases of PD is a serious threat to today’s 
socioeconomic societies. Most parts of PD’s clinical manifestation are explainable by the 
progressive loss of mesencephalic dopaminergic (mDA) neurons of the substantia nigra and 
the concomitant loss of dopamine. However, the loss of mDA neurons is likely only a small 
part of PD, and a rather final step in a long, slow, and diversely modulated disease progression. 
The understanding of PD is complicated by the sheer diversity of clinical manifestation and 
molecular processes proposed to modulate the onset of PD. Preventing PD will only be 
possible with a far better understanding of PD’s pathomechanisms, allowing an early detection 
of the onset of PD as well as PD risk evaluation and preventive treatment. 
Here I focused on detecting a neurodevelopmental component that could predispose to PD. 
The existence of such a component would open up a new aspect in PD-aethiology, and allow 
a better understanding of the penetrance of PD-associated mutations and PD-progression. 
The concept that neurodevelopmental aspects contribute to neurodegenerative diseases like 
PD is relatively new but gaining increasing acceptance. In this context I studied the G2019S 
mutation of the leucine-rich repeat kinase 2 (LRRK2) as a monogenic risk factor for PD. I 
utilized a human iPSC based neural model to mimic LRRK2-G2019S’ impact on early 
embryonic neurodevelopment. More precisely, I studied multipotent ‘neuroepithelial stem cells’ 
(NESCs) the ultimate lineage progenitors of the central nervous system and NESC based 
neuronal differentiation. I applied state-of-the-art technologies like automated high-content 
screening and 3D image analysis, mitochondrial activity evaluation, and single cell RNA 
sequencing to elucidate PD associated neurodevelopmental alterations. In parallel, I 
contributed to the development of an improved genome editing method and an advancement 
of autophagy and mitophagy screenings. 
In our studies we highlight a LRRK2-G2019S specific priming of human NESCs as a 
neurodevelopmental aspect of PD. The priming is evident in reduced viability and self-renewal, 
mitochondrial dynamics, metabolic activity, mitochondrial clearance alterations, and gene 
expression. More importantly, NESC priming manifests in altered dynamics during neuronal 
differentiation. The LRRK2-G2019S specific neuronal differentiation dynamics is the most 
evident in mesencephalic dopaminergic (mDA) neuron appearance; along with reduced 
neural-stem-cell-state stability, faster loss of stemness, and earlier cell cycle exit. Our results 
highlight a LRRK2-G2019S linked impact on early human neurodevelopment which might 
result in a predisposition to PD. Our efforts for the advancement of methodologies were 
successful. In this context the developed autophagy screening methods revealed the first 
indications of a common PD phenotype manifesting in limited cellular clearance capacities. 
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1. Introduction 
1.1. Parkinson’s disease 
Parkinson’s disease (PD) is one of the most frequent age-related neurodegenerative disorders 
that humankind is facing, with currently 2% of the population over 65 years of age affected. 
PD was first described as a neurological syndrome by James Parkinson (UK) in ‘An essay on 
the Shaking Palsy’ (Parkinson, 1817). In the following, among others, Jean-Martin Charcot 
(FR) influenced the definition of PD, specifically the discriminability based on motor symptoms 
(Przedborski, 2017). With today’s state of knowledge, PD could almost be subdivided in 
several PD-like diseases or sub-groups, all ultimately converging in similar late-stage clinical 
manifestations (Calne, 1989; Lawton et al., 2015; Thenganatt and Jankovic, 2014). 
Consequently, PD is rather an ‘umbrella term’, breaking down something immensely complex 
and diverse into something simple and understandable. The diversity of pathological 
hallmarks, reaching from clinical symptoms to genetic and molecular triggers, highlights the 
complexity of the PD aethiology. The prevalence of PD varies between regions; 
epidemiological rates indicate ~1% of people above 60 years of age, reaching up to ~5% above 
80 years – more conceivable: in total, more than 10 million people worldwide are currently 
diagnosed with PD (according to the ‘Parkinson’s Disease Foundation’, 2013) (Reeve et al., 
2014). The foremost hallmark of PD is the age-dependent risk of onset. PD is the second most 
common neurodegenerative disease after Alzheimer’s Diseases (AD). It is assumed that the 
percentage of individuals affected by PD worldwide is even underestimated because PD is 
often not diagnosed properly, specifically in developing countries (Zou et al., 2015). Due to the 
demographic development of western societies towards longevity, the demographic group at 
risk for PD is growing, resulting in an increasing prevalence of neurodegenerative diseases as 
a social and growing economic burden (Figure 1) (Dorsey et al., 2007; Gasser, 2011).  
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Figure 1: Parkinson’s disease associated demographic development versus age-dependent risk. 
Demographic ‘pyramid’ showing the current state (2014, light color) of demographic distribution and the predictions 
for the future (2080, dark (outline only) bars), women and men separated by color. The comparison of current and 
future prediction visualizes the increasing fraction of population in the European countries above 65 years of age 
(red bar). The group ≥65 years is at elevated risk of age-dependent disease like PD. According to these predictions 
the work-force fueling our socioeconomic societies declines while the burden of individuals at risk of age-related 
disorders substantially raises, this potentially result in a collapse of the systems. Effective treatment strategies need 
to be developed to slow down this development, e.g. ensuring long life quality, raising the red PD-risk-bar (Source: 
Eurostat, 2014). 
So far, no effective cure or neuroprotective treatments for PD are available, only a reduction 
of symptoms is possible to a limited extent and even that is accompanied by side effects 
(Przedborski, 2017). New preventive approaches need to be developed to delay the time of 
the onset of PD or even prevent the disease altogether. It is a task that will only be 
accomplishable with a better knowledge of PD-pathogenic mechanisms and the course of 
progression. 
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1.1.1. Clinical manifestation and treatments of PD 
PD is a progressive neurodegenerative disorder involving multiple complex neurotransmitter 
pathways within the brain and autonomic nervous system, both being associated with a broad 
spectrum of clinical features (Figure 2) (Schapira et al., 2017). As a general consequence, the 
clinical manifestations of PD are highly diverse and comprise of a wide range of symptoms 
reaching from multiple motor symptoms (MS) to diverse non-motor symptoms (NMS). 
Clinicians mostly utilize initial disease defining MS like bradykinesia, rigidity, and tremor for 
definite diagnosis of PD (Berardelli et al., 2013). Absence or reduction of dopamine levels due 
to the progressively degenerating mesencephalic dopaminergic (mDA) neurons of the 
Substantia Nigra pars compacta (SNc) has been linked to the appearance of motor deficits 
(Dauer and Przedborski, 2003). The discovery of dopamine replacement therapies (levodopa) 
brought substantial symptomatic benefits for PD patients, at least concerning MS. Disease 
progression and administration of increasing doses of levodopa result in phases when the 
medication is ineffective. PD’s MS can additionally be treated using a deep brain stimulator, 
but requiring a surgical procedure that is usually bringing great relief at 3-4% morbidity risk 
(Burchiel et al., 1999; Groiss et al., 2009). Further, several labs are currently working on 
bringing mDA neuron replacement therapies from bench-to-bedside (Kirkeby et al., 2017; 
Steinbeck and Studer, 2015). Notably, MS only appear at later stages of PD progression, when 
50-60% of SNc mDA neurons have already degenerated (Gibb and Lees, 1991). Thus, the 
majority of the damage has already irreversibly happened (Figure 2) and such treatment is not 
taking pre-/extranigral pathologies into consideration. NMS like hyposmia, sleep disorders, and 
depression precede MS by several years and clinicians are now starting to utilize NMS for 
early PD diagnosis, which is necessary for preventive proactive treatments to slow down PD 
progression. NMS are the less prominent part of PD symptoms, but patients describe the 
burden by NMS as equally high to MS (Bugalho et al., 2016). Like MS, NMS can only currently 
be treated symptomatically and not causally. Considering all NMS and MS, the progression of 
PD can be divided into four stages that can span 30 years or more (Figure 2). 
There are currently four major challenges for PD diagnosis and therapy: 1. Identification of the 
earliest predisposition to develop PD. 2. The development of tools allowing early diagnosis or 
indication of an elevated risk for PD. 3. The development of disease-modifying treatments to 
slow or prevent the progression of neurodegeneration. 4. The development of effective 
detection and symptomatic interventions of non-motor symptoms. Addressing these four 
challenges can finally lead to a much earlier diagnosis of PD and a refocusing of the current 
development of treatment methods towards early intervention strategies. An effective 
treatment for PD will only be found with a much better understanding of early PD-progression 
and the inducing underlying mechanisms. 
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Figure 2: Progression of the clinical manifestations of PD and accompanying non-motor 
symptoms (NMS) and motor symptoms (MS). A) A schematic depiction of a timeframe by which NMS and 
MS may manifest. Highlighting the timeframe of PD progression and the MS/NMS appearing during these stages. 
NMS develop years before the onset of MS in the early prodromal phase. Over the course of PD progression, 
numerous NMS sum up mostly resulting even in severe psychosis. MS only appear in the later stages of PD but 
are still necessary for diagnosis in most cases of PD. NMS and MS in PD can strongly vary among patients. B) 
Graphic representation outlining PD progression. Showing an estimation of time on the X-axis and the ‘level’ of 
different depicted factors on the Y-axis. The graph highlights the loss of dopaminergic neurons in direct correlation 
with the diagnosability of PD. Two different outcomes of MS progression are indicated, highlighting the reduction of 
symptoms by effective treatment. The NMS graph is preceding the MS graph by several years, the steep increase 
in NMS levels highlights the absence of treatability of NMS (adapted from Schapira et al., 2017). 
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1.1.2. Histo-/neuropathological hallmarks of PD 
Besides the age-dependent onset, PD has been linked to other hallmarks of quite diverse 
histo-/neuropathological nature. The main neuropathological hallmark associated with PD is 
the degeneration of mesencephalic dopaminergic (mDA) neurons (Forno, 1996) forming the 
substantia nigra pars compacta (SNc). The ‘substantia nigra’ is named after the dark 
appearance, caused by neuromelanin accumulation in mDA neurons throughout its lifetime, in 
contrast to the surrounding tissue (Figure 3A). The exact function of neuromelanin 
accumulation remains unclear. Neuromelanin is thought to be rather neuroprotective and a 
side product of high metabolic activity of mDA neurons (Zecca et al., 2008). High metabolic 
activity of mDA neurons is required for their pacemaker activity, requiring elevated levels of 
energy (Pissadaki and Bolam, 2013). The PD-associated neurodegeneration of mDA neurons 
diminishes the pigmentation and the distinguishing dark color faints, resulting in the major 
histo- /neuropathologic hallmark of PD. However, the scientific community is sometimes too 
focused on mDA neuron degeneration, neglecting other pre-/extranigral pathologies covered 
by this omnipresent neuropathological hallmark (Figure 3A).  
Figure 3: Histopathological hallmarks of PD. A) Different stages of mDA neuron degeneration, mapped to the 
Braak staging (c). Loss of mDA neurons of the substantia nigra pars compacta (SNc) but also of the SN pars 
reticulate (SNr) over time, highlighted by fainting neuromelanin. mDA neurons of the VTA are not affected that 
severely, indicated by the remaining neuromelanin in indicated VTA area. B) Different kind of Lewy aggregates of 
different kind of neurons a. Punctated inclusions in mDA neurons, which might precede Lewy body formation b. 
hippocampal Lewy bodies c. Lewy bodies (Pale body (faint blue) in the background, Lewy body (dark blue)) in mDA 
neurons of the SNc in a neuromelanin containing cell d. Club-shaped e. filiform and f. varicose Lewy neurites g. 
Lewy body containing an Aβ core surrounded by a perimeter of α‑synuclein‑immunoreactive dystrophic neurite, 
Scale bars 20 μm. C) Braak staging (Braak et al., 2003) of the neurodegenerative progression within the brain. 
Affected brain areas indicated (adapted from Goedert et al., 2012; Shulman et al., 2011; Surmeier et al., 2017) 
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A common histo-/neuropathological hallmark of neurodegenerative diseases is the 
appearance of proteinaceous inclusions of misfolded proteins in various brain regions. In PD, 
these inclusions are termed Lewy bodies and Lewy neurites (Figure 3B). The nature behind 
the appearance of Lewy neurites/bodies remains mainly elusive and is under heavy 
discussion. Lewy bodies are spheric/elongated eosinophilic intracytoplasmic protein inclusions 
with a dense core surrounded by a pale halo. Lewy neurites are abnormal neurites, containing 
granulose and filamentous cytosolic inclusions (Braak et al., 2003) (Figure 3B). Both kinds of 
inclusions mainly consist of aggregates of α-synuclein (Spillantini et al., 1997, 1998) of which 
around 90% is phosphorylated at S129P (Anderson et al., 2006; Fujiwara et al., 2002). The 
existence of Lewy-bodies without α-synuclein immunoreactivity was confirmed (van Duinen et 
al., 1999; Wong et al., 2004). The physiological function of -synuclein is not yet fully 
understood. However, some protein conformations were shown to be toxic in dose dependent 
manner (Lashuel et al., 2012). Post-mortem Lewy-extracts induce Lewy pathology and 
neurodegeneration (Recasens et al., 2014). Interestingly, a genetic variant of α-synuclein 
encoding SNCA was associated with PD as the first genetic risk-factor (Polymeropoulos, 
1997). The absence of Lewy-pathology is only a rare exception (Luk and Lee, 2014). Lewy 
bodies were also shown to be present in other neurodegenerative diseases like AD (Hansen 
et al., 1990) and Gaucher’s disease (Wong et al., 2004) containing α-synuclein and other type 
of proteins. So far it is an ‘open’ question if Lewy aggregates are a cause or consequence of 
PD-pathology. Oftentimes, the remaining small number of PD cases without Lewy-pathology, 
e.g. in association with LRRK2-G2019S (Gaig et al., 2007), contain valuable information. 
Importantly, in this context, Lewy body pathology is also found in the brains of 10-30% of aged 
adults without any PD symptoms, termed incidental Lewy body disease (ILBD). Those cases 
are thought to be presymptomatic, but without PD-onset or an undiagnosed prodromal phase 
during life time (Markesbery et al., 2009). There were attempts to link Lewy pathology and PD 
progression, resulting in a staging model (Braak et al., 2003) (Figure 3C), but a classification 
staging is difficult, if not virtually impossible, due to the variety of Lewy pathologies (Burke et 
al., 2008; Jellinger, 2009). In addition, it is worth mentioning that Lewy pathology is not only 
restricted to the brain, but also present in e.g. enteric nervous system, pointing to a systemic 
deregulation, a fact that is so far barely understood and studied (Jager and Bethlem, 1960; 
Wakabayashi and Takahashi, 2008). Summing up, Lewy pathology is a major 
neuropathological hallmark of PD, is present in almost all PD cases, and linked to Lewy body 
dementia (also in AD). However, Lewy pathology spreading is neither an ultimate 
correlator/indicator for PD progression, nor for the onset of PD. Given the current state of the 
literature, Lewy aggregates seem to be a consequence rather than a cause. 
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1.1.3. Genetics of PD: Sporadic, idiopathic, and familial/genetic PD 
The terms familial/sporadic/idiopathic PD are all present in literature and there is a need for 
sharp discrimination between the terms. In a first classification, PD cases are separable in 
genetic and idiopathic (without known pathomechanism) PD, with a rough prevalence of 10-
15% genetic to 85-90% idiopathic. Genetic PD can be further subdivided into sporadic (3-5%) 
and familial history PD (95-97%) (Klein and Westenberger, 2012). Sporadic genetic PD-
associated mutations can appear de novo in one parent’s germline and inherit to an offspring, 
affecting all somatic cells, eventually resulting in a new familial history of genetic PD. In a 
theoretical context every genetic familial history PD once was sporadic. Most monogenic PD 
mutations appear heterozygously and are mostly autosomal, dominantly or recessively 
inherited (Klein and Westenberger, 2012). Idiopathic PD (iPD) is mostly sporadic with an 
unknown or a not-yet-determined genetic trigger. Classification is further aggravated by the 
sporadic appearance of somatic mutations during the course of prenatal postzygotic brain 
development outside the germline (Kim and Jeon, 2014). The resulting mosaicism leaves most 
somatic cells unaffected but might be sufficient to induce PD via spreading (Proukakis et al., 
2013). Often even low levels of mosaicism were shown to be able to cause severe 
macroanatomic alterations (Gammill and Bronner-Fraser, 2003). In such cases, genetic 
screening would indicate iPD, even though a PD-associated mutation is the causative factor 
for the onset of PD. Unfortunately, there is currently no effective method to exclude genetic 
mosaicism as a trigger of iPD. Genetics of PD is far more complex than assumed in the past, 
requiring further investigations especially of patient genetic backgrounds. 
 
1.1.4. Genetic forms of PD 
During 20 years of genetic research in PD, genotyping, functional candidate approaches, next 
generation sequencing (NGS), and genome-wide association studies (GWAS) revealed 
several monogenic forms of PD and several genetic risk factors. Specifically, the advancement 
of screening techniques led to a quickly increasing number of disease linked (single-nucleotide 
polymorphisms) SNPs (Nalls et al., 2014). In around 5-10% of analyzed cases of PD a genetic 
component was identifiable. Monogenic forms of PD provide a unique and valuable tool for a 
better understanding of PD pathogenic mechanisms, allowing to study of the potential PD-
inducing molecular dysfunctionalities. Carriers of these genetic forms usually reveal 
Parkinsonism or are at elevated risk for developing PD. The initial identification of a genetic 
contribution to PD was made in one Italian and three Greek families (Polymeropoulos, 1997). 
The identified point mutation at position 209 from G to A (G209A) of SNCA (PARK1/4) resulted 
in an alanine to threonine (p.A53T) substitution. In the following, scientists introduced the 
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terminology of PARK(inson) loci. A terminology still in use to specify chromosomal regions 
(loci) that were linked to familial PD, without the responsible gene identified yet (Marras et al., 
2012). Even today, the responsible genes of five PARK loci are not yet identified (Table 1). 
After the initial identification of the first PD-associated genetic risk factor, 24 additional 
chromosomal loci were associated with PD (Table 1).  
Table 1: Genes and chromosomal loci linked to PD (adapted from Dr. Xiaobing Qing, (Klein and Westenberger, 2012))
 
Chromosomal loci linked to PD are not following a specific pattern. It is worth noticing that 
some of them interfere with either mitochondrial biogenesis (LRRK2, Parkin, PINK1, DJ-1, 
HTRA2, SNCA, PLAG6, ATP13A2), autophagosomal-lysosomal-pathways (ALP) (LRRK2, 
SNCA, VPS35, ATP13A2, ATP12A2, VPS35), or endocytic/lysosomal activities (ELA) (VPS35, 
DNAJC6, SYNJ1) (Brás et al., 2015), with the ALP and ELA also directly connected to 
mitochondrial biogenesis. These processes are all declining over time resulting in age as being 
the biggest risk factor for PD. The penetrance of the PD-linked mutations differs strongly 
between individuals and ethnic groups. Inter-individual genetic diversity and non-genetic 
factors are forming a predisposing susceptibility to contributing to the onset of PD. Recently, 
the group of Dr. Rudolf Jaenisch (Whitehead, USA) provided further insights showing an effect 
of a non-coding distal enhancer element that regulates the expression of SNCA, thereby 
altering the susceptibility to PD (Soldner et al., 2016). PD cases associated with a monogenic 
PD-associated risk factor, like LRRK2-G2019S, are a highly valuable source and important for 
a better understanding of PD in the future. 
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1.1.4.1. LRRK2 (PARK8) 
The PARK8 locus on chromosome 12 was first linked to PD during the investigations of a large 
familial history PD case (Funayama et al., 2002). Two years later the multi-exonic LRRK2 gene 
[PARK8; Online Mendelian Inheritance in Man (OMIM) no. 609007] at PARK8 chromosomal 
loci (12q12) was detected (Paisán-Ruı́z et al., 2004; Zimprich et al., 2004). The gene codes 
for the Leucine-rich repeat kinase 2 (LRRK2) protein. LRRK2 is a complex, relatively large 
protein of 2527 amino acids and 286 kDa. LRRK2 is a multidomain protein consisting of several 
functional and protein-protein interaction domains (depicted in Figure 4). The LRRK2 protein 
contains a catalytic core composed of: a gTP-binding ras of complex (Roc) domain, a carboxy-
terminal of Roc (COR) domain, and a kinase domain. LRRK2 can be classified as a member 
of the Roco protein family. LRRK2 harbors protein-scaffolding domains, or dimerization 
capacity implying widespread functions (Rideout, 2017). The exact molecular function of 
LRRK2 is still under debate, with multiple functions proposed (Wallings et al., 2015). LRRK2 
was predicted to have a wide range of cellular functions and activities due to its complex 
domain structure and widespread expression, from brain, to high levels in the kidney and lung 
as well as immune cells (Cook et al., 2017). High expression levels of LRRK2 were proposed 
to be toxic (Skibinski et al., 2014). LRRK2 functions as a dimer, where dimerization is 
necessary for LRRK2 function with different confirmations proposed (Guaitoli et al., 2016). 
Mutations of LRRK2 are associated with familial and sporadic Parkinson’s disease (PD) and 
are present in both catalytic domains, as well as in several of its multiple putative regulatory 
domains of LRRK2. Among those PD-associated mutations LRRK2 p.G2019S is the most 
frequent mutation as well as the most frequent genetic determinant of PD (Gasser, 2009a) 
(Figure 4). LRRK2-linked PD clinically manifests typically with mid-to-late onset and 
progresses rather slowly (Klein and Westenberger, 2012). Patients respond favourably to 
levodopa therapy and dementia is not common. Interestingly, there can be a high frequency 
of non-manifesting LRRK2 mutation carriers (Sierra et al., 2011). Hitherto, more than 100 
different missense and nonsense mutations have been reported in LRRK2 but only a small 
number of them was linked to PD e.g. p.R1441C, p.R1441G, p.R1441H, p.Y1699C, p.I2020T, 
and p.G2019S. PD-associated mutation of LRRK2 cluster in exons encoding the ROC, COR 
or kinase domains. (Hernandez et al., 2016; Nuytemans et al., 2010). Since the exact function 
of LRRK2 is still not well defined, the pathogenic mechanism by which mutant LRRK2 is 
triggering PD neither.  
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Figure 4: Schematic representation of a LRRK2 predicted domain structure. LRRK2 is depicted schematically as 
a dimer. The domains of LRRK2 and some of the proposed intra-/extramolecular interactions are listed above. LRRK2 is a 2527AA 
multidomain protein with several potential protein-protein interaction regions surrounding a central catalytic core. The catalytic 
core region contains a gTP-binding ras of complex (Roc) domain, a carboxy-terminal of Roc (COR) domain, and a kinase domain. 
The best defined pathogenic human mutations are shown below the diagram, with proposed alterations indicated. The LRRK2-
G2019S mutation is located in the kinase domain inside the catalytic core and is associated with increased kinase activity. Outside 
of the catalytic regions are several domains that are thought to provide protein-protein interaction regions, including the leucine-
rich repeats and WD40 domains (modified from Cookson, 2010). 
 
1.1.4.2. LRRK2 p.G2019S 
Mutations within the LRRK2 gene represent the most prevalent cause of genetic autosomal 
dominant PD. Among LRRK2’s mutations, the heterozygous LRRK2 p.G2019S is responsible 
for up to 37% of Mendelian cases of PD (Gasser, 2009b), dependent on ethnicity. LRRK2-
G2019S is also at 2% frequency associated with sporadic genetic PD (Berg, 2005). At least 
29 patients have been reported to carry genetic LRRK2-G2019S causative 6055G>A 
homozygously, interestingly not resulting in 100% penetrance of LRRK-G2019S, implicating 
the presence of additional factors that in combination lead to PD (Ishihara et al., 2006). 
Penetration of LRRK2-G2019S is age-dependent and incomplete, a fact implicating a role for 
other factors modulating the onset of LRRK2-G2019S PD. Although p.G2019S shows reduced 
penetrance, sometimes estimated to be as low as 24%, the p.R1441 mutation is highly 
penetrant (95% at the age of 75 yr) (Haugarvollet al. 2008). LRRK2-G2019S was associated 
with NMS, specifically, being high in asymptomatic LRRK2-G2019S carriers (Gammill and 
Bronner-Fraser, 2003). LRRK2-G2019S associated neuropathological ﬁndings are diverse 
where individuals are mostly showing Lewy body (and sometimes tau- and ubiquitin-containing 
inclusions) pathology and/or pure nigral degeneration without Lewy bodies, inconsistently 
accompanied by neuroﬁbrillary tangles (Giasson et al., 2006). 
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1.1.5. Non-genetic impacts / idiopathic PD 
The high frequency of cases of iPD and asymptomatic or paucisymptomatic carriers of 
monogenic forms of PD lead to investigation efforts towards non-genetic factors modulating 
the age of onset of PD, but also the susceptibility for developing PD. In vivo, the inheritable 
epigenetic landscape beyond the genome, already associated with neurodegeneration (AD) 
(De Jager et al., 2014; Lunnon et al., 2014), is gaining more attention in PD research (Moore 
et al., 2014). The knowledge about all those factors is still limited (De Lau and Breteler, 2006; 
Lesage et al., 2010). An important in vivo factor playing a significant role in PD, which is 
inherited independent of the genome, are mitochondria (Winklhofer and Haass, 2010). A 
recent meta-analysis based on 104 studies strongly indicates the ex vivo environment as an 
additional risk factor for the onset of PD (Pezzoli and Cereda 2013). In the 1980s first 
conclusive evidence for ex vivo PD triggers was found. As a causative factor inducing PD, the 
toxin MPTP was identified, a side product of the chemical synthesis of 1-Methyl-4-phenyl-4-
propion-oxy-piperidin (MPPP), an opioid analgesic drug and a preform to MPP+ (Büchi et al., 
1952). MPP+ is highly toxic to mDA neurons, consequently inducing PD symptoms (Langston 
et al., 1983). This led to the establishment of the MPTP model of PD, which was further utilized 
for drug discovery research (recently summarized Langston, 2017). Apart from MPTP, a 
variety of (potential) PD inducing toxins was identified. Starting from herbicides, pesticides 
over heavy metals - have all been associated to the onset of PD (Kamel and Hoppin, 2004). 
As an example, pesticide compounds interfering with aldehyde dehydrogenase (ALDH), which 
is strongly expressed in mDA neurons, were shown to be a PD inducing factor. Pesticides 
inhibiting ALDH were associated with 2-6 fold increased PD risk (Fitzmaurice et al., 2014). 
Also, recently, the general pollution by cars was shown to trigger PD (Chen et al., 2017a). 
Worth mentioning, in the context of ex vivo PD trigger identification, it is interesting and 
surprising that tobacco smoking was linked to a reduced risk of developing PD (Searles 
Nielsen et al., 2012). Also interesting and important to mention is the controversial ‘prion-like 
disease hypothesis’ for PD, adding another level of complexity (Frost and Diamond, 2010; 
Makin, 2016). The hypothesis is based on two host-to-graft findings (Kordower et al., 2008; Li 
et al., 2008), showing a transfer of Lewy body inclusions from the host to the graph of 
transplanted fetal mDA neurons. In the following it was shown many times that α-synuclein is 
able to spread when applied in vitro to cell culture media as well as when applied in vivo in 
mouse and macaque brains (Luk et al., 2012; Recasens et al., 2014). This awoke the fear of 
xenogeneic α-synuclein spreading and subsequent seeding as the trigger of PD. However, two 
recent studies show that mouse-α-synuclein significantly attenuates the formation of 
aggregates of human-α-synuclein (Fares et al., 2016; Rochet et al., 2000). This not only 
confirms a xenogeneic barrier for α-synuclein research, but also excludes an external uptake 
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and subsequent seeding of xenogeneic mouse-α-synuclein in PD. To date, it is impossible to 
estimate the frequency of ex vivo triggered PD among iPD cases. The complexity of PD with 
these numerous disease triggers led to the establishment of the ‘multiple-hit’ hypothesis 
(Sulzer, 2007). In most cases, PD is likely triggered by a combination of genetic susceptibility 
SNPs, non-genetic in vivo predispositions, and diffuse environmental ex vivo factors. Only 
additional investigative efforts will further complete this puzzle, enable future generations to 
track disease risk in real-time, and develop proactive preventive personalized therapy 
approaches.  
 
1.2. Parkinson’s disease cellular/molecular mechanisms 
The main obstacle in the development of efficient neuroprotective drugs for PD is the missing 
knowledge on the specific cascade of molecular events that provoke the associated 
neurodegeneration. The sheer number of molecular alterations associated with different 
monogenic forms of PD is overwhelming and mostly difficult to interpret. For some genes linked 
to monogenic PD the exact function of the underlying protein is not yet known. Thus, it is 
difficult to distinguish between direct and indirect effects of the associated mutation. 
Consequently, newly reported phenotypes, dependent on the study setup, need to be 
interpreted with extreme caution. Some of the observed phenotypes can certainly be seen as 
side effects, indirectly induced by the underlying direct deregulation induced by the altered 
protein. In most cases, only the identification of the exact cellular/molecular function of the PD-
associated protein is going to further elucidate the nature of the PD triggering mechanisms. 
 
1.2.1. LRRK2-G2019S associated cellular/molecular mechanisms 
The protein LRRK2 in the focus of our work is a protein with not yet fully uncovered function 
(Wallings et al., 2015). LRRK2 is hypothesized to be a scaffolding protein, a transmitter inside 
the cell, integrating a variety of different signals (Herzig et al., 2011). This is because LRRK2 
was shown to interact with an enormous variety of proteins. LRRK2 was shown to have various 
potential pathogenic interactions with: α-synuclein (Alegre-Abarrategui et al., 2008; Guerreiro 
et al., 2013; Qing et al., 2009), tau (Gammill and Bronner-Fraser, 2003), RAB7 (MacLeod et 
al., 2013; Steger et al., 2016), Drp1 (Wang et al., 2012), and even amyloid precursor protein 
(APP) (Chen et al., 2017b). Mechanistically LRRK2 was linked to: inflammatory response 
(Cook et al., 2017; Gardet et al., 2010; Kim et al., 2012; Moehle et al., 2012), mitochondrial 
dysfunction (Wang et al., 2012), synaptic dysfunction (Matikainen-Ankney et al., 2016; 
Parisiadou et al., 2014), autophagy-lysosomal system (Roosen and Cookson, 2016), 
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regulation of microRNA-mediated translational repression (Gehrke et al., 2010), and vesicle 
transport (Abeliovich and Gitler, 2016; Biskup et al., 2006) . 
The LRRK2-G2019S mutation is located in the kinase domain resulting in increased kinase 
activity (West et al., 2007) affecting inter- but also intra-protein phosphorylative activity 
between GTPase and kinase domain (Gilsbach and Kortholt, 2014). The exact nature of 
intramolecular interaction between GTPase and kinase domain is not conclusively described 
and still under debate. Molecular alterations associated with LRRK2-G2019S are extremely 
diverse and numerous. The most promising targets in the context of LRRK2-G2019S are 
interferences with mitochondrial metabolism (1.2.2.) and ALP (1.2.3.). Figure 5 outlines the 
diversity of these molecular events shown to be altered by LRRK2-G2019S. Thereby, the focus 
on LRRK2-PD linked interventions in mitochondria, mitochondrial biogenesis, and the 
autophagosomal-lysosomal-pathway (ALP), is most relevant for our studies (for more details 
see Figure 6).  
 
Figure 5: Molecular interferences linked to mutant Leucine-rich repeat kinase 2 (LRRK2). Depiction of 
putative cellular mechanisms that are impacted by one or more pathogenic mutations of LRRK2. LRRK2 has been 
reported to regulate lysosomal positioning and autophagy (Alegre-Abarrategui et al., 2009; Dodson et al., 2014; Niu 
et al., 2012; Plowey et al., 2008; Su and Qi, 2013; Wang et al., 2012), synaptic vesicle endocytosis (Matta et al., 
2012), synaptogenesis (Matikainen-Ankney et al., 2016; Parisiadou et al., 2014), cytoskeleton and neurite 
outgrowth (Jaleel et al., 2007; MacLeod et al., 2006; Parisiadou et al., 2009; Smith et al., 2005; West et al., 2007), 
protein synthesis (Gehrke et al., 2010; Imai et al., 2008; Martin et al., 2014a), golgi sorting, and retromer function 
(Lin et al., 2009; MacLeod et al., 2006; Stafa et al., 2014), endosomal biogenesis via Rab interaction (MacLeod et 
al., 2013; Steger et al., 2016). Mutations reported to affect the particular molecular function are indicated (adapted 
from Martin et al., 2014). 
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1.2.2. Mitochondria and mitochondrial biogenesis  
Mitochondria are organelles of endosymbiotic origin, found in most eukaryotic cells. The small 
(0.5-1 µm in diameter, sized like bacteria), double-membraned mitochondria harbor the ability 
to biochemically catalyze adenosine triphosphate (ATP) with high efficiency. ATP is a small 
molecule that functions in cells as a coenzyme and is also termed the "(unit of) molecular 
currency", the most important intracellular energy transporter. Mitochondria synthesize ATP 
mainly via oxidative phosphorylation (OXPHOS). By this nature, a fast catalysis of ATP is a 
significant evolutionary advancement and advantage. Hence, mitochondria are crucially 
involved in numerous cellular processes that rely on energy such as cell growth, maintenance, 
proliferation, activity, and neurogenesis (Beckervordersandforth et al., 2017). During the 
course of evolution, endosymbiotic mitochondria progressively lost already their genetic 
independence. Only a small fraction (13 proteins) of 1000 mitochondrial proteins is synthesized 
exclusively inside mitochondria, as most genes are outsourced to the nucleus and proteins are 
shuttled to mitochondria on-demand (Calvo and Mootha, 2010). The remaining essential 
proteins are encoded by the mitochondrial genome, circular polyploid DNAs (mDNAs) with up 
to several thousand copies existing within one cell (Taylor and Turnbull, 2005). Mitochondrial 
number varies strongly between cell types as most human cells contain several hundred up to 
thousands mitochondria. Maternally inherited mitochondria are a non-genetic (nuclear DNA) 
variable factor in PD. The functionality of mitochondria is affected by the mutation frequency 
in mDNA. Certain combinations of mDNA mutations were shown to induce ‘mDNA disorders’, 
which exhibit a strong phenotype in neural stem cells (Lorenz et al., 2017). Theoretically, 
mitochondrial inheritance is a genetic bottleneck, and even though there are rigorous control 
mechanisms, homo-/heteroplasmic transfer of mitochondria allows the existence of oocytes of 
different mitochondrial quality, with respect to mitochondrial DNA mutations (Johnston et al., 
2015; Li et al., 2016). A low quality mitochondria oocyte in combination with e.g. a monogenic 
PD-associated mutation, is hypothesized to contribute to the risk developing PD during aging 
(Coxhead et al., 2016). However, there is so far only weak evidence for this hypothesis (Schon 
et al., 2012). 
Mitochondria are the major sources of cellular reactive oxygen species (ROS), and when 
dysfunctional, mitochondria even consume cytosolic ATP (Chinopoulos and Adam-Vizi, 2010; 
Finkel and Holbrook, 2000). Hence, mitochondria possess a kind of ‘janus-like‘ nature. Apart 
from all the advantages in energy (ATP) supply, mitochondria can also be highly toxic to cells, 
being involved in apoptosis, necroptosis, and necrosis (Thornton and Hagberg, 2015; Wang, 
2001) (Figure 6). The upmost danger originating from mitochondria is the passive and 
uncontrolled release of reactive oxygen species (ROS) as a byproduct of OXPHOS. ROS can 
induce severe damage by oxidizing e.g. mDNA, DNA, and proteins, a process that is more 
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endangered during ageing, since ROS clearance mechanisms were shown to have an age-
dependent decline. Deregulation of ROS clearance mechanisms is associated with 
neurodegeneration of mDA neurons (Dias et al., 2013). Maintaining healthy mitochondria is 
therefore crucial for the overall cellular fitness. Controlling the risk of mitochondrial toxicity is 
for cells of high importance for survival, specifically of mDA neurons (Dias et al., 2013). 
Mitochondria are highly plastic and motile, being able to fuse (join forces) but also to fission 
(separate parts from the network, usually associated with malfunction), processes under 
constant pressure of cellular demands and mitochondrial health (Youle and Van Der Bliek, 
2012). Fission/fusion are part of ‘mitochondriogenesis’, which is directly related to cellular 
homeostasis and clearly a cellular mechanism of utmost importance (Kornmann, 2014) (Figure 
6). In a healthy situation, mitochondrial turnover is well-balanced in an equilibrium between 
fission and fusion and is where sufficient clearance of defective mitochondria is taking place 
(mitophagy) (Figure 6). Mitophagy summarizes mitochondria-specific autophagy, the cell’s 
mechanism to deal with abnormal mitochondria and thus controls the quality of the 
mitochondrial pool. Mitochondrial quality control mechanisms are specifically important for long 
living neurons and stem cell maintenance (summarized in Sun et al., 2016). There are four 
major pathways of mitochondrial quality control (summarized in Sugiura et al., 2014), ordered 
after cargo size: 1. Misfolded mitochondrial membrane proteins are degraded by two AAA 
protease complexes carrying catalytic sites facing both sides of the mitochondrial inner 
membrane (Langer, 2000). 2. Ubiquitination of mitochondrial proteins and targeted 
degradation via proteasome (Neutzner et al., 2007). 3. Segregation of larger mitochondria 
derived vesicles (MDVs) of selected mitochondrial cargos and degradation via fusion to 
lysosomes of ALP (Micromitophagy, direct fusion without autophagosome formation) 
(Soubannier et al., 2012a, 2012b). 4. Macromitophagy, a subtype of autophagy involves the 
sequestration of entire mitochondria within a double-membrane vesicle, autophagosome, 
followed by further degradation via the lysosome (Gammill and Bronner-Fraser, 2003). In 
addition, in neurons there seems to exist a kind of ‘transmitophagy’, which aims at shuttling 
defective mitochondria to astrocytes (Davis et al., 2014). Multiple times, mitochondriogenesis 
in PD was shown to differ from normal cellular status (Abou-Sleiman et al., 2006; Exner et al., 
2012; Henchcliffe and Beal, 2008). As introduced already, some of the PD-associated genes 
are critically involved in mitophagy. PINK1 coding for mitochondrial associated PTEN-induced 
kinase 1 and the E3 ubiquitin ligase Parkin are important for the accomplishment of 
macromitophagy (Jin and Youle, 2012; Jones, 2010; Wang et al., 2011). PINK1 is imported 
into healthy mitochondria where it is normally cleaved by the mitochondrial protease 
Presenilins-associated rhomboid-like protein (PARL). Upon damage this process is disrupted, 
PINK1 localizes to the outer mitochondrial membrane and recruits polyubiquitination of 
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mitochondrial substrates and by that recruits cytosolic Parkin, which induces phosphor(p)-
polyubiquitination and mitophagy via p62/LC3 (Deas et al., 2011; Jung et al., 2010). In PD-
associated mutations of PINK1 and Parkin carrying neurons, damaged mitochondria are not 
removed sufficiently (Geisler et al., 2010; Narendra et al., 2008) inducing cellular degeneration 
(Surmeier et al., 2010).  
 
Figure 6: Schematic representation of mitochondriogenesis and connected mitochondrial clearance via 
ALP. Both depicted pathways are omnipresent in the context of PD. LRRK2 is interacting with Drp1 and LRRK2-
G2019S induces fission, altering the balance of mitochondriogenesis (Wang et al., 2012). At the same time LRRK2 
is interacting with the ALP and LRRK2-G2019S limits degradation capacities (Roosen and Cookson, 2016). A) 
Mitochondriogenesis is comprising the permanent fission/fusion, quality control, and clearance dynamics of 
mitochondria while providing the cell with sufficient ATP. Fission is taking place in interaction with the ER and is 
mediated by Mitofusin 2 (Mfn2), involving Drp1. Fission is also taking place when the mitochondrial network is 
damaged. Fission in this case results in a damaged mitochondrion. The damaged mitochondrion is depolarized and 
exposed to elevated level of ROS. Four mitochondrial quality control mechanisms prevent further damage to the 
cell (yellow, 1-4). In case these are not working sufficiently the damaged mitochondrion can induce apoptosis or 
necrosis, mostly via cytochrome C release and activation of Bcl-2 pro-apoptotic proteins. Mitochondrial quality 
control mechanisms (1-3) work in parallel to mitochondriogenesis, preventing further damage and even fission. 
These mechanisms involve clearance of damaged mitochondrial proteins (1-2) via AAA-proteases and the 
proteasomal system, both permanently active, preventing damage. Mitochondria and mitochondrial cargo clearance 
mechanisms (3-4) involve the degradation via ALPs. (3) In a mechanism involving local PINK1 and Parkin 
recruitment damaged cargo is exported via budding from a mitochondrion. The budded vesicle fuses ultimately to 
a multivesicular body (MVB) or directly to a lysosome for further degradation. (4) In an ultimate step, in case 
mechanisms 1-3 were not sufficient, a whole mitochondrion can be degraded via mitophagy. In such case PINK1, 
Parkin, and ubiquitination mediated target the mitochondrion for degradation. Upon targeting it is engulfed in an 
autophagosome (involving p62, LC3-II recruitment), resulting in a mitoautophagosome. B) The mitoautophagosome 
(any autophagosome and budded vesicle (3)) fuses to a mature acidified lysosome for final degradation of the waste 
cargo. Sufficient supply of mature and acidified lysosomal is part of lysosomal biogenesis. The lysosomal fusion 
releases proteases and hydrolases degrading the potentially toxic cargo. The terminal of two of four known 
mitochondrial quality control mechanisms in the lysosome highlights the potential rate limitation by insufficient 
lysosome supply for mitochondrial clearance mechanisms (adapted from Füllgrabe et al., 2014; Sugiura et al., 
2014). 
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1.2.2.1. Mitochondrial dysfunction in aging and Parkinson  
Aging is a particularly complex and multifactorial process and the most important risk factor 
contributing to PD progression (Antony et al., 2013). Aging is characterized by a progressive 
decline of the efficiency of physiological function and by an elevated vulnerability to disease 
and death (Finkel and Holbrook, 2000; Gemma et al., 2007). Aging and eventual death of 
multicellular organisms is related to macromolecular damage by passively released 
mitochondrial ROS (López-Otín et al., 2013; Turrens, 2003). Loss of mitochondrial function 
including elevated ROS levels is a general hallmark of aging and more prominent in PD 
(Gammill and Bronner-Fraser, 2003). In this context, one can hypothesize three different 
possible scenarios for the age-dependent decline of mitochondrial function: 1) The function of 
mitochondrial quality control mechanism is stable over time, but is finally overloaded by 
increasing byproducts resulting from mitochondrial or mitochondria-independent, age-
dependent cellular processes 2) Accumulation of byproduct remains constant, but the 
efficiency of mitochondrial quality control mechanism is declining in an age-dependent manner 
3) Parallel decline of both, functioning as a circulum vitiosum. 
Mitochondrial dysfunction is extremely common in age-dependent neurodegenerative disease 
including PD (Lin and Beal, 2006). Mitochondrial dysfunctionality can be seen as a molecular 
hallmark of PD (Winklhofer and Haass, 2010). PD-postmortem brains show oxidative damage 
related pathology in particular in SNc (Drechsel and Patel, 2008). The exact mechanisms, with 
respect to the proposed models, are not fully understood, yet. Long-lived post-mitotic cells, 
such as neurons, are particularly vulnerable to mitochondrial dysfunctionality and ROS. mDA 
neurons produce high levels of ROS by their continuous robust autonomous pacemaker 
activity (Guzman et al., 2009) and the resulting energy demand mostly addressed by 
mitochondria. Further, DA synthesis byproducts are reactive side-products like H2O2 (Graham, 
1978). Both resulting in chronically high levels of ROS in SNc (Jenner, 2003). Consequently, 
mDA neurons are more prone to age-dependent decline of ROS clearance mechanisms. 
Besides, long-lived cells, stem cell pools, were shown to be vulnerable to ROS (García-Prat et 
al., 2016). In this context ROS levels were shown to be specifically high in neural stem cell 
niches, in early progenitor cells (Walton et al., 2012). ROS is also linked to a faster depletion 
of stem cells pools (Chen et al., 2016). Apart from directly triggering cell death, elevated ROS 
levels also alter the finely-tuned balance between self-renewal and differentiation, resulting in 
reduced stem cell maintenance (Ito and Suda, 2014). Over time, the stem cell pool exhausts 
in this scenario as the number of controlled cellular genesis consequently reduces, which was 
interestingly observed in a LRRK2-G2019S mouse model (Winner et al., 2011a) and could 
indicate earlier depletion of neurogenesis during aging in PD. Autophagy was shown to be the 
                                                                                                                                 Introduction 
 
                                                                                                                                                  18 
main regulatory mechanisms for ROS in stem cell pools and stem cell maintenance (Chen et 
al., 2016; García-Prat et al., 2016) and also declines during aging (Rubinsztein et al., 2011). 
Autophagy is also important in mDA neurons, thus the underlying mechanisms are likely the 
same. Further, aging influences the positioning of mitochondria between stem and daughter 
cell. The future stem cell maintains younger mitochondria. A non-optimal positioning 
compromises stem cell niches and reduces the capacity to give rise to new daughter cells 
(Gammill and Bronner-Fraser, 2003). With respect to the three initially proposed hypothetical 
scenarios, the current literature supports the third scenario for PD, while the particular PD-
associated mutation negatively impacts, either directly or indirectly, mitochondriogenesis. 
PD-associated dysfunctions in this context are reaching from elevated mitochondrial ROS, 
reduced mitochondrial membrane potential, and elevated mutation rate of mitochondrial DNA 
over accumulation of fragmented mitochondria up to altered mitochondrial clearance 
mechanisms.  
 
1.2.3. Cellular (and mitochondrial) clearance mechanisms 
Cellular clearance mechanisms, specifically autophagy, gained much attention during the last 
decades, resulting in an exponential increase in autophagy related studies (Klionsky, 2007, 
Figure 1). The term autophagy is derived from the Greek “auto = self” “phagein = to eat “, 
accurately “self-eating”. Here, only autophagy-dependent clearance eventually merging with a 
lysosome, composing the autophagosomal-lysosomal pathway (ALP) which is a major axis of 
the cellular degradation system, crucial for cellular homeostasis are highlighted (Martinez-
Vicente and Cuervo, 2007) (Figure 6). The cellular degradation system additionally consists of 
the proteasomal (Adams, 2004) and exocytic (Raposo and Stoorvogel, 2013) pathways – 
being similarly important for complete cellular homeostasis. Even though an involvement of 
the latter in cellular clearance is still under debate, it is a potential way to export e.g. defective 
mitochondria (Phinney et al., 2015). Exocytosis alteration in a neurodegenerative disease 
context was recently highlighted (Kanninen et al., 2016; Sarko and McKinney, 2017).  
Groundbreaking work (Bucci et al., 2000; Cuervo and Dice, 1996; Mizushima et al., 1998; 
Takeshige et al., 1992) lead to a better understanding of cellular clearance related 
autophagosomal (Klionsky, 2007) and lysosomal pathways (Luzio et al., 2007). Alteration of 
ALP has been associated with numerous neurodegenerative diseases (Nixon, 2006, 2013 
(Table 2); Pan et al., 2008). Functional autophagy is crucial for survival, development, 
differentiation, and homeostasis (Levine and Brivanlou, 2007). Autophagy involves multiple 
steps comprising the formation of a double membrane structure, the autophagosome, 
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engulfing the cargo to be cleared (Figure 6). Once the formation is completed the 
autophagosome fuses with lysosomes and forms an autophagolysosome, both referred to as 
autophagic vacuoles, characteristic for autophagy (Takeuchi et al., 2005). After fusion, the 
former inner membrane of the autophagosome disintegrates and the lysosomal hydrolytic 
enzymes degrade the autophagosomal cargo. The whole process is referred to as 
macroautophagy. Besides that, microautophagy also exists, comprising the gradual, 
continuous turnover of specific subsets of cytosolic proteins, carrying a CMA targeting motive 
(Bejarano and Cuervo, 2010). This so called chaperone-mediated autophagy (CMA) is a 
secondary ‘line of defense’ usually following macroautophagy. It was shown that CMA is a 
heat-shock cognate protein of 70 kDa (hsc70) mediated. hsc70 binds to the CMA targeting 
motive and guides the protein via LAMP-2A receptor binding inside the lysosome (Crotzer and 
Blum, 2005). Normal function of both pathways require the availability of a sufficient number 
of lysosomes that further need to be sufficiently acidified to conduct their degradative function 
(Luzio et al., 2007). Insufficient function of lysosomes forms the class of the so called lysosomal 
storage disease (LSD), based on major malfunctioning of lysosomes, and results in 
accumulation of unprocessed waste (Neufeld, 1991). Interestingly, it was stated specifically 
that lysosomal turnover rather than autophagosomal LC3 levels are an indicator for ALP 
capacity (Tanida et al., 2005). Alterations in ALP biogenesis are directly linked to mitophagy, 
and thus mitochondriogeneis (Youle and Narendra, 2011)(Figure 6). 
Alterations of both parts of ALP have been associated with PD (Pan et al., 2008). The following 
PD-associated proteins were shown to alter autophagy when mutant: VPS35 (Zavodszky et 
al., 2014), GBA1 (Schöndorf et al., 2014), ATP13A2 and SyT11 (Bento et al., 2016), α-
synuclein (Winslow et al., 2010), and LRRK2 (Roosen and Cookson, 2016). LRRK2-G2019S 
was shown to increase basal autophagy levels, while overall autophagic flux was reduced 
(Sánchez-Danés et al., 2012). LRRK2 was shown to localize to compartments involved in ALP 
(Biskup et al., 2006; Gomez-Suaga et al., 2012). LRRK2 also interplays with CMA, an 
interaction which seems to have a LRRK2 self-perpetuating function (Orenstein et al., 2013) 
and might compromise degradation of other factors (like α-synuclein) via CMA (Cuervo, 2004). 
LRRK2 directly interacts with Rab7 (MacLeod et al., 2013; Steger et al., 2016) a key factor in 
autophagosomal-lysosomal biogenesis, specifically lysosomal maturation (Bucci et al., 2000; 
Hyttinen et al., 2013). 
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1.3. Neurodevelopment and PD 
Recent studies have collected increasing evidence indicating a contribution of the 
neurodevelopment to PD progression (reviewed in Le Grand et al., 2014; Marxreiter et al., 
2013). The exact implication of this new aspect of PD-pathology is so far unclear, but could 
predispose to the onset of PD. In this context particularly interesting is the observation that a 
α-synuclein knock out in mice results in a reduced number of mDA neurons formed in the SNc 
during embryonic neurogenesis (Garcia-Reitboeck et al., 2013), showing the importance of the 
PD-associated SNCA also for mDA neuron development. Further, in human PD-patient post-
mortem brains an 100% increase of mDA neurons in the olfactory bulb was observed (Huisman 
et al., 2004). A very interesting observation when taking in consideration that the olfactory bulb 
development ends around 18 month post-natal (Sanai et al., 2011) and is afterwards basically 
absent (Wang et al., 2011), the observed dramatic differences can be only the result of early 
developmental differences. In the neurodevelopment LRRK2 was shown to be important for 
the regulation of neurogenesis (Gammill and Bronner-Fraser, 2003; Winner et al., 2011b). 
LRRK2 is expressed in proliferative neural stem cell (NSC) niches of the developing embryonic 
mouse brain. This was verified in ex vivo cultured embryonic NSCs (Galter et al., 2006; Zechel 
et al., 2010) and indicates that NSCs as a potential model for studying G2019S-PD. In relevant 
mouse models, embryonic and adult neurogenesis is affected (Bahnassawy et al., 2013; Le 
Grand et al., 2014; Winner et al., 2011b). LRRK2-G2019S transgenic-mice possess reduced 
hippocampal synaptic plasticity (Sweet et al., 2015) without recapitulating a neurodegenerative 
phenotype. The loss of neural plasticity is correlated to neurodegeneration and reduced adult 
neurogenesis in PD (Gammill and Bronner-Fraser, 2003). Induced pluripotent stem cell (iPSC) 
derived LRRK2-G2019S NSCs progressively degenerate and retain indications for altered 
neurodevelopment (Liu et al., 2012). These observations, together with the fact that iPSC 
derived material resembles embryonic identity (Mariani et al., 2012), point at a potential 
predisposition to PD already formed during early human embryonic development. 
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1.3.1. Early embryonic neurodevelopment 
Neurodevelopment can be defined as the birth of all central nervous system (CNS) contributing 
cells in spatiotemporal arrangement, establishment of connectivity, and functional specification 
(Götz and Huttner, 2005). Neurodevelopment bases on a pre-defined genetically encoded 
developmental blueprint under constant evolutionary pressure (Gammill and Bronner-Fraser, 
2003). The complexity of the CNS development in humans is not recapitulated by the used 
animal models, a fact that highlights the limitations of non-human models (Bakken et al., 2016). 
Neurodevelopment starts early in embryogenesis, in humans, post-conception neural 
induction takes place around day 15 (Figure 7). Around this point gastrulation starts and meso-
, endo-, ectoderm start forming the triploblastic embryo. Neural induction at the future dorsal 
side is seen as the earliest step in the determination of neuroectodermal cell fate (Muñoz-
Sanjuán and Brivanlou, 2002). Extrinsic signaling acts on the inner cell mass (ICM) of the 
blastocyst, de facto pluripotent stem cells (PSC), a concept that was highlighted already in 
1924 in xenopus (1924, Spemann and Mangold). Autocrine signaling induces neural induction 
and blocks differentiation into mesendodermal, trophectodermal, and ectodermal cells. Neural 
induction is passively induced via inhibition of bone morphogenetic proteins (BMP)/Nodal 
signaling (TGFb/BMP receptor mediated), resulting in intracellular SMAD signal inhibition and 
downregulation of associated gene expression (Levine and Brivanlou, 2007). Neural induction 
results in neural cells of neuroectoderm with rostral forebrain identity as this is the default 
tendency (Sasai, 2013) (Figure 7). During the following reorganization and expansion, the 
notochord is formed and induces an axial (along cranial-caudal axis) thickening of the 
endoderm. Following this, the neurulation takes place, forming the neural plate first around day 
19, the key developmental structure of the developing CNS. The neural plate is separated from 
surrounding epidermis by the neural plate border. The central part of the neural plate then 
migrates anterior and at the same time the neural plate borders migrate towards each other, 
forming the neural grove. The neural grove then closes and during the fourth week of 
embryogenesis, is covered by the bordering epidermis at the end of the process. The most 
dorsal part of the neural tube is formed by the neural plate borders and contains the neural 
crest cells, the future peripheral nerve system (PNS/spinal cord) and former neural plate border 
cells. The neural tube gives rise to the future CNS, with further specification during the next 
stages of neurodevelopment. During the process of early embryonal neurodevelopment, 
diverse types of neural stem cells (NSC) exist (Alvarez-Buylla et al., 2001; Gage, 2000; Götz 
and Huttner, 2005). NSC, to a certain extent, possess the ability to further proliferate and self-
renew, expand the CNS, and give birth to neuronal or glial cell types. The diverse NSC stages 
in this context are mostly transient, triggered by extrinsic, micro-environmental factors and 
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automated developmental programs (Kriegstein and Alvarez-Buylla, 2009). In mammals like 
humans and mice, certain neural stem cell niches are maintained in adulthood (Gage et al., 
2008). In mice, a foundation of definite adult NSC niches is already made during early 
development and further specified during aging (Fuentealba et al., 2015). Overall, the 
introduced parts of neurodevelopment are highly conserved and of utmost importance for the 
following neurodevelopment (Mieko Mizutani and Bier, 2008). 
 
 
Figure 7: Timing and events during early human neurodevelopment. Depicted in spatiotemporal manner with 
exemplified in vivo electron microscopy pictures of whole mount embryos and transverse plane slices along the 
vertical axis of the future neural tube. Early neurodevelopment starts around day 14 post-conception, after the 
embryo embedded in the endometrium. Neurodevelopment starts with neural induction forming the primitive streak 
dorsal to the notochord. From rostral to caudal alongside the primitive streak neuroepithelial cells line up and form 
the neural plate border surrounding the neuroectoderm. During neurulation the cells neighboring the neural plate 
direct the neuroectodermal cells to proliferate, invaginate, and pinch off the exterior side to form a hollow tube. The 
neurulation continues by further invagination of neuroectodermal cells towards the ventral side of the embryo while 
the neural plate border cells at the neural fold comigrate towards medial. During the fourth week post conception 
and the second week of neurodevelopment the neural groove closes at the dorsal side towards rostral and caudal, 
as a result the neural tube is forms. The neural tube is giving rise to all parts of the central nervous system. The 
neural crest cells originating from the neural fold give rise to the peripheral nervous system. (Parts of the figure 
kindly provided by Lisa M Smits, adapted from: Bear et al., 2016; Gammill and Bronner-Fraser, 2003). Scanning 
electron microscopy pictures of whole mount in vivo situation were kindly provided Hill, M.A. 2017 Embryology Main 
Page. August 3, 2017, from https://embryology.med.unsw.edu.au/embryology/index.php/Main_Page. 
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1.3.2. Embryonic midbrain specification  
Along with the closing of the neural tube, specification of cells continues during the fourth and 
fifth week of neurodevelopment. Regionalization and subdivision results in various brain 
regions, so called “neuromeres”, along the dorsal-ventral (D-V) axis (Figure 8). Neuromeres 
are morphologically or molecularly defined transient segments of the early developing brain. A 
better understanding of this process of early CNS development was established only recently. 
Around 1990, the cell lineage restriction boundaries of the hindbrain were identified in the 
embryonic vertebrate hindbrain (rhombencephalon), subdividing it into a series of tight 
compartments (termed rhombomeres) (Fraser et al., 1990; Wilkinson et al., 1989). Shortly 
after, the first regionalization genes were identified (Figdor and Stern, 1993; Simeone et al., 
1992) and the concept of further subdivision of the mid-fore brain was proposed (Rubenstein 
et al., 1994). Also the midbrain-hindbrain boundary (MHB) was identified, separating 
mesencephalon and rhombencephalon within the developing CNS (Crossley et al., 1996). A 
finding that initiated an ongoing search for additional compartmentation in other regions of the 
developing CNS. Since then further boundaries were identified, separating the primary brain 
vesicles prosencephalon (forebrain) from the mesencephalon, subdivided in the anterior 
telencephalon and the more caudal diencephalon (Stiles and Jernigan, 2010). The 
regionalization of the developing CNS is only possible by the interplay between various 
extrinsic and intrinsic cell fate determinants along anterior-posterior (A-P) and D-V axes 
(Figure 8). 
Along the A-P axis, the midbrain is enclosed by the MHB (isthmic organizer) and the 
diencephalon-midbrain boundary (DMB). The formation of the boundaries is the best 
understood for the MHB. The MHB is defined by counteracting expression of homeobox genes 
Otx2 (fore-/midbarin) and Gbx2 (Only hindbrain). Important are further extrinsic signaling 
gradients of FGFs, Nodal, retinoic acid and WNTs, which are involved (Niehrs, 2004; Wilson 
and Houart, 2004). More precisely, MHB specifies A-P patterning (Nakamura et al., 2008) via 
its signaling molecule fibroblast growth factor 8 (FGF8) under tight regulation of OTX2/Gbx2. 
Besides the expression of FGF8, WNT1, another extrinsic signaling factor, is expressed at the 
MHB and building a gradient to anterior (Figure 8). FGF2 is present during whole 
neurodevelopment (Woodbury and Ikezu, 2014). During regionalization FGF2 induces the 
formation of MHB-like tissue, indicating a dorsalizing role (Dorey and Amaya, 2010). FGF2 
suppresses forebrain markers such as OTX2 and enhances expression of MHB markers FGF8 
and WNT1 (Muguruma et al., 2015). Along the D-V axis, further specification of the developing 
mesencephalon takes place. Roof plate cells release BMP and floor plate cells sonic hedgehog 
(SHH) leading to a dual gradient, both fainting along the D-V axis. SHH in combination with 
WNT1 signaling are an important signal for SNc formation and mDA neuron determinants. 
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Figure 8: Simplified early neural patterning and midbrain specification: The neural tube closes during the 4th-
5th week post-conception. Regionalization and subdivision of the CNS starts, resulting in various brain regions. A) 
Schematic drawing of the mid-sagittal plane of the superior part of the embryo. SHH and FGF8 mainly determine 
regionalization. SHH is expressed by the notochord and the ventral neural tube of the forebrain. In parallel FGF8 is 
expressed and released by the cells at the MHB. From superior/rostral to inferior/caudal: Telencephalon, 
Diencephalon, Mesencephalon, Hindbrain, MHB – mid-hindbrain border, Notochord, Spinal cord B) Coronal plane 
of the neural tube as indicated in A, allowing visualization of a more detailed distribution of mDA neuron patterning 
factors C) Specific regionalization leads to a mDA neuron favorable niche at the most ventral side of the neural 
tube. mDA neuron progenitors ideally originate this favorable zone, expressing LMX1A, FOXA2 and TH. Orientation 
along the axes indicated. (Figure kindly provided by Lisa M. Smits, adapted from Lumsden and Graham, 1995) 
 
1.3.3. Development of midbrain dopaminergic neurons  
Dopaminergic (DA) neurons of the brain are an anatomically and functionally heterogeneous 
group involved in a wide range of neuronal network activities and behavior, using 
predominantly dopamine as a neurotransmitter. Heterogeneity, even within mDA neurons was 
recently highlighted (Gammill and Bronner-Fraser, 2003; La Manno et al., 2016), outlining the 
complexity of the dopaminergic system. An important function of mDA neurons of the SNc is 
the synthesis of the majority fraction of the brain’s dopamine (DA). DA is important for 
locomotion, cognition, affect, and emotion (Grace, 2016). mDA neurons possess robust 
autonomous pacemaker activity (Guzman et al., 2009; Pissadaki and Bolam, 2013). Groups 
of DA neurons originate at the mesencephalic/diencephalic junction and project to various 
forebrain targets. Among the different groups of mDA neurons, A9 DA (mDA) neurons are the 
best described and associated with locomotion and emotion. The ventral tegmental area (VTA, 
A10 group) contains the second group for DA neurons, associated with motivational function 
and arises more medially, as a part of the mesolimbic and mesocortical dopamine systems. 
A9 mDA neurons are considered the most relevant cell type for PD research (Arenas et al., 
2015). 
FOXA2, LMX1A, LMX1b, NGN2, MSX1/2, NURR1 and SHH were all shown to be required for 
regular A9 mDA neuron development, but only SHH and LMX1A are both necessary and 
sufficient to induce mDA neurons (Prakash and Wurst, 2006). Specification of mDA A9 
neurons in the midbrain is modulated by PAX6 expression, defined by BMP/SHH gradients 
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(Figure 8). PAX6 is another regional specifier assumed to interact with the mesencephalic 
markers EN/PAX2 in order to further define the DMB (Matsunaga et al., 2000). The ventral 
midbrain, SNc region is further specified by the expression of two homeobox proteins engrailed 
homeobox 1 and engrailed 2 (EN1/2), both activated by FGF8 (Gammill and Bronner-Fraser, 
2003; Wurst and Bally-Cuif, 2001). Other important determinants of A9 mDA neurons are 
LMX1A and FOXA2, both induced by SHH signaling. Further, expression of LMX1A triggers 
dopaminergic differentiation and recruits MSX1/2, an inhibitor of negative regulators of 
neurogenesis. MSX1 induces the expression of proneural factors such as Neurogenin 2 
(NGN2) which is necessary for the correct development of mDA neurons (Gammill and 
Bronner-Fraser, 2003). mDA progenitors migrate to exit the proliferative zone and start to 
synthesize DA, which is indicated by tyrosine hydroxylase (TH) expression activated by Nurr1 
and mDA progenitors, indicated by the expression of TUJ1 (Abeliovich and Hammond, 2007; 
Sakurada et al., 1999). A last marker important for SNc development is PITX3, an expression 
that is required for the development and survival of A9 mDA neurons of the SNc but not 
required for the A10 VTA mDA neuron development (Oliveira et al., 2017). The dopaminergic 
neuron development continues postnatal. 
 
1.4. Modeling Parkinson’s disease 
The better understanding of the developmental processes that guide the formation of the 
human midbrain is an important step towards an understanding of PD pathomechanisms. This 
knowledge also resulted in the generation of more advanced cellular PD models that allow 
targeted experimental approaches on human mDA neurons. Nevertheless, the history of 
modeling attempts in PD is long. A variety of models were utilized to study PD-associated 
pathological mechanisms (Beal, 2001; Dauer and Przedborski, 2003). PD modeling attempts 
can be divided into genetic and neurotoxin based models (Jagmag et al., 2016). Toxin based 
animal models serve as inducible models, exhibiting mDA neuron specific brain lesions post-
induction. After artificially induced brain lesion, some animal models recapitulate PD-
associated symptomatic clinical manifestation, e.g. the amphetamine 6-OHDA-Lesioned Rat 
model (Olsson et al., 1995). These models mostly serve to study recovery potential and 
pharmacological treatments to rescue the loss of cells and motor-function. Unfortunately, toxin 
based models are substantially variable, limiting the usefulness for therapeutic development 
(Beal, 2010). To that extent, the MPTP modeling in primates and mice can be seen as the best 
model, however, not reproducing Lewy-pathology. None of the toxin induced models 
recapitulates Lewy pathology (Beal, 2010). To what extent neurotoxin based models 
reproduce human-PD is controversially discussed. These models do not allow the study of PD 
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progression, and thus are only utilizable for the development of symptomatic therapies, but not 
for neuroprotective proactive treatments. 
Genetic models for PD reach from in vivo Saccharomyces cerevisiae (Khurana and Lindquist, 
2010), Caenorhabditis elegans (Harrington et al., 2010), Drosophila melanogaster (Feany and 
Bender, 2000), Mus musculus (Antony et al., 2011; Blesa and Przedborski, 2014), rattus 
norvegicus (Björklund et al., 2002), and monkeys like macaca mulatta, to diverse in vitro 
models like immortalized cell lines, primary cell cultures, and patient derived cell cultures. All 
cross species models are limited by their xenogeneic nature, as only functionally, highly 
conserved proteins can be sufficiently studied. Specifically, the central nervous systems differ 
strongly between most of these models and humans. The closest evolutionary relative to homo 
sapiens of the introduced PD models, Macaca mulatta, diverged 25 million years ago (Bakken 
et al., 2016). During these 25 million years, constant evolutionary pressure continuously 
separated homo sapiens from prehistoric ancestors (Bae et al., 2015). Apart from structural 
differences of the neural system, genetics and specifically the long post-natal 
neurodevelopment differs strongly between species (Bakken et al., 2016), exacerbating 
translatability of observations. Notably, just in 2016, the Japanese researcher Dr. Hideyuki 
Okano (Keio University) claimed to have genetically engineered monkeys to develop PD. Dr. 
Hideyuki Okano claimed that these monkeys recapitulate NMS, MS, and Lewy-pathology, all 
appearing within 3 years. Clearly an interesting model to better understand the progression of 
PD, however, the study is not yet published. 
Modeling PD in the cell culture dish started with immortalized cells. The function of PD-related 
proteins and mutations was mostly studied in over-, transient-, and mostly uncontrolled-
expression experiments, resulting in a reduced physiological relevance of the findings. Protein-
protein interaction studies or phenotyping in a not fully controlled situation in immortalized cells 
are extremely difficult to translate (Gibson et al., 2013). With the appearance of controlled, 
targeted genetic engineering tools (1.4.2. Genome editing) transient or transduced expression 
was quickly stigmatized as not ideal. However, despite being more elegant, genetic 
engineering also requires further improvements to ultimately be considered as ‘fast, clean, and 
footprint-free’ (Schaefer et al., 2017). Furthermore, patient primary somatic skin cells 
(fibroblasts) were utilized for disease phenotyping mostly in comparison to age and gender 
matched controls. In addition to not being part of the nervous system these cell cultures are 
not uniform/homogenous, hampering translatability to the nervous system. The recent 
introduction of human stem cell models and stem cell based cultures provides a unique tool 
for recapitulating PD in the dish (Mertens et al., 2016). 
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1.4.1. Patient derived iPSC 
The group of Dr. Shinya Yamanaka (Riken, Japan) introduced the conversion (reprogramming) 
of terminal differentiated mature cells to an immature primitive pluripotent stem cell state 
(Takahashi and Yamanaka, 2006). A permanent conversion was previously assumed to be 
impossible and thought to be unidirectional (Marchetto and Gage, 2012). Cellular 
reprogramming by ectopic expression of defined transcription factors results in reprogramming 
to induced pluripotent stem cells (iPSCs) and was first successfully performed using mouse 
derived cells (Takahashi and Yamanaka, 2006) and soon after in human mature skin cells 
(fibroblasts) (Takahashi et al., 2007; Wernig et al., 2007; Yu et al., 2007). iPSC are intriguingly 
similar to embryonic stem cells (ESC) of the ICM of the blastocyst, which were shown to be 
cultivable beforehand (Thomson et al., 1998). PSC (ESC/iPSC) are able to give rise to all cell 
types of the organism apart from the extraembryonic tissue (Niwa, 2007). iPSC provide a new 
way to model and investigate human in vivo development and disease (Marchetto and Gage, 
2012). PSC are specifically useful for diseases in which the tissue of interest is not accessible 
for cell extraction. 
When studying iPSC based models some small ‘weaknesses’ need to be considered. For 
example, it was shown that iPSC retain some gene expression signatures linkable to their 
origin, which could impact gene expression studies (Chin et al., 2009). The epigenetic memory 
(DNA methylation) of those iPSC was shown to preserve residuals of their somatic tissue of 
origin, accountable for the previously described gene expression effects. Linked to this, 
induced reprogramming efficiency is strongly modulated by several factors e.g. donor age, 
terminality of cells and the methylation state (Kim et al., 2010). Within the epiblast of the post-
implantation blastocyst, different kinds of stem cells exist, naïve and primed (Nichols and 
Smith, 2009). Pluripotency is a transient state and only homogenously represented by 
epiblasts of pre-implantation blastocysts (surrounded by trophoblast (future extraembryonic 
tissue) and hypoblast) (Plusa and Hadjantonakis, 2014). This state is defined as the naïve 
ground state of pluripotency (Arnold and Robertson, 2009). Stem cell priming also appears in 
vitro (Gafni et al., 2013). Priming of iPSC cultures results in lineage restriction (Weinberger et 
al., 2016), a restriction that was shown to be reversible (Gafni et al., 2013; Theunissen et al., 
2014). Maintaining naïve PSC for a long time at the most primitive PSC state was recently 
shown to also bear pitfalls, permanently altering DNA methylation and restricting 
developmental potential, specifically when using MEK inhibition (Choi et al., 2017; Yagi et al., 
2017; Zwaka, 2017). However, since PD is an age-dependent disease, the biggest 
‘disadvantage’ of modeling PD using iPSC based models is the rejuvenation of the cell 
material, resulting in cells mapping to human embryonic development (Mariani et al., 2012). 
Researchers try to overcome this problem now, either by artificial aging iPSC based material 
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(Miller et al., 2013) or by direct reprogramming, avoiding rejuvenation by avoiding the 
pluripotent stem cell step (Han et al., 2012). Another approach to overcome this issue is 
transdifferentiating (lineage reprogramming) (Graf and Enver, 2009; Orkin and Zon, 2008). 
Though, transdifferentiation was not yet utilized in the context of PD research. Another clear 
disadvantage of current reprogramming methods is the clonal step during picking, introducing 
a loss of genetic diversity of donor material (Mertens et al., 2016). Researchers now bring 
iPSC based models closer to humans by using 3D-cultures, better recapitulating the in vivo 
conditions (Kelava and Lancaster, 2016; Lancaster et al., 2013; Monzel et al., 2017).  
iPSC based technologies hold great promise for PD-research and iPSC from PD patients have 
already been derived several times (Cooper et al., 2012; Gammill and Bronner-Fraser, 2003; 
Reinhardt et al., 2013a). Patient specific autologous or human leukocyte antigens (HLA) 
perfectly matching allogeneic cells are good tools for cell replacement strategies, avoiding 
immunosuppression necessary in non-matched allogenic situations (Okita et al., 2011). Even 
though phenotyping PD in 2D cell culture systems is already meaningful, current developments 
are going to bring phenotyping and the translatability of results closer to an in vivo situation, 
allowing better recapitulation of complete PD progression in the ‘dish’. 
 
1.4.2. Genome editing  
The meaningfulness of any experiment is strongly dependent on an appropriate control, for 
iPSC based models this means an age and gender matched control individual, ideally of the 
same ethnicity. However, this approach also bears a likelihood for false-positive/negative 
results. This problem can either be overcome by increasing the number of cell lines or by using 
a smaller set of iPSCs, including genome edited isogenic controls (Germain and Testa, 2017). 
Genome editing describes the introduced, stable, targeted, and permanent manipulation of a 
genomic DNA of choice. DNA bases in the targeted locus can either be replaced, inserted, or 
deleted. Besides, theoretically, any ‘DNA-cargo’ up to a certain size (bp), can be directed to a 
previously specified position in the genome, allowing controlled ectopic expression driven by 
an artificial designer-promoter, e.g. in a ‘safe-harbor’ (Hockemeyer et al., 2009, 2011), as 
applied in the high-throughput analysis of autophagy and mitophagy in the context of this 
thesis. Genome editing presents a new opportunity to create isogenic in vitro models for 
phenotyping purposes, but also shows potential for therapeutic interventions in vivo. 
Genome editing tools comprise of the targeted induction of DNA double strand break (DSB) 
into DNA followed by a manipulation of choice at that targeted position. Up to now, three major 
engineering systems: Zinc-finger nuclease (ZFN), Transcription activator-like effector (TALE) 
nuclease (TALEN) and Clustered regularly interspaced palindromic repeats (CRISPR) 
                                                                                                                                 Introduction 
 
                                                                                                                                                  29 
associated (Cas) systems (CRISPR/Cas) have been utilized to induce specific DSB in genomic 
DNA (Figure 9). None of the methods is ‘perfect’ and the development of less cost/labor 
intensive, more specific, and efficient nucleases is still ongoing (Carroll, 2016). ZFN and 
TALEN both combine the guide with a rather non-specific DNA cleavage domain (Fok1). 
CRISPR/Cas based editing, introducing the DSB via more specific Cas, is currently the best 
choice, lacking the Fok1-induced off-target effects. DSB activates DNA repair pathways, 
including non-homologous end joining (NHEJ) and homology-directed repair (HDR), which can 
be used for different purposes in the context of genome editing (Stracker and Petrini, 2011) 
(Figure 9). NHEJ requires the recruitment of Ku70/80, DNA ligase IV (LIG4), XLF and XRCC4 
(Mari et al., 2006). It can take place throughout the cell cycle without the need of a homologous 
DNA template. NHEJ is very likely to cause unspecific small insertions or deletions, resulting 
in frameshift and gene knock-out (Gaj et al., 2013). Thus, NHEJ can be used to engineer gene 
knock-out as a more reliable replacement for RNAi technologies. In contrast, HDR only occurs 
in S and G2 phases of cell cycle when a homologous template is available (Dehé and Gaillard, 
2017). Although the frequency of HDR is 1000 times less than that of NHEJ due to its complex 
multi-step machinery, HDR is more specific and less prone to the disadvantages of NHEJ 
(Vasquez et al., 2001). The process of exchanging genetic materials between the target DNA 
and homologous templates during HDR allows to introduce modification of choice though an 
appropriately designed donor DNA template (Ding et al., 2013). So far, all applied methods still 
bear the risk of off-targets like unsolicited indels (point mutation) or unspecific random 
integration in the genome (Wang et al., 2015), requiring excessive control steps. 
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Figure 9: Current state of targeted DSB induction and DSB repair methods. DSB in the DNA, the starting point 
of genome editing is currently initiated using three different methods, here in chronological order of appearance. 
Zinc-finger nuclease (ZFN), transcription activator-like effector (TALE) nuclease (TALEN) and CRISPR-Cas. 
Endogenous DSB repair mechanisms are important for targeted specific manipulation, here non-homologous end 
joining (NHEJ) and homology-directed repair (HDR). NHEJ is mostly used for gene knock out experiments. HDR is 
the current method of choice for targeted manipulations, even of single nucleotides. (sg-RNA, single guided RNA) 
(adapted from Yin et al., 2017). 
Using edited isogenic cell lines allows more precise phenotyping in the context of PD. This 
approach diminishes the uncertainty of studying individual PD-unrelated phenotypes instead 
of PD-associated phenotypes. Previously, PD-phenotyping was based on the comparison 
between healthy controls and patient cells with mutation, sometimes even only of one 
healthy/PD pair (Skibinski et al., 2014). Genome-edited isogenic pairs ensure the validity of 
the observed phenotypes, which are directly linkable to a monogenic PD-associated mutation 
independent of genetic background variations. ZFN-mediated editing of LRRK2-G2019S was 
shown to sufficiently induce or reverse PD-associated phenotypes (Reinhardt et al., 2013a; 
Sanders et al., 2014). Further, it is specifically useful for the dissection of susceptibility factors 
in the genetic backgrounds of patients, accountable e.g. for penetrance variations of PD-
associated variations. 
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1.4.3. In vitro neural stem cells 
Probably the best way of recapitulating neurodevelopment in vitro is starting at its basis, the 
neural fold (Figure 7, Figure 10). During the development of the mammalian central nervous 
system, only multipotent neuroepithelial stem cells (NESCs) are the ultimate embryonic 
lineage precursors/progenitors, accountable for the major expansion of the CNS (Kriegstein 
and Alvarez-Buylla, 2009). The term NSCs encompasses all cell stages possessing the ability 
to proliferate, self-renew, and give rise to all cell types of the neural lineage (Gage, 2000). For 
long, it was assumed that neurodevelopment stops with birth and NSC are not existent 
afterwards. The first hints showing the existence of proliferative cells post-natal was delivered 
in 1963 by J. Altman in rats and cats (Altman, 1963). It took almost half a century, until 1998, 
till the group of Dr. Fred H. Gage (Salk Institute, USA) verified this for humans (Eriksson et al., 
1998), showing the stable maintenance of distinct niches of NSC in the human adult brain. As 
introduced (1.3.), the majority of developmental NSC stages are transient. However, three/four 
main categories can be defined during embryonic development and within the adult 
brain: Neuroepithelial (progenitor or) stem cells (NESC) and Rosette-type NPCs, both at the 
neural-plate-tube, and further, early and late radial glial(-like) NPCs within fetal and adult brain 
(Conti and Cattaneo, 2010; Götz and Huttner, 2005; Mertens et al., 2016) (Figure 10). 
In vitro neural stem cell cultures were not existing before 1992, when the first protocols for 
maintaining mouse primary embryonic and adult NSC in the dish were published (Reynolds 
and Weiss, 1992; Reynolds et al., 1992). The following evolution of in vitro NSC cultures was 
highlighted by Conti and Cattaneo, 2010. Here, only a few achievements are introduced. After 
the establishment of ESC in vitro maintenance conditions (Evans and Kaufman, 1981; Martin, 
1981) the first in vitro NSC derivation and culture protocol from mouse ESC was established 
only 15 years after (Okabe et al., 1996). Due to the known signaling cues, the derivation and 
establishment of human ESC (Thomson et al., 1998) deriving neural stem cells was 
substantially faster (Reubinoff et al., 2001; Zhang et al., 2001). In the meantime NSC derivation 
protocols were continuously improved, resulting in low-cost maintenance of more primitive 
NSC via small molecules (Reinhardt et al., 2013b). The protocol allows the maintenance of 
cell at a NESC stage that can be clonally directed to differentiate into neural tube and neural 
crest lineages, including both peripheral neurons and mesenchymal cells, a potency or 
plasticity usually only matched by PSC. The latter protocol was applied throughout all studies 
summarized in this thesis. However, we are continuously trying to improve the protocol, 
maintaining high proliferation rate with further improved mDA-specific pre-patterning. The 
protocol used utilizes double SMAD inhibition (Chambers et al., 2009)(1.4.4. In vitro midbrain 
patterning and dopaminergic neurons derivation) and subsequent SHH/WNT pathway 
modulation for regionalization (ventralization/opposing SHH signaling - expansion) in the 
                                                                                                                                 Introduction 
 
                                                                                                                                                  32 
presence of retinoic acid (RA) (Jacobs et al., 2006) allowing stable maintenance while 
maintaining neural plate border identity. 
Figure 10: hPSC based human in vitro neurodevelopment recapitulation and in vivo counterparts. Mapping 
in vitro cell types to actual in vivo counterparts is difficult without direct comparison. Mapping is mostly based on 
lineage restrictions and similarly potent in vivo counterparts. The plasticity of transient in vivo neural stem cell states 
substantially increases the likelihood of the existence of a similar counterpart (Conti and Cattaneo, 2010). Mertens, 
Gage et alia applied the depicted classification and mapping of in vitro neural stem cell like material. The pluripotent 
stem cells stage (iPSC/ESC) is easily mappable to in vivo PSCs of the blastocyst’s ICM. Neuroepithelial NPSs or 
neural plate border stem cells have the potential to develop the CNS and PNS. Only NSCs at the neural plate 
possess are capable of developing towards PNS. Rosette-type NPCs appear after neurulation when the neural 
tube closed, they are more restricted and lost capability to develop into PNS but are capable to develop to neurons 
and glia. In vitro radial glia(-like) NPCs are even more restricted and only give rise to postmitotic neurons, 
resembling the NSCs of the residual neural stem cell niches of the developed brain (SVZ, DG). (adapted from 
Mertens et al., 2016) 
In the periphery of PD research NSC in vitro cultures are specifically valuable for 
understanding the effect of PD-associated mutations e.g. LRRK2-G2019S at an early NSC 
stage (Liu et al., 2012). In vitro NSC allow to recapitulate the in vivo neurodevelopmental cell 
conversions, and thus, the detection of altered neurodevelopment, e.g. to neuronal lineage 
(Figure 10). Further, iPSC derived NSC are a valuable tool for cell replacement therapies, 
allowing flexible integration after transplantation in an in vivo context (Gage et al., 1995; 
Reinhardt et al., 2013b). 
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1.4.4. In vitro midbrain patterning and dopaminergic neurons derivation 
With the appearance of PSC technologies researchers focused on disease recapitulation, 
directing PSCs into any kind of disease associated tissues. For PD research this made 
phenotyping of patient derived mDA neurons (Perrier et al., 2004) possible and opened up a 
new source for cell replacement therapies (Kirkeby et al., 2017; Steinbeck and Studer, 2015).  
To mimic in vivo neurodevelopment, as a first step for directing PSCs to neural lineage, neural 
induction had to be recapitulated. Neural induction is now efficiently recapitulated via dual 
SMAD inhibition (dSMADi), allowing effective PSC to neural conversion with high efficiency to 
neuroectodermal lineage, avoiding mesoderm and ectoderm (Chambers et al., 2009). dSMADi 
is achieved via blocking bone morphogenic protein (BMP) receptor binding (SMAD1/5/8) 
complemented by inhibition of TGFβ receptor induced pathways (SMAD2/3/4). After dSMADi 
cells need to be directed along A-P, D-V, and rostro-caudal axis within the hypothetical neural 
tube, to achieve utmost midbrain specific regionalization within the future brain. 
Regionalization is achieved by using neurodevelopmental patterning factors. For midbrain 
specificity, patterning and further direction to mDA neurons, the following characteristics need 
to be achieved: 1. Cells originating from the floor plate of the ventral mesencephalon (VM-
progenitors) (Arenas et al., 2015), giving rise to mDA neuron progenitors expressing LMX1A, 
FOXA2, and OTX2 (Doi et al., 2014; Kirkeby et al., 2017; Kriks et al., 2011). Ventralization 
along D-V axis is usually achieved via SHH pathway activation. 2. Patterning along A-P axis 
can be achieved via WNT pathway activation 3. Evaluation of rostro-caudal patterning revealed 
that caudalization of VM is essential, achieved via FGF8b substitution. 4. Temporal pattern of 
substitution of regionalization factors is crucial. 5. Once cells are successfully pre-patterned to 
mDA progenitors (Figure 10). Maintenance and successful maturation of mDA neurons in vitro 
using factors like: TGFb3, dcAMP, hGDNF (Rolletschek et al., 2001; Young et al., 2010), RA 
(Yan et al., 2001), and hBDNF (Swistowski et al., 2010). 
Without doubts, PSC based in vitro mDA neuron modelling is not yet at its final stage. The 
here mentioned, most commonly used protocols, all start from PSC stage and thus are long 
and laborious. The underlying concept of the protocol applied throughout this thesis is to 
shortcut and allow more precise regionalized pre-patterning (Reinhardt et al., 2013b). The goal 
of all protocols is the efficient derivation of high numbers of post-mitotic mature A9-mDA 
neurons expressing: LMX1α, FOXA2, NR4A2 (NURR1), PITX3, DAT, ALDH1 and TH positive 
mDA neurons (Gale and Li, 2008). 
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2. Motivation and aims 
In the field of PD research the scientific community mostly focuses on the omnipresent mDA 
neuron degeneration as one of the major neurodegenerative hallmarks of PD. This focus 
persists when it comes to modeling PD in the dish or in vivo (Langston, 2006). Approaching 
PD that way is narrowing the research focus considerably, mostly neglecting pre-/extranigral 
PD-associated phenomena. Braak and colleagues suggest a start of PD progression in the 
olfactory bulb and brainstem, and nigral pathology appearing only later, in the mid-phase of 
the disease (Braak et al., 2001, 2003). Interestingly, Lewy pathologies are not exclusively 
nigral and even present in the peripheral nervous system (Jager and Bethlem, 1960; 
Wakabayashi and Takahashi, 2008). These results and the fact that some NMS are hardly 
linkable to nigral pathologies, initiated a slow paradigm change. It is now accepted that 
progressive neurodegeneration of mDA neurons is rather the ultimate consequence of a long 
and slow PD-progression and very likely not an fundamental initiator (Przedborski, 2017; 
Schapira et al., 2017). Consequently, the fundamental question formulated by Dr. William C. 
Koller: ‘When does Parkinson’s disease begin’ is not yet answered (Koller, 1992). This implies 
that major parts of PD-aethiology are not sufficiently understood yet. 
In the periphery of PD α-synuclein (Garcia-Reitboeck et al., 2013) and LRRK2 (Sweet et al., 
2015) have been both linked to neurodevelopment in mouse models, altering the brains’ 
cytoarchitecture. These facts leave the door wide open for the question: ‘Is there an early 
predisposition forming an anlage of PD and where is PD factually starting?’. Work from several 
labs, including ours, indicates mutant LRRK2 as an trigger that alters adult (Winner et al., 
2011a), but also embryonic neural stem cells (Bahnassawy et al., 2013; Liu et al., 2012; 
Sanders et al., 2014). Findings that strongly point at a neural stem cell problem related to PD. 
Since neural stem cells are the most important entities in central nervous system development, 
and PD linked mutations show an effect in these cells, we speculated that an altered 
neurodevelopment could be part of the predisposition to PD. We hypothesized that, if there is 
such predisposition existing in PD, this needs to manifest in distinct phenotypes in vitro. 
Consequently, the fundamental question addressed in this thesis was ‘Is Parkinson’s disease 
factually a neurodevelopmental disorder?’. Taking the incidences together, we formulated our 
main hypothesis: 
 
Main hypothesis: 
“Parkinson’s Disease-associated LRRK2-G2019S impacts the embryonic 
neurodevelopment, resulting in an early predisposition to PD” 
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2.1. Aims: 
1. Verify human iPSC based NESCs as a meaningful model for PD.  
2. Verify, identify, and extend NESC stage phenotypes. 
3. Dissect LRRK-G2019S dependency of these phenotypes. 
4. Investigate how the NESC stage phenotypes influence in vitro neuronal 
differentiation, resembling neurodevelopment. 
5. Identify cellular and molecular mechanisms underlying these phenotypes 
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3. Results 
The four manuscripts summarized in my thesis cover different topics, all in the context of 
Parkinson’s Disease and life-sciences. Manuscript 1 (M1) and Manuscript 2 (M2) have the 
same impetus, both aim at elucidating a potential neurodevelopmental contribution to 
Parkinson’s disease. For any disease an early alteration from a developmental blueprint 
displays a first potential negative interference, for other neurologic disease such interference 
was already shown to be disease triggering. Both manuscripts try to identify if such early 
alteration actually exists in Parkinson’s Disease. Further proof in this direction would be from 
fundamental importance, since the question about the start or origin of Parkinson’s Disease 
has not been answered yet. To gain further proof, we based both studies on stable 
neuroepithelial stem cells at the neural plate border, an early neurodevelopmental model, and 
their transition to midbrain dopaminergic neurons. In Manuscript 1 we showed that, starting 
from a neuroepithelial stem cell state, the in vitro transition to dopaminergic neurons is altered 
in a LRRK2-G2019S-dependent manner. Such direct effect on dopaminergic 
neurodevelopment was not yet shown before. Importantly, we were able to show that the 
changes are the result of alterations already taking place in the neuroepithelial stem cells. In 
Manuscript 2 we mainly focused on the alterations taking place in the stable neuroepithelial 
stem cells itself. In contrast to Manuscript 1, this study covered more the LRRK2-G2019S 
specificity of the observed phenotypes, identifying the genetic background contributions to the 
phenotypes. Essentially, the study highlights that the detected changes in gene expression are 
mostly related to neurodevelopment. 
In contrast, Manuscript 3 (M3) and Manuscript 4 (M4) aim clearly at advancing the current 
state of the laboratory techniques applied. Overcoming technical limitations to finally answer 
important research question is an omnipresent problem in any sciences. Manuscript 3 was 
driven by the limitations of the currently most commonly applied techniques for studying 
mitophagy and autophagy. The latter biological processes are both reported to be 
dysfunctional in Parkinson’s Disease. For this purpose we advanced an already available dual- 
fluorophore based monitoring system by targeting its genomic integration, as well as controlling 
its expression. Noteworthy, in a small set of edited PD-iPSC the PD-related pathway limitations 
were already visible. Further, the detailed study of any disease-related mutation requires 
genomic edited isogenic controls for best practice result validation. Genome editing to obtain 
isogenic controls is specifically tricky and particularly labour-intensive. In Manuscript 4 we 
further advanced Crispr-CAS9-based genome editing in an FACS-assisted approach. Our 
newly developed approach dramatically facilitates the success of genome editing of most loci 
tested and represents a highly valuable tool for future projects. 
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3.1. Manuscript I 
‘Genetic forms of Parkinson’s Disease prime neural stem cells and 
alter neurodevelopment’ 
 
Jonas Walter1, Paul M.A. Antony1,6, Sarah L. Nickels1,2,6, Suresh Kumar Poovathingal1,6, Luis 
Salamanca1, Stefano Magnin1, Rita Perfeito4, Frederik Hoel3, Xiaobing Qing1, Javier Jarazo1, Jonathan 
Arias-Fuenzalida1, Tomasz Ignac1, Anna Monzel1, Laura Gonzalez-Cano1,6, Silvia Bolognin1, Luis 
Almeida4,5, Alexander Skupin1, Karl Johan Tronstad3, Jens C. Schwamborn1 
1 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Belvaux, 
Luxembourg 
2 Life Science Research Unit (LSRU), University of Luxembourg, L-4362 Belvaux, Luxembourg 
3 Department of Biomedicine, University of Bergen, Bergen, 5020, Norway 
4 CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Rua Larga, Coimbra 3004-504, 
Portugal 
5 Faculty of Pharmacy, University of Coimbra, Coimbra 3000-548, Portugal 
6 These authors contributed equally 
Status: The manuscript preparation is ongoing, I am preparing the story for Cell (Cell Press) 
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3.1.1. Preface 
This was the main project of my PhD. Here we followed our initial impetus, introduced in the 
objectives and aim section. We were able to verify our hypothesis and detected strong 
alterations of in vitro neurodevelopment in LRRK2-G2019S NESC. There alterations might 
predispose to develop PD during adulthood. Neurodevelopmental phenotypes manifest in 
stem cell problems at the NESC stage (Figure1-7; pages 67-73) and an altered transition to 
mDA neurons (Figure 1-4; pages 67-70). 
I did the initial reprogramming and characterization of some of the used iPSC. I further 
generated of some of the NESC lines we utilized. I did the stocking and characterization of 
NESCs in collaboration with Sarah L. Nickels. I further did all cell culture related work, 
established the relevant assays for NESCs screenings, and screened the cells. I processed 
and plotted the resulting data of experiments. I provided the samples for and contributed to the 
data analysis and interpretation of single cell RNA sequencing and mitochondrial 3d 
morphology analysis. I used the resulting graphs for final figure composition. Most of the work 
would not have been possible without the further substantial contribution by and collaboration 
with others. In collaboration with Paul Antony we performed extensive high content screening 
(HCS) image analysis after independent assay design and HCS image acquisition. We based 
the analyses of the mDA differentiation phenotype on scripts resulting from the collaboration 
with Silvia Bolognin and further developed analyses for Ki-67, c.PARP. Together with Paul 
Antony we further analyzed the NESC stage. In this context we developed HCS analyses for 
mitochondrial morphology, lysosomal morphology via LAMP2, mature lysosome morphology 
analysis via acidotrophic LysoTracker in live staining. The 3d mitochondrial morphology 
analysis was performed by Karl Johan Tronstad and Frederik Hoel, experts on 3d-imaging 
quantification. HCS and 3D-based analysis approaches of mitochondrial morphology verified 
each other, with more details revealed in 3D. Single cell RNA sequencing was done in 
collaboration with Suresh Kumar Poovathingal. The success of scRNA sequencing analysis 
would not have been possible without the great contribution of Luis Salamanca, Stefano Magni, 
Tomasz Ignac, and Alexander Skupin. To complete our analyses on ALP pathway we started 
an additional collaboration with Rita Perfeito and Luis Almeida, experts on autophagy analysis. 
Together, we confirmed limitations of ALP in NESCs already at the level of autophagosome 
formation. Collaborators from our laboratory helped me with technical problems, assay design, 
and gave substantial input relevant for the success of the project. Jens C. Schwamborn 
supervised and guided the project, added new aspects, and had the initial research idea. In 
this case it was a truly interesting experience for me to combine so many state-of-the-art 
techniques and to team up with numerous collaborators. 
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3.1.2. Manuscript 
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Figure 1:  
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Figure 2: 
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Figure 3: 
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Figure 4: 
  
                                                                                                                                        Results 
 
                                                                                                                                                  72 
Figure 5: 
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Figure 6: 
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Figure 7: 
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3.2. Manuscript II 
‘The genetic background of Parkinson’s disease complements 
LRRK2 pathogenicity in neural stem cells’ 
 
Sarah Louise Nickels1,2, Jonas Walter1, Silvia Bolognin1, Christian Jaeger1, Xiaobing Qing1, Johan 
Tisserand1, Javier Jarazo1, Kathrin Hemmer1, Amy Harms3, Paul M.A. Antony1, Enrico Glaab1, Thomas 
Hankemeier3, Christine Klein4, Lasse Sinkkonen2, Thomas Sauter2, Jens C. Schwamborn1 
 
1 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Belvaux, 
Luxembourg 
2 Life Science Research Unit (LSRU), University of Luxembourg, L-4362 Belvaux, Luxembourg 
3 Leiden Academic Centre for Drug Research (LACDR), Analytical Biosciences, Leiden University, NL-
2333 CC Leiden, Netherlands 
4 Institute of Neurogenetics, University of Luebeck, D-23538 Luebeck, Germany 
Status: submitted to Developmental Cell (Cell Press) 
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3.2.1. Preface 
Here my colleague Sarah Louise Nickels followed a similar impetus and further dissected the 
LRRK2-G2019S effect at the NESC stage. In her study she included some of the NESC lines 
I derived. We initially identified a reduced viability of NESCs in the presence of LRRK2-
G2019S. She pursued this phenotype and was able to verify a LRRK2-G2019S’ impact on 
NESC viability. While doing so she verified not only the LRRK2-G2019S specific viability 
phenotypes, but also detected a contribution of the PD-patient specific genetic background to 
the phenotypes (Figure 2g,h & 3b,c, page 145). This was only possible by the utilization of 
genetically engineered LRRK2-G2019S corrected patient lines. She identified the patient 
genetic background as the main contributor to the gene expression changes detected via 
microarray, with no major changes upon insertion or correction of LRRK2-G2019S (Figure 4, 
page 149). Correcting the mutation was not sufficient to rescue viability and self-renewal 
phenotypes at NESC state (Figure 2, 3; page 146-7). Incomplete introduction or rescue of the 
phenotypes was also visible in my manuscript (M1, Figure 7G, H; page 73), but not in the main 
focus. In her microarray analysis she identified serine racemase (SRR) as being 
downregulated in PD-LRRK2-G2019S-patients, and only partially being dependent on the 
LRRK2-G2019S (Figure 4g; page 149). Thus, serving as a genetic background susceptibility 
factor. qPCR verification verified approximately a 50% expression level in comparison to the 
control level. SRR catalyzes the conversion of L-serine to D-serine. D-serine metabolism is 
involved in several neurodegenerative diseases and neurodevelopment. Further, SRR is 
regulating apoptosis and necrosis. Accordingly, metabolic analyses verified L-Serine 
accumulation in PD-patients (Figure 5; page 149). Patient data verified this as a LRRK2-
G2019S specific phenotype. D-Serine supplementation of the media was sufficient to rescue 
the viability and self-renewal phenotypes (Figure 6; page 150). Rescue attempts with D-Serine 
had no effect on neuronal differentiation dynamics. Thus, D-Serine was unfortunately not 
interesting for a pharmacological rescue of the phenotypes in manuscript 1.  
My main contribution to this project was the establishment of the initial NESC cell death 
phenotype in LRRK2-G2019S NESCs. I was substantially involved in the generation of 4 iPSC 
lines used throughout the study and I derived seven of the 19 NESC lines used. 
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3.2.2. Manuscript 
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3.3. Manuscript III 
‘Automated high-throughput high-content autophagy and mitophagy 
phenotyping in Parkinson's disease’ 
Jonathan Arias-Fuenzalida
1,2,5,6, Javier Jarazo1,2,6, Jonas Walter1,2,6, Gemma Gomez-Giro1,2,4, 
Julia Forster
1,3, Paul M.A. Antony1,3,7 & Jens C. Schwamborn1,2,7 
 
1 Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg, 7 avenue des Hauts-Fourneaux 
2 Laboratory of Developmental and Cellular Biology 
3 Laboratory of Experimental Neurobiology 
4 Max Planck Institute for Molecular Biomedicine, Laboratory of Cell and Developmental Biology, Roentgenstrasse 20, 
Muenster, Germany 
5 Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan 
6 Authors equally contributed to this article 
7 Correspondence should be addressed to P.A. (paul.antony@uni.lu) and J.S. (jens.schwamborn@uni.lu) 
Status: submitted to Journal of Autophagy (Taylor & Francis) 
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3.3.1 Preface 
One of the initial research tasks described in my PhD project was to study mitophagy. It turned 
out that most of the methods applied in literature for analyzing mitophagy deliver only 
indications of such events, without any definite proof. Thus, we develop a more reliable tool to 
study mitophagy with sufficient robustness, not only delivering indications but real proof. While 
reviewing the literature I got the idea to utilize a so called Rosella-sensor system that was 
applied before on human cells (Sargsyan et al., 2015). However, no one, so far, has applied 
controlled and targeted ectopic expression of the Rosella or similar systems. This is exactly 
what we did; we combined two available systems TALEN genome editing and the Rosella-
reporters for mitophagy and autophagy (Figure 1, page 188). The Rosella system is a dual-
fluorophore system of RFP and pHluorin (eGFP derivative). The latter is efficiently quenched 
in low pH environments like inside a lysosome (Figure 1). The system can be tagged in 
principle to any kind of protein of choice. Here mitochondrial complex V: ATP synthase 
subunits (ATP5C1) and autophagosomal microtubule associated protein 1 light chain 3 alpha 
(LC3) were tagged. After fusing the systems we nucleofected them first in one control iPSC 
line, with good success. We expanded iPSC and purified reporter expressing cells in two FACS 
rounds. Subsequent imaging confirmed purity of resulting culture of stably 
autophagy/mitophagy reporting iPSCs (Figure 1). We then extended the approach to three 
PD-patient lines carrying different mutations associated with PD and in parallel established the 
image analysis in collaboration with Paul Antony (Figure S1, S2; page 205-206). In the 
following we performed several imaging rounds and confirmed the validity of the system. We, 
in addition to basal levels, applied different modulators of autophagy and mitophagy inducers. 
Our results (Figure 2-6, pages 188-191) in combination with lysosome analyses (Figure 4, 
page 189) highlighted the ALP as a commonly shared pathological feature of PD, even at a 
primitive PSC-stage. 
Here I contributed with the initial idea of utilizing the Rosella-sensors applied throughout the 
study. For me, it was specifically important to have a readout for autophagy and mitophagy 
that was not just an indication, not leave any space for doubts about the results and 
interpretations. I contributed to the discussions about the strategy of how to deliver the system 
to the cells, resulting in the approach of generating stable reporter lines. I reprogrammed and 
characterized two of the four iPSC lines utilized in this project. I contributed to the conceptual 
design of the screening applied on the cells and helped with the experiments. I performed 
some image acquisitions which we used for this manuscript. I contributed to the numerous 
discussions in the context of this study. 
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3.3.2. Manuscript 
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3.4.1 Preface 
In this manuscript we developed a deterministic genome editing approach. We termed this 
technique FACS-assisted CRISPR/Cas9-mediated genome editing (FACE). Our strategy uses 
dsDNA donors containing fluorescent protein markers allowing the rapid screening of biallelic-
edited cells. The approach utilizes a pair of donors, each with a different fluorescent-proteins-
coding sequence (EGFP or dTOMATO) and a linked mutation or single nucleotide 
polymorphism aimed to each allele. Dependent on the design of the donor template, editing 
success is directly assessable using fluorescence based screening. Furthermore, FACS can 
be used to enrich one of the marker combinations. Using this strategy, two donors with a 
defined genotype combination can enter in each allele of the same gene. This strategy allows 
external screening of internal events, indicating bi-allelic integration. To detect random 
integration, which occur in any type of genome editing approach, a third fluorescent marker 
was placed in the backbone of the donor plasmid to select against random integration. We 
used the FACE method to generate isogenic hiPSCs that were precisely mutated with either 
A30P, A53T in α-synuclein, or I368N in PINK1. We were able to successfully edit the iPSC, 
purify them, and quality control them. For phenotype recapitulation, we derived NESC and 
performed mitochondrial activity analysis as a proof of concept (Figure 4, page 238). We 
successfully recapitulated the PD associated mitochondrial phenotypes previously described 
for the A53T α-synuclein mutation (Ryan et al., 2013). My main contribution was the 
recapitulation of the PD-associated mitochondrial phenotypes. 
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3.4.2. Manuscript 
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4. Discussion and perspectives 
The fundamental question addressed in this thesis was ‘Is Parkinson’s disease factually a 
neurodevelopmental disorder?’. The theory of a contribution of the neurodevelopment to the 
vulnerability to PD is relatively young, but can be considered of utmost importance for a better 
understanding of PD-aethiology and progression. If such a theory turns out to be true, this 
could induce a complete rethinking of PD as an age-related disease and induce a paradigm 
shift, being even beneficial for other diseases. Furthermore, a neurodevelopmental 
contribution to PD would have tremendous implications for the development of proactive 
treatment strategies. It is accepted that nigral neurodegenerative pathologies start not until the 
early-mid phase of PD-progression while clinical MS appear even later (Schapira et al., 2017). 
Nonetheless, the question of when Parkinson’s disease begins has not yet been answered, 
even a quarter of a century after being formulated (Koller, 1992). This fact highlights that the 
current way of approaching PD might not necessarily be the best one. Additionally, the focus 
of PD research, in general, could be wrong – being too focussed on late nigral pathologies that 
are not the ultimate start and underlying triggers of PD. 
Providing a theoretical answer to the question formulated by Dr. William C. Koller: ‘When does 
Parkinson’s disease begin’, was the main impetus behind our research efforts, in the hope to 
contribute to a better understanding of the PD-aethiology. In literature, the 
neurodevelopmental approach we followed does not have much support yet, mostly adult 
neurogenesis has been highlighted so far (Le Grand et al., 2014; Marxreiter et al., 2013). In 
the context of a neurodevelopmental aspect, two reported findings were specifically important. 
First, the observation of an increased number of mDA neurons in the olfactory bulb of post-
mortem brains of PD-patients, indicated a different cytoarchitectural composition in humans 
(Huisman et al., 2004). And secondly, a study of an α-synuclein knock out in a murine model 
highlighted the neurodevelopmental role of α-synuclein in the development of the nigral mDA 
neuron niche (Garcia-Reitboeck et al., 2013). Since mDA neurons are maintained by complex 
interactions with astrocytes, oligodendrocytes, and microglia, an alteration from a certain 
homeostasis could critically create more vulnerable niches within the brain, like the SNc. 
Following our initial research hypothesis, we were able to further prove an effect of LRRK2-
G2019S on a neuroepithelial embryonic stage highlighting a potential contribution to the early 
neurodevelopment. 
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4.1. NSC and neurodevelopment in PD 
During the development of the mammalian central nervous system, multipotent neuroepithelial 
stem cells (NESCs) are the ultimate embryonic neural lineage precursors (Gage, 2000). 
Increasing evidence indicates a link between embryonic neurodevelopment and the onset of 
PD. During the development, NSC stages are considered as being rather transient as different 
kinds of NSCs are present throughout the whole neurodevelopment. The adults’ neural stem 
cell niches in the subventricular zone (SVZ) and the dentate gyrus (DG) are maintained 
throughout the whole life span (Eriksson et al., 1998). Both adult neural stem cell niches 
originate from embryonic neurodevelopment (Fuentealba et al., 2015). Adult neural stem cell 
deregulations were reported as part of extranigral pathologies of PD (Curtis et al., 2007; 
Höglinger et al., 2004). LRRK2-G2019S is associated with neural stem cell problems of adults 
(Winner et al., 2011a) and embryonic neural stem cells (Bahnassawy et al., 2013; Liu et al., 
2012; Sanders et al., 2014). In the adult brain, neural stem cell pools are maintained but are 
not as potent as neuroepithelial stem cells. The research community is not yet entirely sure 
about the human in vivo implications and the translation of the LRRK2-G2019S associated 
neural stem cell dysfunctionalities. The question remaining now is if the stem cell pool is 
already, inherently formed smaller during embryonic neurodevelopment, or simply declines 
faster. From our findings on NESCs, it is not possible to draw a final conclusion on this question 
yet. However, we are clearly able to confirm the neural stem cell problem related to LRRK2-
G2019S. In which form this phenotype is present also in vivo only future studies are going to 
be able to answer. 
After the recapitulation of LRRK2-G2019S related neural stem cell alterations, we monitored 
the transition from NSC to neuron. The question here was if there were any indications present 
supporting the hypothesis of an altered embryonic neurodevelopment. The approach was 
mainly based on the idea that the alteration of NSC almost mandatorily needed to have further 
impacts on cellular transitions. The idea was further fueled by the findings that a knock out of 
α-synuclein results in a different embryonic manifestation in the composition of the SNc, with 
less mDA neurons present (Garcia-Reitboeck et al., 2013). Further, there was the indication 
of an increased number of mDA neurons in olfactory bulbs of post-mortem brains of PD-
patients (Huisman et al., 2004). Specifically the latter finding is surprising, since the adult OB 
is fueled by the rostral migratory stream (RMS), connecting SVZ and olfactory bulb. In humans, 
the RMS is only highly active very shortly post-natal (18 months) (Sanai et al., 2011) and is 
afterwards basically absent (Wang et al., 2011). Thus, these cytoarchitectural alterations, with 
more mDA neurons present, are likely already made during early neurodevelopment, latest 
when the RMS stops being active. The results we obtained support the hypothesis of an altered 
embryonic neurodevelopment, potentially resulting in the foundation of more vulnerable niches 
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predisposing to PD during aging (Manuscript (M) 1, Figure 1B, C, D; M2, Figure 2). More mDA 
neurons formed, while i.e. the number of support cells stays the same, could specifically 
expose the mDA neuron niche of the SNc to stress during the age-dependent decline in 
support. 
In summary, we are able to conclude an instability NSC in the periphery of PD-aethiology that 
could result in an altered embryonic neurodevelopment. The latter is likely creating more 
vulnerable niches more predisposed to neurodegeneration. 
 
4.2. Modeling age-related disorders using embryonic cells? 
(i)PSC-based modeling bears many advantages, it provides the research community a source 
for any kind of terminal somatic cells. Although initially, the exact cues to guide PSCs towards 
a particular cell type had to be identified. A positive side-effect of this process was a better 
understanding of in vivo developmental processes, e.g. the mechanisms of neural induction 
via dual SMAD inhibition (Chambers et al., 2009). PSC based disease phenotyping is 
specifically valuable for the identification of the molecular alterations in the context of disease. 
Specifically disease affected tissues that would normally not be accessible for phenotyping are 
now possible to assess. Thus, disease recapitulation and molecular phenotyping in vitro are 
the current main applications. The reprogramming process converting somatic cells to PSC 
stage acts as a ‘rejuvenation’, resetting several age-related hallmarks (summarized in Studer 
et al., 2015). For our particular research approach of studying LRRK2-G2019S effects on 
embryonic neurodevelopment, the reprogramming related rejuvenation effects were a superior 
advantage. The iPSC based NESCs used throughout most projects mimic cells around third 
week post-conception, at the neural plate border (Reinhardt et al., 2013b). Apart from modeling 
this particularly early event in neurodevelopment, iPSC-derived neural material resembles 
embryonic nature per se (Mariani et al., 2012). Since the LRRK2-G2019S mutation is in most 
cases already present right after fertilization of the oocyte, the reprogramming process enabled 
us to study particularly early phenotypes associated with monogenic LRRK2-G2019S induced 
PD. However, since classically PD is regarded as an age-associated disorder, rejuvenation is 
considered the major disadvantage of iPSC based PD-phenotyping. For age-associated 
phenotyping there are approaches for solving this problem. It is possible to avoid the PSC 
stage related rejuvenation via transdifferentiation approaches to induced neural stem cells 
(Han et al., 2012) or to reverse rejuvenation using artificial aging approaches (Miller et al., 
2013). However, this is not necessary if PD actually is a developmental disorder. Thus, iPSC 
based disease modeling was an ideal approach for recapitulating early neurodevelopment in 
the dish, independent of age-dependent effects. 
                                                                                                                                  Discussion 
 
                                                                                                                                                  257 
The rejuvenation of iPSC based models has some additional advantage. The observable 
phenotypes in such models, even without aging, are certainly of high relevance and will only 
become more severe during aging (Finkel and Holbrook, 2000; Gemma et al., 2007). These 
phenotypes theoretically indicate the major deregulations underlying PD. One could even 
argue that these phenotypes could be masked by the general age-related physiological 
decline. Most phenotypes at an early developmental stage can be considered similar in similar 
cell types during aging, specifically in vulnerable cell types like mDA neurons. However, with 
our approach we had to keep in mind that a carry-over of the tissue of origin with respect to 
DNA-methylation and gene expression profile is possible. When comparing the cell lines we 
used throughout the studies, this effect was neglectable, only in manuscript 2, a cell line of 
non-fibroblast origin was included, including the necessary isogenic control. 
 
4.3. Autophagosomal-lysosomal alterations underlying PD 
With these facts about iPSC derived material, the observed subcellular phenotypes at the 
embryonic stages have a high relevance for PD. LRRK2 interferes with the autophagosomal-
lysosomal-pathway at many stages (Roosen and Cookson, 2016). Consequently, we detected 
extensive alterations of the ALP, starting from autophagosome formation alterations to 
limitations of the lysosomal turnover (M1, Figure 7). In our western blot analyses, we detected 
no differences in autophagosome (LC3bII) presence at basal conditions (M1, Figure 7I). This 
indicates only a very low activity of this pathway at NESC stage in basal conditions. However, 
the elevated presence of autophagy receptor SQSTM1 (p62) indicated a potentially higher 
activity (M1, Figure 7K). In literature LRRK2-G2019S is associated with higher levels of basal 
LC3bII, while the autophagic-flux is reduced (Sánchez-Danés et al., 2012). Here we were not 
able to find any differences in basal conditions, while the autophagic flux seems to be 
increased in LRRK2-G2019S NESCs. We could proof the latter by blocking the 
autophagosome to lysosome fusion via chloroquine, which results in autophagosome 
accumulation. That speed of accumulation of LC3bII is a better indicator of the 
autophagosomal pathway activity (Klionsky et al., 2012). The observed effects in comparison 
with the current literature indicate a cell type dependent effect and our results might be a result 
of a low dependency of NESCs on that pathway. In a next analysis we starved NESCs, while 
fusion with lysosomes was blocked. This resulted in elevation of levels of LC3bII in kind of a 
linear increase in the PD2.GC control NESCs, which was not the case in PD2.G2019S. These 
results highlight the contribution of mitochondria. As soon as the cells are forced in a metabolic 
state, more similar state to neurons, this induces similar effect like observed in literature in 
LRRK2-G2019S mutant iPSC derived mDA neurons (Sánchez-Danés et al., 2012). When 
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taking into consideration the parallel quantification of Beclin-1, a upstream activator of 
autophagy (Kang et al., 2011), we observe a strong activation signal (3h, 6h CLQ 100 µM). 
However, in PD2.G2019S NESCs this is not resulting in autophagosome formation or LC3bII 
synthesis, probably because of the missing abundance of LC3bII under the same conditions. 
This might implicate a negative regulation via mTOR signaling pathway (He and Klionsky, 
2009). In literature, though, LRRK2 mediated regulation of macroautophagy was shown to be 
independent of mTOR and ULK1 but dependent on Beclin-1 activation signaling (Manzoni et 
al., 2016). This implies either an additional, unknown, interference of LRRK2-G2019S with this 
pathway or the existence of negative feedback loops. 
In summary, our results indicate a significantly higher autophagic flux in PD-patient NESCs, a 
higher sensitivity to induced metabolic stress, which might indicate limitation in metabolically 
demanding situations. As Dr. Daniel Klionsky et alia stated, the accumulation of LC3bII is a 
better indicator of autophagy activity (Klionsky et al., 2012). However, high levels of LC3bII 
could indicate autophagic induction, but could conversely be a sign that the complete ALP is 
defective, resulting in accumulation of LC3bII within autophagosomes or lysosomes. 
Consequently, we had to complete our ALP analysis with a lysosome analysis. 
Throughout the ALP the sufficient supply of lysosomes is rate and capacity limiting. Literature 
specifically highlights lysosomal turnover rather than autophagosomal LC3 levels as an 
indicator for ALP capacity (Tanida et al., 2005). As a logical consequence the study of 
limitations of the ALP needs to contain an analysis of lysosomes, or should be even started 
with such analysis. Macroautophagy and CMA are both dependent on sufficient supply of 
functional lysosomes (Settembre et al., 2013). Consequently, an extensive lysosomal 
morphology analysis was included in the investigations downstream of autophagy. We 
detected a reduced number of lysosomes in LRRK2-G2019S NESCs, and by this a rate-
limitation in the final step of ALP. Based on this one could argue that the lower number of 
lysosomes results in insufficient fusion of autophagosomes with lysosomes. Limitations of 
lysosomal turnover were consistent present as an ALP limitation in NESC, but also in iPSC 
(M3, Figure 2F, I). Two different methods to analyze lysosomal morphology were applied, 
using PFA fixation and subsequent antibody staining (ICC) with LAMP2 (Cuervo and Dice, 
2000). Since there is a potential LRRK2 - LAMP2 interaction, indirect via Rab-protein family 
(MacLeod et al., 2013; Steger et al., 2016), a LAMP2 independent acidotrophic live stain was 
included, too. The LAMP2 protein is not only present in mature acidified lysosomes but also in 
more immature states, thus, the ICC approach is staining both immature and mature 
lysosomes. The live staining approach, however, only captures mature acidified lysosomes. In 
ICC based lysosome formation, in almost all comparisons consistent differences between 
LRRK2-G2019S and the particular controls were observed. However, the isogenic LRRK2-
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G2019S insertion in the healthy genetic background was not fully inducing the phenotype. 
Consequently, this phenotype is a combination of LRRK2-G2019S and patient genetic 
background. In the analysis of mature lysosomes only, a much lower number of stained puncta 
was observed, mostly verifying the initial staining based results. Interestingly, a rescue effect 
in PD.GC NESC, like that observed in ICC was absent.  
The results clearly highlight a limitation in the lysosomal turnover which, according to the 
literature, is a rate limiting factor of the ALP. On the one hand these results verified an 
interference of LRRK2-G2019S with LAMP2 synthesis and lysosome supply, but it also 
highlights an LRRK2-G2019S independent effect as observed by the missing rescue in the PD 
patient on the level of mature lysosomes. A possible contribution of the genetic background is 
further highlighted by the incomplete induction of lysosome phenotypes via LRRK2-G2019S 
insertion in control NESCs (M1, Figure 7G, H). As introduced, LAMP2 not only necessary for 
lysosome formation (Cuervo and Dice, 1996) but also for CMA mediated α-synuclein 
degradation (Orenstein et al., 2013). Thus a lower number of LAMP2 puncta indicates a 
limitation not only of ALP but also of CMA.  
In summary, the observed limitations in combination with Lewy-pathology that is mostly 
observed in PD are very similar to lysosomal storage diseases (LCD). In fact, Lewy aggregates 
can be also observed in Gaucher's disease (GD) (Wong et al., 2004). The link between PD 
and GD was finally made by the identification that GBA mutations (Sidransky and Lopez, 2012) 
not only induce GD, but also serve as a risk factor for PD. The effect in PD is however much 
weaker, more age-dependent, and mostly manifests in nigral pathology. This means, any 
genomic mutation that is affecting the ALP similarly is a potential risk factor for PD.  
 
4.4. Mitochondriogenesis 
Mitochondrial dysfunctionalities have been linked to almost all forms of monogenic PD 
(Winklhofer and Haass, 2010) and are considered a fundamental problem associated with PD 
(Abou-Sleiman et al., 2006; Henchcliffe and Beal, 2008). In mitochondriogenesis (Figure 6) 
mitochondrial health and ALP deregulations are theoretically directly linkable. ALP 
dysfunctionalities could cause mitochondrial phenotypes the other way around is hardly 
imaginable. Thus there are the following different hypothetic scenarios possible: 1. Direct 
interaction with factors mandatory for mitochondriogenesis 2. Indirect interaction with 
mitochondriogenesis via ALP deregulation, independent of factors important for 
mitochondriogenesis itself 3. LRRK2 is interacting and affecting both, thus several events 
happen in parallel and eventually exaggerate each other. 
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Since stem cells are strongly dependent on glycolysis rather than mitochondria for energy 
supply, we were skeptic when we started our investigations (Ito and Suda, 2014). But, 
consistent with the literature (Cooper et al., 2012; Sanders et al., 2014; Su and Qi, 2013), we 
detected mitochondrial problems in NESCs carrying the LRRK2-G2019S mutation (M1, Figure 
5, 6). The relevance of our findings was further strengthened by the group of Dr. Alessandro 
Prigione, highlighting NESCs as an excellent model for mitochondria phenotyping (Lorenz et 
al., 2017). Throughout our morphology studies the maturity of the mitochondria in NESCs was 
confirmed. Mitochondria in NESCs form a highly fused network (Figure 5G). However, in 
LRRK2-G2019S NESCs the network is fragmented. Mitochondrial maturation supposedly 
further advances during neuronal differentiation (Fang et al., 2016), requiring a functional 
mitochondrial fission fusion machinery (Youle and Van Der Bliek, 2012). Fission and fusion is 
exactly the demerit shown to be altered by LRRK2 (Wang et al., 2012). LRRK2-G2019S in this 
context was linked to a higher degree of mitochondrial fragmentation, which was confirmed to 
be directly LRRK2 kinase domain dependent. The whole process is mediated via direct LRRK2 
to Dynamin-1-like protein (DNM1L/Drp1) interaction. Drp1 is directly involved in fission. 
Initiated by an ER contact Drp1 binds to adaptor proteins on the mitochondrial surface, dimers 
and oligomers into a spiral-shaped superstructure, a ring around the mitochondrion. A 
successful fission event further requires the recruitment of other proteins of the fission 
machinery like FIS1 and MFF. In a last step, Drp1 hydrolyzes GTP and divides the OMM and 
IMM, generating two daughter mitochondria (Smirnova et al., 2001). Fission and fusion are 
controlled by metabolic demands of the cell, in situations of higher demand in the absence of 
glucose, mitochondria would normally fuse and join forces (Rossignol et al., 2004). Altered 
fission/fusion homeostasis results in either more elongation or fragmentation of the 
mitochondrial network. Smaller mitochondria need to pump more protons to meet the energy 
demands of the cells, resulting eventually in more ROS. Interestingly, mitochondrial 
fragmentation was shown to be essential for cell conversion during reprogramming (Prieto et 
al., 2016). This might be true for any cellular conversions, e.g. NESC to neuron. Thus, a 
combination of elevated ROS levels (M1, Figure 5B) and smaller, more fragmented 
mitochondria (M1, Figure 5D-M) might be beneficial for a faster NESC to neuron transition. 
However, meeting the higher energy demands in neurons is in the end even more difficult. 
Since the clearance mechanisms at the same time do not function properly, this results 
ultimately in cell death and faster depletion of the stem cell pool (M1, Figure 2C, A, B). 
Mitochondrial phenotypes in NESCs were directly linkable to LRRK2-G2019S, however, 
specifically in the functionality assay the capacity of corrected PD.GC NESCs (corrected) was 
only minorly rescued. This highlights the contribution of other susceptibility factors, in this case 
likely, the insufficient rescue of the ALP might be a triggering factor. The dependency of both 
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phenotypes needs to be further investigated prior final conclusions are possible. With the 
current knowledge number three of the proposed option would be the most likely, parallel 
alteration of mitochondria via excessive fission in combination with ALP limitations. 
 
4.5. Susceptibility factors of PD 
As highlighted in the introduction, the susceptibility to PD is modulated by diverse genetic and 
non-genetic factors. GWAS studies outline the variety of potential genetic risk factors (Nalls et 
al., 2014). One could hypothesize, the more of these factors are present, the earlier the onset 
of PD is going to be. This may certainly be the case, however, a final systematic correlative 
proof is still missing. This theory resulted in the multiple hit hypothesis and indicates the 
complexity of PD modulation by in vivo and ex vivo factors (Sulzer, 2007). Additionally, the fact 
that only around 30% of LRRK2-G2019S carrier develop symptomatic PD is a good example 
of the contribution of other factors apart from the mutation (Paisán-Ruiz et al., 2013). Thus, we 
were inquisitive if it was possible to detect such contributions of the patient’s susceptibility 
background. The usage of isogenic controls, insertion and correction of LRRK2-G2019S in 
control and patient cells enabled us to distinguish between effects directly linkable to LRRK2-
G2019S and those not linkable to the mutation. However, the contribution of several genetic 
factors to a potential phenotype is dependent on the expression of that or those genes in a 
particular tissue. NESCs seem to express only extremely low levels of LRRK2 mRNA thus, the 
effect of the susceptibility factors should be even easier dissectible. In other cell types that 
express high levels of LRRK2, the impact of LRRK2-G2019S is certainly higher. However, 
higher LRRK2 expression would likely mask or cover, at least partially, the possible 
contribution effect of the patient’s susceptibility factors, being indistinguishable in the end. 
NESCs are therefore specifically suitable for dissecting patient background contributors in 
LRRK2 linked PD. 
Throughout our studies of NESCs and NESC derived neuronal material we detected a few 
factors that seem to be independent of LRRK2-G2019S. Starting at the gene expression level 
(M2), the majority of genes differently regulated were dependent on the background, whereas 
the correction of LRRK2-G2019S was not having a big effect on gene expression in NESCs 
and most of the regulated genes were dependent on the individual background of PD-patient. 
The correction of LRRK2-G2019S in this context was consequently having only a minor effect, 
with 17 genes differently regulated. In contrast, between patients and healthy control subjects, 
778 genes were differently regulated. Those genes are mostly attributable to the patients’ 
susceptibility background deregulation. Major deregulation was detected for: RAB32, 
CHCHD2, DNAJC15, and SRR. The regulation of those genes was not reversed to a healthy 
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level in a PD.GC vs. PD.G2019S comparison. Phenotypes that are associated with an 
insufficient rescue at NESC stage are: viability, total ROS level, mitochondrial membrane 
potential (MMP), mitochondrial activity (OCR), levels of mature lysosomes and proliferation. 
Interestingly, in contrast, neuronal differentiation phenotypes were more clearly dependent on 
LRRK2-G2019S. The results mostly fit to our observations during single cell analysis where 
we observed an upregulation of LRRK2.  
 
4.6. PD beyond nigral degeneration 
As introduced already, the scientific community mostly focuses on the omnipresent mDA 
neuron degeneration as the major hallmark of PD. This focus persists when it comes to 
modeling PD in vitro or in vivo (Langston, 2006). However, this way of approaching PD is 
narrowing the focus considerably, mostly neglecting pre-extranigral disease-linked 
phenomena. Recently the immune system was more and more linked to PD. The involvement 
of LRRK2 was highlighted by expression in immune cells (Gardet et al., 2010; Hakimi et al., 
2011), which is altered in PD (Cook et al., 2017). In this context it is important to mention that 
LRRK2 was associated with autoimmune diseases like Crohn’s disease or leprosy (Barrett et 
al., 2008; Zhang et al., 2009). In addition, α-synuclein pathologies were recently linked to 
T cells, which might be a part of α-synuclein clearance. This fact is substantially increasing the 
likelihood of an involvement of the immune system in PD (Sulzer et al., 2017). Of additional 
interest is the fact that Lewy pathology is not exclusively nigral and even present in the PNS 
(Jager and Bethlem, 1960; Wakabayashi and Takahashi, 2008). Our lab is having unpublished 
data indicating that specifically mDA neurons possess high levels of p129-synuclein (Qing et 
al., in revision). Specifically the p129-synuclein peptide was shown to induce immune reactions 
in the T cells of PD patients (Sulzer et al., 2017). In this context one could hypothesize an 
autoimmune reaction against cells with particularly high levels of p129-α-synuclein – mostly 
mDA neurons. The triggers of such overload could be: age-dependent decline or insufficient 
activity by supportive cell types, resulting in further elevating levels. This would ultimately result 
in a p129-synuclein overload and downstream immune reaction against mDA neurons. A 
triggered autoimmune reaction might also explain the kind of necroptotic cell death of mDA 
neurons, which is common in immune system triggered cell death (Pasparakis and 
Vandenabeele, 2015).  
Our findings in combination with the current literature fit the slow paradigm change and support 
that the progressive neurodegeneration of mDA neurons is rather the ultimate consequence 
of PD-progression and likely not the initial trigger of PD (Przedborski, 2017; Schapira et al., 
2017).  
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4.7. Hypothetical in vivo translation and vision of PD 
Here a vision of PD, combining our new findings with the current literature is outlined. Our 
studies summarized in this thesis support the likelihood of an altered neurodevelopment 
underlying PD. The already known problems in neural stem cells, lower viability, faster exhaust 
of the stem cell pool, were confirmed by our findings at an embryonal stage (M1, M2). However, 
the exact in vivo impact of these findings is difficult to estimate. At the neural stem cell level I 
propose an inherently smaller and definitely less stable neural stem cell pool by default. At the 
same time the observed alterations of neuronal transition create imbalanced, more vulnerable 
niches within the brain. Since no severe macroanatomic abnormalities were reported in the 
context of PD, the neurodevelopmental alterations necessarily take place at a cytoarchitectural 
level and a subtle scale. Apart from the hypothesized more fragile interconnections between 
cells might not be that well established, which is very likely since LRRK2 was shown to be 
involved in synapse formation (Parisiadou et al., 2014). Vulnerability of imbalance niches might 
manifests in altered cell composition in certain areas of the brain. Hypothetically, if there are 
more mDA neurons forming the SNc in a LRRK2-G2019S patient, while the quantity of glial 
cells stays similar, this theoretically creates a more vulnerable toxic niche within the brain. 
More precisely, less support cells per mDA neuron resulting in an increased vulnerability of 
the mDA neurons present. Toxicity, however, becomes only relevant with a decreased turnover 
and renewal rate of non-neuronal cells during aging (Spalding et al., 2013; Yeung et al., 2014), 
resulting in a decline of support of those niches. Since mDA neuron myelination is already 
naturally low (Sulzer and Surmeier, 2013), mDA neurons consequently would be particularly 
vulnerable to such loss of support. Interesting in this context is a study that is showing the 
importance of rapid production of oligodendrocytes for early stages of motor-skills (Xiao et al., 
2016). If oligodendrocytes are important for motor-skills by default, a loss of oligodendrocyte 
support might explain parts of the uncontrolled loss of motor-skills in PD. 
In my vision of PD the observed alterations of the ALP and mitochondria mostly become 
relevant only with the age-dependent additional loss of physiological function. Alteration 
already present at the PSC stage seem to be within a physiological range, otherwise this would 
result in more severe abnormalities. Both findings were already highlighted by several studies, 
however, not that clearly in neural stem cells and even PSCs (Pan et al., 2008; Rivero‑ Ríos 
et al., 2015). Also the clear identification of a rate limitation of the ALP in the very last step, the 
lysosomes, was so far not highlighted in such detail and mostly only one single readout was 
used for the assessment (M1, Figure 7). Our stable sensor cells (M3) in this context, will allow 
us to observe the ALP in any kind of setups in the future. Our approach is going to allow us to 
identify the exact steps in autophagy where LC3 is accumulating and the autophagosomal 
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pathway is blocked. Our findings further strengthen the link between PD and GD (Wong and 
Krainc, 2016; Wong et al., 2004). The similarities in pathologies of both diseases is highlighted 
by the shared risk factor GBA (Sidransky and Lopez, 2012). However, the differences in 
lysosomal abnormalities are rather subtle in PD and not as obvious as in GD. Only with the 
age-dependent decline of physiological functions in an untreated individual at risk of PD, the 
differences become severe. As one of the consequence α-synuclein but also mitochondria are 
not efficiently degraded anymore. Neurons, in particular mDA neurons, starts to engulf α-
synuclein in inclusions bodies. As mentioned, during aging, the support of mDA neurons by 
oligodendrocytes and astrocytes declines. In addition to a physiological reduction of the 
turnover of those cells, the disease-associated reduction might be further intensified by the 
mitochondrial and ALP alterations. Upon this loss of support mDA neurons need to increase 
their already high activity level, resulting in an overload of ALP by mitochondria. As a 
consequence, cytosolic p129 synuclein levels increase and the cell is not able to efficiently 
distribute it to Lewy aggregates anymore. High p129 synuclein levels might ultimately trigger 
an autoimmune reaction leading to necroptotic cell death of mDA neurons. 
The outlined vision of PD differs strongly from the current view of the disease. In such scenario 
the cell death of mDA neurons is of course still the ultimate and obvious histopathological 
phenotype and certainly being part of the PD-associated MS. However, loss of mDA neurons 
would be only secondary and ultimate event primarily initiated by the loss of support and 
secondly finalized by an autoimmune reaction triggered. In such scenario the question 
concerning the factual start of PD would still be open and could be, as we suggest, 
neurodevelopmental. Unravelling the exact cascade of those events is an interesting, exciting, 
and extremely difficult challenge ahead. 
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4.8. Conclusions 
Our findings throughout the studies summarized in this thesis suggest an effect of the PD-
associated monogenic LRRK2-G2019S mutation at an early developmental stage, resembling 
embryonic neurodevelopment. Our finding, of an altered LRRK2-G2019S specific phenotype 
in the dynamics of mDA neuron appearance, highlight the aspect of an altered development 
as a potential contributor to PD-progression. Those findings hopefully contribute to a paradigm 
change and a rethinking of where PD factually starts. Apart from that, we highlight the necessity 
to investigate the neuronal environment in addition to purely mDA neuron pathology. 
Throughout our studies we identified extensive stem cell deregulations linked to monogenic 
PD. The LRRK2-G2019S related neurodevelopmental phenotype manifests specifically in the 
early transition phase from NESC to mDA neuron. NESCs carrying the LRRK2-G2019S 
mutation initially produce elevated abundance of mDA neurons. This is an interesting and 
much unexpected finding, as in vitro nothing in this direction was reported before. For the sake 
of the fact that mDA neuron numbers converge at later time points analyzed, it is likely that 
others might missed this phenotype while analyzing mostly mature mDA neurons. We assume 
the unexpected mDA neuron dynamics to be highly meaningful, since others reported already 
in a similar direction in vivo (Huisman et al., 2004). With our findings, we add a new aspect 
and challenge to PD research. A potential scenario of how the predisposition might works was 
outlines (4.7). 
In more detail, our research highlights the following new aspects as potential contributors to 
PD-progression: 1. LRRK2-G2019S alters the neural epithelial stem cell stage. NESCs 
carrying LRRK2-G2019S are primed and more prone to spontaneous differentiation. 2. During 
neuronal differentiation, the NESC stage priming manifests in significantly higher initial mDA 
neuron quantities, faster loss of stemness and cell cycle exit. 3. All cell stages in LRRK2-
G2019S cultures were accompanied by significant loss of viability, likely induced by the 
observed mitochondriogenesis and ALP limitations. 4. Genome edited isogenic controls 
rescue or induce most phenotypes in direct relation to presence of LRRK2-G2019S. 5. The 
patient-specific genetic background complements the observed viability phenotypes at NESC 
stage.  
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4.8.1. Major achievements 
1. NESCs are a meaningful model of PD. 
2. LRRK2-G2019S strongly alters mDA neuronal differentiation dynamics.  
3. Phenotypes at NESC stage are mostly LRRK2-G2019S dependent and 
comprise: Gene expression, metabolism, mitochondria, autophagosomal, and 
lysosomal turnover limitation. 
4. Cell death and lack of mature lysosomes at NESC stage are not rescuable by 
isogenic LRRK2-G2019S correction. 
5. PD-patient genetic background acts as a susceptibility factor at NESC stage. 
6. Development of a more advanced technique to capture autophagy dynamics.  
7. The stable reporter cell lines indicate the ALP as a common PD-phenotype.  
8. The need of isogenic controls resulted in an advancement of CRISPR/Cas9 
genome editing. 
 
4.8.2. Future directions 
Based on the results obtained throughout our studies, neurodevelopment needs to be 
considered as an important predisposing factor to PD. It going to be interesting to see to what 
extent the observed neurodevelopmental alterations are transferable to in vivo situations. 
However, it is questionable how to detect and study such a disease predisposition at birth. 
Especially, since this could be an alteration of rather minor nature. Likely, also the stability of 
the inherent neural stem cell pool at birth is a critical factor, also an assessment of that is 
impossible to date. In the neurodevelopmental context, it would be advisable to follow up the 
study (M1) and investigate the LRRK2-G2019S interference with WNT and Notch signalling 
pathways. Both of them were shown to be connected to LRRK2 and certainly to 
neurodevelopment (Berwick and Harvey, 2012; Imai et al., 2015). WNT signalling modulation 
is used for patterning the regionalization of NESCs and testing different WNT modulations in 
NESCs resulted in modulation of the number of TH+ cells in healthy conditions but not in 
LRRK2-G2019S (data not shown). Thus, there is a likelihood that part of LRRK2-G2019S 
NESCs phenotype manifestations is an effect of a slightly different sensitivity to the WNT 
modulator; a fact, however, that is further supporting the likelihood of neurodevelopmental 
interference. 
As a first test of the in vivo relevance of the observed neurodevelopmental alterations, 
screenings of the phenotype manifestation in self-organizing 3d organoid systems would be 
interesting to see and easily applicable, since such systems are available in our lab (Monzel 
et al., 2017, Smits et al. in press). In this context, it would also be interesting to extensively 
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characterize non-neuronal cells, or the ratios of neuronal to non-neuronal cells. Verification in 
such an organoid system would also allow further conclusions about the robustness of the 
phenotypes and translatability to other in vitro systems. If translatability is given, this 
substantially increases the likelihood of in vivo relevance. Apart from cell type quantity ratios it 
would be interesting to also do myelination analyses of mDA neurons in PD vs. healthy 
backgrounds. Once the baselines for certain phenotypes are well defined, manipulation via 
known non-genetic risk factors can be introduced. For example ROS elevation or continuous 
high level activation of mDA neurons. Also, in such a scenario, the effect of an exposure to 
primed PD-patient and healthy microglia could be tested to address a potential autoimmunity 
aspect.  
For the 3d modelling approach in the context of our perception of PD as a potential 
neurodevelopmental disease and with the knowledge about the in vivo manifestation of an α-
synuclein knock out in mouse (Garcia-Reitboeck et al., 2013), it would be highly interesting to 
see a verification of the in vivo phenotype in 3d organoids. It would be specifically interesting 
to see the impact of the opposite, the α-synuclein triplication in contrast. α-synuclein triplication 
is the ultimate trigger of PD with a penetrance of 100% (Hernandez et al., 2016). A study 
including different synuclein mutations, isogenic controls, a knock out and a triplication of 
synuclein in contrast would be desirable. 
The fact that we were able to clearly detect LRRK2-dependent phenotypes in NESC while 
mRNA levels are barely detectable tells us how little we know about the LRRK2 protein itself. 
Protein turnover of LRRK2 was not yet analyzed in detail. A multidimensional LRRK2 protein 
analysis in the near future is desirable. Apart from already available transcriptomics data 
(showing barely LRRK2 expression at NESC stage), additional proteomics data would also be 
interesting, both preferable in dynamics. Since the antibodies currently present in the market 
are of doubtful quality, one needs to think of alternative, more robust approaches of how to 
analyze LRRK2 further. It would be recommendable to endogenously tag the LRRK2 protein 
with a fluorophore. Ideally, such endogenous tag would be inducible, a system that could also 
be used to study the half-life time and localization of LRRK2.  
Taken the results obtained during the ALP phenotyping one could speculate that the observed 
limitations of the turnover of this pathway are a widely common phenotype of PD and might 
serve as a kind of amplifier underlying PD. Finding a treatment ameliorating the capacity 
limitation of the ALP will be a future challenge. In this context, it would be interesting to 
investigate the plasticity of the underlying regulatory gene network, the so called Coordinated 
Lysosomal Expression and Regulation (CLEAR) gene network in more detail (Sardiello et al., 
2009). Based on the results, we observed that this could be a good target and could be 
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commonly deregulated as a disease mechanism. It would be interesting to see the regulations 
in healthy vs. LRRK2-G2019S in the presence of defined stimuli. The CLEAR network is also 
an interesting target for treatments approaches (Decressac et al., 2013). The transcription 
factor EB (TFEB) is the master regulator, controlling the expression of many ALP involved 
genes. In case there are no differences observable, this may still be meaningful, excluding this 
pathway as commonly altered. In this context the autophagy/mitophagy reporters would be 
quickly applicable to conduct further characterize the ALP deregulations as a common PD 
phenotype. 
                                                                                                                                Appendix 
 
                                                                                                                                                  IX 
5. Appendix 
 
5.1. Abbreviations 
ALDH   aldehyde dehydrogenase 
ATP   adenosine triphosphate 
ALP   autophagosomal-lysosomal-pathways 
A-P   anterior-posterior 
BMP   Bone morphogenetic proteins 
bp   base pairs 
BSA   bovine serum albumin 
CNS    central nervous system 
DA   dopamine 
DMB   diencephalon-midbrain boundary 
DNA   deoxyribonucleic acid 
DSB   double strand break 
dSMADi  dual SMAD inhibition 
D-V    dorsal-ventral 
EGFP   enhanced green fluorescent protein 
ELA    endocytic/lysosomal activities 
ER   endoplasmic reticulum 
FACE   FACS-assisted CRISPR/Cas9-mediated genome editing 
FACS   fluorescence-activated cell sorting 
FGF   fibroblast growth factor 
GD   Gaucher’s disease 
GWAS   genome-wide association studies 
HCS   high content screening 
HLA   human leukocyte antigens 
ICM   inner cell mass 
iPSC    Induced pluripotent stem cell 
IMM   inner mitochondrial membrane 
ILBD   incidental Lewy body disease 
iPD   idiopathic PD 
M1, 2, 3, 4  manuscript 1, 2, 3, 4 
mDNA   mitochondrial DNA  
mDA   mesencephalic dopaminergic 
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MHB   midbrain-hindbrain boundary 
MMP   mitochondrial membrane potential 
MS   motor symptoms 
MVB   multivesicular body 
NGS   next generation sequencing 
NESC   neuroepithelial stem cells 
NMS   non-motor symptoms 
NSC   neural stem cell 
ss/dsDNA  single/double stranded DNA 
kb   kilo base 
OMM   outer mitochondrial membrane 
OXPHOS  oxidative phosphorylation 
PD   Parkinson’s disease 
PSC   pluripotent stem cells 
RA   retinoic acid 
RNA   ribonucleic acid 
ROS   reactive oxygen species 
RT   room temperature 
SEM   standard error of mean 
SHH   sonic hedgehog 
SNPs   single-nucleotide polymorphisms 
SNc   substantia nigra pars compacta 
SNr   SN pars reticulate 
VTA   ventral tegmental area 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                Appendix 
 
                                                                                                                                                  XI 
5.3. Index of Figures and Tables 
 
5.3.1. Figures 
Figure 1: Parkinson’s disease associated demographic development versus age-dependent 
risk.. ................................................................................................................................ 2 
Figure 2: Progression of the clinical manifestations of PD and accompanying non-motor 
symptoms (NMS) and motor symptoms (MS).................................................................. 4 
Figure 3: Histopathological hallmarks of PD. .......................................................................... 5 
Figure 4: Schematic representation of a LRRK2 predicted domain structure.. ..................... 10 
Figure 5: Molecular interferences linked to mutant Leucine-rich repeat kinase 2 (LRRK2).. . 13 
Figure 6: Schematic representation of mitochondriogenesis and connected mitochondrial 
clearance via ALP.. ....................................................................................................... 16 
Figure 7: Timing and events during early human neurodevelopment.. ................................. 22 
Figure 8: Simplified early neural patterning and midbrain specification ................................ 24 
Figure 9: Current state of targeted DSB induction and DSB repair methods.. ...................... 30 
Figure 10: hPSC based human in vitro neurodevelopment recapitulation and in vivo 
counterparts. ................................................................................................................. 32 
 
 
5.3.2. Tables 
Table 1: Genes and chromosomal loci linked to PD ............................................................... 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                Appendix 
 
                                                                                                                                                  XII 
5.4. Bibliography 
Abeliovich, A., and Gitler, A.D. (2016). Defects in trafficking bridge Parkinson’s disease pathology and genetics. 
Nature 539, 207–216. 
Abeliovich, A., and Hammond, R. (2007). Midbrain dopamine neuron differentiation: Factors and fates. Dev. Biol. 
304, 447–454. 
Abou-Sleiman, P.M., Muqit, M.M.K., and Wood, N.W. (2006). Expanding insights of mitochondrial dysfunction in 
Parkinson’s disease. Nat. Rev. Neurosci. 7, 207–219. 
Adams, J. (2004). The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349–360. 
Alegre-Abarrategui, J., Ansorge, O., Esiri, M., and Wade-Martins, R. (2008). LRRK2 is a component of granular 
alpha-synuclein pathology in the brainstem of Parkinson’s disease. Neuropathol. Appl. Neurobiol. 34, 272–283. 
Alegre-Abarrategui, J., Christian, H., Lufino, M.M.P., Mutihac, R., Venda, L.L., Ansorge, O., and Wade-Martins, R. 
(2009). LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human 
genomic reporter cellular model. Hum. Mol. Genet. 18, 4022–4034. 
Altman, J. (1963). Autoradiographic investigation of cell proliferation in the brains of rats and cats. Anat. Rec. 145, 
573–591. 
Alvarez-Buylla, A., García-Verdugo, J.M., and Tramontin, A.D. (2001). A unified hypothesis on the lineage of neural 
stem cells. Nat. Rev. Neurosci. 2, 287–293. 
Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., Caccavello, R.J., Barbour, R., Huang, J., 
Kling, K., Lee, M., et al. (2006). Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein 
in Familial and Sporadic Lewy Body Disease. J. Biol. Chem. 281, 29739–29752. 
Antony, P.M.A., Diederich, N.J., and Balling, R. (2011). Parkinson’s disease mouse models in translational 
research. Mamm. Genome 22, 401–419. 
Antony, P.M.A., Diederich, N.J., Krüger, R., and Balling, R. (2013). The hallmarks of Parkinson’s disease. FEBS J. 
280, 5981–5993. 
Arenas, E., Denham, M., and Villaescusa, J.C. (2015). How to make a midbrain dopaminergic neuron. Development 
142, 1918–1936. 
Arnold, S.J., and Robertson, E.J. (2009). Making a commitment: cell lineage allocation and axis patterning in the 
early mouse embryo. Nat. Rev. Mol. Cell Biol. 10, 91–103. 
Bae, B.-I., Jayaraman, D., and Walsh, C.A. (2015). Genetic Changes Shaping the Human Brain. Dev. Cell 32, 423–
434. 
Bahnassawy, L. ’a, Nicklas, S., Palm, T., Menzl, I., Birzele, F., Gillardon, F., and Schwamborn, J.C. (2013). The 
Parkinson’s Disease-Associated LRRK2 Mutation R1441G Inhibits Neuronal Differentiation of Neural Stem Cells. 
Stem Cells Dev. 22, 2487–2496. 
Bakken, T.E., Miller, J.A., Ding, S.-L., Sunkin, S.M., Smith, K.A., Ng, L., Szafer, A., Dalley, R.A., Royall, J.J., Lemon, 
T., et al. (2016). A comprehensive transcriptional map of primate brain development. Nature 535, 367–375. 
Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., Brant, S.R., Silverberg, M.S., Taylor, 
K.D., Barmada, M.M., et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for 
Crohn’s disease. Nat. Genet. 40, 955–962. 
Beal, M.F. (2001). Experimental models of Parkinson’s disease. Nat. Rev. Neurosci. 2, 325–334. 
Beal, M.F. (2010). Parkinson’s disease: a model dilemma. Nature 466, S8–S10. 
Bear, M.F., Connors, B.W., and Paradiso, M.A. (2016). Neurowissenschaften: ein grundlegendes Lehrbuch für 
Biologie, Medizin und Psychologie (Berlin Heidelberg: Springer Spektrum). 
                                                                                                                                Appendix 
 
                                                                                                                                                  XIII 
Beckervordersandforth, R., Ebert, B., Schäffner, I., Moss, J., Fiebig, C., Shin, J., Moore, D.L., Ghosh, L., Trinchero, 
M.F., Stockburger, C., et al. (2017). Role of Mitochondrial Metabolism in the Control of Early Lineage Progression 
and Aging Phenotypes in Adult Hippocampal Neurogenesis. Neuron 93, 560–573.e6. 
Bejarano, E., and Cuervo, A.M. (2010). Chaperone-Mediated Autophagy. Proc. Am. Thorac. Soc. 7, 29–39. 
Bento, C.F., Ashkenazi, A., Jimenez-Sanchez, M., and Rubinsztein, D.C. (2016). The Parkinson’s disease-
associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat. Commun. 7, 11803. 
Berardelli, A., Wenning, G.K., Antonini, A., Berg, D., Bloem, B.R., Bonifati, V., Brooks, D., Burn, D.J., Colosimo, C., 
Fanciulli, A., et al. (2013). EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur. J. 
Neurol. 20, 16–34. 
Berg, D. (2005). Type and frequency of mutations in the LRRK2 gene in familiar and sporadic Parkinson’s disease. 
Brain. 
Berwick, D.C., and Harvey, K. (2012). LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and 
membrane-localized LRP6. Hum. Mol. Genet. 21, 4966–4979. 
Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.-W., Savitt, J.M., 
Waldvogel, H.J., et al. (2006). Localization of LRRK2 to membranous and vesicular structures in mammalian brain. 
Ann. Neurol. 60, 557–569. 
Björklund, L.M., Sánchez-Pernaute, R., Chung, S., Andersson, T., Chen, I.Y.C., McNaught, K.S.P., Brownell, A.-L., 
Jenkins, B.G., Wahlestedt, C., Kim, K.-S., et al. (2002). Embryonic stem cells develop into functional dopaminergic 
neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. 99, 2344–2349. 
Blesa, J., and Przedborski, S. (2014). Parkinson’s disease: animal models and dopaminergic cell vulnerability. 
Front. Neuroanat. 8. 
Braak, E., Sandmann-Keil, D., Rüb, U., Gai, W.P., de Vos, R.A., Steur, E.N., Arai, K., and Braak, H. (2001). alpha-
synuclein immunopositive Parkinson’s disease-related inclusion bodies in lower brain stem nuclei. Acta 
Neuropathol. (Berl.) 101, 195–201. 
Braak, H., Del Tredici, K., Rüb, U., De Vos, R.A., Steur, E.N.J., and Braak, E. (2003). Staging of brain pathology 
related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. 
Brás, J., Guerreiro, R., and Hardy, J. (2015). SnapShot: Genetics of Parkinson’s Disease. Cell 160, 570–570.e1. 
Bucci, C., Thomsen, P., Nicoziani, P., McCarthy, J., and van Deurs, B. (2000). Rab7: a key to lysosome biogenesis. 
Mol. Biol. Cell 11, 467–480. 
Büchi, J., Prost, M., Eichenberger, H., and Lieberherr, R. (1952). Synthese und analgetische Wirkung einiger 1-
Methyl-4-phenyl-piperidin-(4)-alkylsulfone. 1. Mitteilung. Helv. Chim. Acta 35, 1527–1536. 
Bugalho, P., Lampreia, T., Miguel, R., Mendonça, M.D., Caetano, A., and Barbosa, R. (2016). Non-Motor symptoms 
in Portuguese Parkinson’s Disease patients: correlation and impact on Quality of Life and Activities of Daily Living. 
Sci. Rep. 6. 
Burchiel, K.J., Anderson, V.C., Favre, J., and Hammerstad, J.P. (1999). Comparison of pallidal and subthalamic 
nucleus deep brain stimulation for advanced Parkinson’s disease: results of a randomized, blinded pilot study. 
Neurosurgery 45, 1375-1382; discussion 1382-1384. 
Burke, R.E., Dauer, W.T., and Vonsattel, J.P.G. (2008). A critical evaluation of the Braak staging scheme for 
Parkinson’s disease. Ann. Neurol. 64, 485–491. 
Calne, D.B. (1989). Is“ Parkinson’s disease” one disease? J. Neurol. Neurosurg. Psychiatry 52, 18–21. 
Calvo, S.E., and Mootha, V.K. (2010). The Mitochondrial Proteome and Human Disease. Annu. Rev. Genomics 
Hum. Genet. 11, 25–44. 
Carroll, D. (2016). A Perspective on the State of Genome Editing. Mol. Ther. 24, 412–413. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XIV 
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, M., and Studer, L. (2009). Highly 
efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 
275–280. 
Chen, H., Ge, H., Wu, G., Cheng, B., Lu, Y., and Jiang, C. (2016). Autophagy Prevents Oxidative Stress-Induced 
Loss of Self-Renewal Capacity and Stemness in Human Tendon Stem Cells by Reducing ROS Accumulation. Cell. 
Physiol. Biochem. 39, 2227–2238. 
Chen, H., Kwong, J.C., Copes, R., Tu, K., Villeneuve, P.J., van Donkelaar, A., Hystad, P., Martin, R.V., Murray, 
B.J., Jessiman, B., et al. (2017a). Living near major roads and the incidence of dementia, Parkinson’s disease, and 
multiple sclerosis: a population-based cohort study. The Lancet 389, 718–726. 
Chen, Z.-C., Zhang, W., Chua, L.-L., Chai, C., Li, R., Lin, L., Cao, Z., Angeles, D.C., Stanton, L.W., Peng, J.-H., et 
al. (2017b). Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and 
neurotoxicity in Parkinson’s disease. Sci. Signal. 10, eaam6790. 
Chin, M.H., Mason, M.J., Xie, W., Volinia, S., Singer, M., Peterson, C., Ambartsumyan, G., Aimiuwu, O., Richter, 
L., Zhang, J., et al. (2009). Induced Pluripotent Stem Cells and Embryonic Stem Cells Are Distinguished by Gene 
Expression Signatures. Cell Stem Cell 5, 111–123. 
Chinopoulos, C., and Adam-Vizi, V. (2010). Mitochondria as ATP consumers in cellular pathology. Biochim. 
Biophys. Acta BBA - Mol. Basis Dis. 1802, 221–227. 
Choi, J., Huebner, A.J., Clement, K., Walsh, R.M., Savol, A., Lin, K., Gu, H., Di Stefano, B., Brumbaugh, J., Kim, 
S.-Y., et al. (2017). Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells. 
Nature. 
Conti, L., and Cattaneo, E. (2010). Neural stem cell systems: physiological players or in vitro entities? Nat. Rev. 
Neurosci. 
Cook, D.A., Kannarkat, G.T., Cintron, A.F., Butkovich, L.M., Fraser, K.B., Chang, J., Grigoryan, N., Factor, S.A., 
West, A.B., Boss, J.M., et al. (2017). LRRK2 levels in immune cells are increased in Parkinson’s disease. Npj Park. 
Dis. 3. 
Cookson, M.R. (2010). The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat. Rev. Neurosci. 
11, 791–797. 
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J.R., Carrillo-Reid, 
L., Xie, Z., Osborn, T., et al. (2012). Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells 
from Patients with Familial Parkinson’s Disease. Sci. Transl. Med. 4, 141ra90-141ra90. 
Coxhead, J., Kurzawa-Akanbi, M., Hussain, R., Pyle, A., Chinnery, P., and Hudson, G. (2016). Somatic mtDNA 
variation is an important component of Parkinson’s disease. Neurobiol. Aging 38, 217.e1-217.e6. 
Crossley, P.H., Martinez, S., and Martin, G.R. (1996). Midbrain development induced by FGF8 in the chick embryo. 
Nature 380, 66–68. 
Crotzer, V.L., and Blum, J.S. (2005). Autophagy and intracellular surveillance: modulating MHC class II antigen 
presentation with stress. Proc. Natl. Acad. Sci. 102, 7779–7780. 
Cuervo, A.M. (2004). Impaired Degradation of Mutant -Synuclein by Chaperone-Mediated Autophagy. Science 305, 
1292–1295. 
Cuervo, A.M., and Dice, J.F. (1996). A receptor for the selective uptake and degradation of proteins by lysosomes. 
Science 273, 501–503. 
Cuervo, A.M., and Dice, J.F. (2000). Regulation of lamp2a levels in the lysosomal membrane. Traffic 1, 570–583. 
Curtis, M.A., Faull, R.L.M., and Eriksson, P.S. (2007). The effect of neurodegenerative diseases on the 
subventricular zone. Nat. Rev. Neurosci. 8, 712–723. 
Dauer, W., and Przedborski, S. (2003). Parkinson’s disease: mechanisms and models. Neuron 39, 889–909. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XV 
Davis, C. -h. O., Kim, K.-Y., Bushong, E.A., Mills, E.A., Boassa, D., Shih, T., Kinebuchi, M., Phan, S., Zhou, Y., 
Bihlmeyer, N.A., et al. (2014). Transcellular degradation of axonal mitochondria. Proc. Natl. Acad. Sci. 111, 9633–
9638. 
De Jager, P.L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L.C., Yu, L., Eaton, M.L., Keenan, B.T., Ernst, 
J., McCabe, C., et al. (2014). Alzheimer’s disease: early alterations in brain DNA methylation at ANK1, BIN1, 
RHBDF2 and other loci. Nat. Neurosci. 17, 1156–1163. 
De Lau, L.M., and Breteler, M.M. (2006). Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525–535. 
Deas, E., Wood, N.W., and Plun-Favreau, H. (2011). Mitophagy and Parkinson’s disease: The PINK1–parkin link. 
Biochim. Biophys. Acta BBA - Mol. Cell Res. 1813, 623–633. 
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., and Bjorklund, A. (2013). TFEB-mediated 
autophagy rescues midbrain dopamine neurons from -synuclein toxicity. Proc. Natl. Acad. Sci. 110, E1817–E1826. 
Dehé, P.-M., and Gaillard, P.-H.L. (2017). Control of structure-specific endonucleases to maintain genome stability. 
Nat. Rev. Mol. Cell Biol. 18, 315–330. 
Dias, V., Junn, E., and Mouradian, M.M. (2013). The role of oxidative stress in Parkinson’s disease. J. Park. Dis. 3, 
461–491. 
Ding, Q., Regan, S.N., Xia, Y., Oostrom, L.A., Cowan, C.A., and Musunuru, K. (2013). Enhanced Efficiency of 
Human Pluripotent Stem Cell Genome Editing through Replacing TALENs with CRISPRs. Cell Stem Cell 12, 393–
394. 
Dodson, M.W., Leung, L.K., Lone, M., Lizzio, M.A., and Guo, M. (2014). Novel ethyl methanesulfonate (EMS)-
induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and 
autophagy in vivo. Dis. Model. Mech. 7, 1351–1363. 
Doi, D., Samata, B., Katsukawa, M., Kikuchi, T., Morizane, A., Ono, Y., Sekiguchi, K., Nakagawa, M., Parmar, M., 
and Takahashi, J. (2014). Isolation of Human Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors by 
Cell Sorting for Successful Transplantation. Stem Cell Rep. 2, 337–350. 
Dorey, K., and Amaya, E. (2010). FGF signalling: diverse roles during early vertebrate embryogenesis. 
Development 137, 3731–3742. 
Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., Marshall, F.J., 
Ravina, B.M., Schifitto, G., Siderowf, A., et al. (2007). Projected number of people with Parkinson disease in the 
most populous nations, 2005 through 2030. Neurology 68, 384–386. 
Drechsel, D.A., and Patel, M. (2008). Role of reactive oxygen species in the neurotoxicity of environmental agents 
implicated in Parkinson’s disease. Free Radic. Biol. Med. 44, 1873–1886. 
van Duinen, S.G., Lammers, G.-J., Maat-Schieman, M.L., and Roos, R.A. (1999). Numerous and widespread α-
synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol. (Berl.) 97, 533–539. 
Eriksson, P.S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D.A., and Gage, F.H. 
(1998). Neurogenesis in the adult human hippocampus. Nat. Med. 4, 1313–1317. 
Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 
292, 154–156. 
Exner, N., Lutz, A.K., Haass, C., and Winklhofer, K.F. (2012). Mitochondrial dysfunction in Parkinson’s disease: 
molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038–3062. 
Fang, D., Qing, Y., Yan, S., Chen, D., and Yan, S.S. (2016). Development and Dynamic Regulation of Mitochondrial 
Network in Human Midbrain Dopaminergic Neurons Differentiated from iPSCs. Stem Cell Rep. 7, 678–692. 
Fares, M.-B., Maco, B., Oueslati, A., Rockenstein, E., Ninkina, N., Buchman, V.L., Masliah, E., and Lashuel, H.A. 
(2016). Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson’s disease. Proc. Natl. Acad. 
Sci. 113, E912–E921. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XVI 
Feany, M.B., and Bender, W.W. (2000). A Drosophila model of Parkinson’s disease. Nature 404, 394–398. 
Figdor, M.C., and Stern, C.D. (1993). Segmental organization of embryonic diencephalon. Nature 363, 630–634. 
Finkel, T., and Holbrook, N.J. (2000). Oxidants, oxidative stress and the biology of ageing. Nature 408, 239–247. 
Fitzmaurice, A.G., Rhodes, S.L., Cockburn, M., Ritz, B., and Bronstein, J.M. (2014). Aldehyde dehydrogenase 
variation enhances effect of pesticides associated with Parkinson disease. Neurology 82, 419–426. 
Forno, L.S. (1996). Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55, 259–272. 
Fraser, S., Keynes, R., and Lumsden, A. (1990). Segmentation in the chick embryo hindbrain is defined by cell 
lineage restrictions. Nature 344, 431–435. 
Frost, B., and Diamond, M.I. (2010). Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 
11, 155–159. 
Fuentealba, L.C., Rompani, S.B., Parraguez, J.I., Obernier, K., Romero, R., Cepko, C.L., and Alvarez-Buylla, A. 
(2015). Embryonic Origin of Postnatal Neural Stem Cells. Cell 161, 1644–1655. 
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S., Shen, J., Takio, K., and 
Iwatsubo, T. (2002). [alpha]-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160. 
Füllgrabe, J., Klionsky, D.J., and Joseph, B. (2014). The return of the nucleus: transcriptional and epigenetic control 
of autophagy. Nat. Rev. Mol. Cell Biol. 15, 65–74. 
Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., and Obata, F. (2002). A new locus for Parkinson’s 
disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296–301. 
Gafni, O., Weinberger, L., Mansour, A.A., Manor, Y.S., Chomsky, E., Ben-Yosef, D., Kalma, Y., Viukov, S., Maza, 
I., Zviran, A., et al. (2013). Derivation of novel human ground state naive pluripotent stem cells. Nature 504, 282–
286. 
Gage, F.H. (2000). Mammalian Neural Stem Cells. Science 287, 1433–1438. 
Gage, F.H. (2008). Adult neurogenesis. Cold Spring Harb. Lab. Press. 
Gage, F.H., Coates, P.W., Palmer, T.D., Kuhn, H.G., Fisher, L.J., Suhonen, J.O., Peterson, D.A., Suhr, S.T., and 
Ray, J. (1995). Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain. Proc. 
Natl. Acad. Sci. 92, 11879–11883. 
Gaig, C., Marti, M.J., Ezquerra, M., Rey, M.J., Cardozo, A., and Tolosa, E. (2007). G2019S LRRK2 mutation causing 
Parkinson’s disease without Lewy bodies. J. Neurol. Neurosurg. Psychiatry 78, 626–628. 
Gaj, T., Gersbach, C.A., and Barbas, C.F. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome 
engineering. Trends Biotechnol. 31, 397–405. 
Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O., and Olson, L. (2006). LRRK2 expression linked 
to dopamine-innervated areas. Ann. Neurol. 59, 714–719. 
Gammill, L.S., and Bronner-Fraser, M. (2003). Neural crest specification: migrating into genomics. Nat. Rev. 
Neurosci. 4, 795–805. 
García-Prat, L., Martínez-Vicente, M., Perdiguero, E., Ortet, L., Rodríguez-Ubreva, J., Rebollo, E., Ruiz-Bonilla, V., 
Gutarra, S., Ballestar, E., Serrano, A.L., et al. (2016). Autophagy maintains stemness by preventing senescence. 
Nature 529, 37–42. 
Garcia-Reitboeck, P., Anichtchik, O., Dalley, J.W., Ninkina, N., Tofaris, G.K., Buchman, V.L., and Spillantini, M.G. 
(2013). Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. 
Exp. Neurol. 248, 541–545. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XVII 
Gardet, A., Benita, Y., Li, C., Sands, B.E., Ballester, I., Stevens, C., Korzenik, J.R., Rioux, J.D., Daly, M.J., Xavier, 
R.J., et al. (2010). LRRK2 Is Involved in the IFN- Response and Host Response to Pathogens. J. Immunol. 185, 
5577–5585. 
Gasser, T. (2009a). Mendelian forms of Parkinson’s disease. Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1792, 
587–596. 
Gasser, T. (2009b). Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. 
Med. 11. 
Gasser, T. (2011). Genetic basis of Parkinson’s disease: inheritance, penetrance, and expression. Appl. Clin. 
Genet. 67. 
Gehrke, S., Imai, Y., Sokol, N., and Lu, B. (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated 
translational repression. Nature 466, 637–641. 
Geisler, S., Holmström, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J., and Springer, W. (2010). 
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119–131. 
Gemma, C., Vila, J., Bachstetter, A., and Bickford, P.C. (2007). Oxidative Stress and the Aging Brain: From Theory 
to Prevention. In Brain Aging: Models, Methods, and Mechanisms, D.R. Riddle, ed. (Boca Raton (FL): CRC 
Press/Taylor & Francis), p. 
Germain, P.-L., and Testa, G. (2017). Taming Human Genetic Variability: Transcriptomic Meta-Analysis Guides the 
Experimental Design and Interpretation of iPSC-Based Disease Modeling. Stem Cell Rep. 8, 1784–1796. 
Giasson, B.I., Covy, J.P., Bonini, N.M., Hurtig, H.I., Farrer, M.J., Trojanowski, J.Q., and Van Deerlin, V.M. (2006). 
Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315–322. 
Gibb, W.R., and Lees, A.J. (1991). Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia 
nigra, and differential cell death in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 54, 388–396. 
Gibson, T.J., Seiler, M., and Veitia, R.A. (2013). The transience of transient overexpression. Nat. Methods 10, 715–
721. 
Gilsbach, B.K., and Kortholt, A. (2014). Structural biology of the LRRK2 GTPase and kinase domains: implications 
for regulation. Front. Mol. Neurosci. 7. 
Goedert, M., Spillantini, M.G., Del Tredici, K., and Braak, H. (2012). 100 years of Lewy pathology. Nat. Rev. Neurol. 
9, 13–24. 
Gomez-Suaga, P., Luzon-Toro, B., Churamani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P.G., Churchill, 
G.C., and Hilfiker, S. (2012). Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent 
pathway involving NAADP. Hum. Mol. Genet. 21, 511–525. 
Götz, M., and Huttner, W.B. (2005). The cell biology of neurogenesis. Nat. Rev. Mol. Cell Biol. 6, 777–788. 
Grace, A.A. (2016). Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. 
Nat. Rev. Neurosci. 17, 524–532. 
Graf, T., and Enver, T. (2009). Forcing cells to change lineages. Nature 462, 587–594. 
Graham, D.G. (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic 
quinones. Mol. Pharmacol. 14, 633–643. 
Groiss, S.J., Wojtecki, L., Südmeyer, M., and Schnitzler, A. (2009). Deep brain stimulation in Parkinson’s disease. 
Ther. Adv. Neurol. Disord. 2, 379–391. 
Guaitoli, G., Raimondi, F., Gilsbach, B.K., Gómez-Llorente, Y., Deyaert, E., Renzi, F., Li, X., Schaffner, A., Jagtap, 
P.K.A., Boldt, K., et al. (2016). Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact 
architecture involving distant interdomain contacts. Proc. Natl. Acad. Sci. 113, E4357–E4366. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XVIII 
Guerreiro, P.S., Huang, Y., Gysbers, A., Cheng, D., Gai, W.P., Outeiro, T.F., and Halliday, G.M. (2013). LRRK2 
interactions with α-synuclein in Parkinson’s disease brains and in cell models. J. Mol. Med. 91, 513–522. 
Guzman, J.N., Sanchez-Padilla, J., Chan, C.S., and Surmeier, D.J. (2009). Robust Pacemaking in Substantia Nigra 
Dopaminergic Neurons. J. Neurosci. 29, 11011–11019. 
Hakimi, M., Selvanantham, T., Swinton, E., Padmore, R.F., Tong, Y., Kabbach, G., Venderova, K., Girardin, S.E., 
Bulman, D.E., Scherzer, C.R., et al. (2011). Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue 
immune cells and upregulated following recognition of microbial structures. J. Neural Transm. 118, 795–808. 
Han, D.W., Tapia, N., Hermann, A., Hemmer, K., Höing, S., Araúzo-Bravo, M.J., Zaehres, H., Wu, G., Frank, S., 
Moritz, S., et al. (2012). Direct Reprogramming of Fibroblasts into Neural Stem Cells by Defined Factors. Cell Stem 
Cell 10, 465–472. 
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M.M., Hofstetter, R., 
Klauber, M., et al. (1990). The Lewy body variant of Alzheimer’s disease: A clinical and pathologic entity. Neurology 
40, 1–1. 
Harrington, A.J., Hamamichi, S., Caldwell, G.A., and Caldwell, K.A. (2010). C. elegans as a model organism to 
investigate molecular pathways involved with Parkinson’s disease. Dev. Dyn. NA-NA. 
He, C., and Klionsky, D.J. (2009). Regulation Mechanisms and Signaling Pathways of Autophagy. Annu. Rev. 
Genet. 43, 67–93. 
Henchcliffe, C., and Beal, M.F. (2008). Mitochondrial biology and oxidative stress in Parkinson disease 
pathogenesis. Nat. Clin. Pract. Neurol. 4, 600–609. 
Hernandez, D.G., Reed, X., and Singleton, A.B. (2016). Genetics in Parkinson disease: Mendelian versus non-
Mendelian inheritance. J. Neurochem. 139, 59–74. 
Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., 
Danner, S., et al. (2011). LRRK2 protein levels are determined by kinase function and are crucial for kidney and 
lung homeostasis in mice. Hum. Mol. Genet. 20, 4209–4223. 
Hockemeyer, D., Soldner, F., Beard, C., Gao, Q., Mitalipova, M., DeKelver, R.C., Katibah, G.E., Amora, R., 
Boydston, E.A., Zeitler, B., et al. (2009). Efficient targeting of expressed and silent genes in human ESCs and iPSCs 
using zinc-finger nucleases. Nat. Biotechnol. 27, 851–857. 
Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., Cassady, J.P., Cost, G.J., Zhang, L., Santiago, Y., Miller, 
J.C., et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731–
734. 
Höglinger, G.U., Rizk, P., Muriel, M.P., Duyckaerts, C., Oertel, W.H., Caille, I., and Hirsch, E.C. (2004). Dopamine 
depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 7, 726–735. 
Huisman, E., Uylings, H.B.M., and Hoogland, P.V. (2004). A 100% increase of dopaminergic cells in the olfactory 
bulb may explain hyposmia in Parkinson’s disease. Mov. Disord. 19, 687–692. 
Hyttinen, J.M.T., Niittykoski, M., Salminen, A., and Kaarniranta, K. (2013). Maturation of autophagosomes and 
endosomes: A key role for Rab7. Biochim. Biophys. Acta BBA - Mol. Cell Res. 1833, 503–510. 
Imai, Y., Gehrke, S., Wang, H.-Q., Takahashi, R., Hasegawa, K., Oota, E., and Lu, B. (2008). Phosphorylation of 
4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432–2443. 
Imai, Y., Kobayashi, Y., Inoshita, T., Meng, H., Arano, T., Uemura, K., Asano, T., Yoshimi, K., Zhang, C.-L., 
Matsumoto, G., et al. (2015). The Parkinson’s Disease-Associated Protein Kinase LRRK2 Modulates Notch 
Signaling through the Endosomal Pathway. PLOS Genet. 11, e1005503. 
Ishihara, L., Warren, L., Gibson, R., Amouri, R., Lesage, S., Dürr, A., Tazir, M., Wszolek, Z.K., Uitti, R.J., Nichols, 
W.C., et al. (2006). Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 
2 G2019S Mutations. Arch. Neurol. 63, 1250. 
Ito, K., and Suda, T. (2014). Metabolic requirements for the maintenance of self-renewing stem cells. Nat. Rev. Mol. 
Cell Biol. 15, 243–256. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XIX 
Jacobs, S., Lie, D.C., DeCicco, K.L., Shi, Y., DeLuca, L.M., Gage, F.H., and Evans, R.M. (2006). Retinoic acid is 
required early during adult neurogenesis in the dentate gyrus. Proc. Natl. Acad. Sci. U. S. A. 103, 3902–3907. 
Jager, W.D.H., and Bethlem, J. (1960). The distribution of Lewy bodies in the central and autonomic nervous 
systems in idiopathic paralysis agitans. J. Neurol. Neurosurg. Psychiatry 23, 283. 
Jagmag, S.A., Tripathi, N., Shukla, S.D., Maiti, S., and Khurana, S. (2016). Evaluation of Models of Parkinson’s 
Disease. Front. Neurosci. 9. 
Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A., and Alessi, D.R. (2007). LRRK2 
phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. 
Biochem. J. 405, 307–317. 
Jellinger, K.A. (2009). A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. 
Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1792, 730–740. 
Jenner, P. (2003). Oxidative stress in Parkinson’s disease. Ann. Neurol. 53, S26–S38. 
Jin, S.M., and Youle, R.J. (2012). PINK1- and Parkin-mediated mitophagy at a glance. J. Cell Sci. 125, 795–799. 
Johnston, I.G., Burgstaller, J.P., Havlicek, V., Kolbe, T., Rülicke, T., Brem, G., Poulton, J., and Jones, N.S. (2015). 
Stochastic modelling, Bayesian inference, and new in vivo measurements elucidate the debated mtDNA bottleneck 
mechanism. Elife 4, e07464. 
Jones, R. (2010). The roles of PINK1 and Parkin in Parkinson’s disease. PLoS Biol. 8, e1000299. 
Jung, C.H., Ro, S.-H., Cao, J., Otto, N.M., and Kim, D.-H. (2010). mTOR regulation of autophagy. FEBS Lett. 584, 
1287–1295. 
Kamel, F., and Hoppin, J.A. (2004). Association of Pesticide Exposure with Neurologic Dysfunction and Disease. 
Environ. Health Perspect. 112, 950–958. 
Kang, R., Zeh, H.J., Lotze, M.T., and Tang, D. (2011). The Beclin 1 network regulates autophagy and apoptosis. 
Cell Death Differ. 18, 571–580. 
Kanninen, K.M., Bister, N., Koistinaho, J., and Malm, T. (2016). Exosomes as new diagnostic tools in CNS diseases. 
Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1862, 403–410. 
Kelava, I., and Lancaster, M.A. (2016). Stem Cell Models of Human Brain Development. Cell Stem Cell 18, 736–
748. 
Khurana, V., and Lindquist, S. (2010). Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with 
baker’s yeast? Nat. Rev. Neurosci. 11, 436–449. 
Kim, H.-J., and Jeon, B.S. (2014). Hypothesis: Somatic Mosaicism and Parkinson Disease. Exp. Neurobiol. 23, 
271. 
Kim, B., Yang, M.-S., Choi, D., Kim, J.-H., Kim, H.-S., Seol, W., Choi, S., Jou, I., Kim, E.-Y., and Joe, E. (2012). 
Impaired Inflammatory Responses in Murine Lrrk2-Knockdown Brain Microglia. PLoS ONE 7, e34693. 
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M.J., Ji, H., Ehrlich, L.I.R., et al. (2010). 
Epigenetic memory in induced pluripotent stem cells. Nature 467, 285–290. 
Kirkeby, A., Nolbrant, S., Tiklova, K., Heuer, A., Kee, N., Cardoso, T., Ottosson, D.R., Lelos, M.J., Rifes, P., Dunnett, 
S.B., et al. (2017). Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of 
hESC-Based Therapy for Parkinson’s Disease. Cell Stem Cell 20, 135–148. 
Klein, C., and Westenberger, A. (2012). Genetics of Parkinson’s Disease. Cold Spring Harb. Perspect. Med. 2, 
a008888–a008888. 
Klionsky, D.J. (2007). Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. 
Rev. Mol. Cell Biol. 8, 931–937. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XX 
Klionsky, D.J., Abdalla, F.C., Abeliovich, H., Abraham, R.T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, 
M., Agostinis, P., Aguirre-Ghiso, J.A., et al. (2012). Guidelines for the use and interpretation of assays for monitoring 
autophagy. Autophagy 8, 445–544. 
Koller, W.C. (1992). When does Parkinson’s disease begin? Neurology 42, 27-31; discussion 41-48. 
Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., and Olanow, C.W. (2008). Lewy body–like pathology in long-
term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 14, 504–506. 
Kornmann, B. (2014). Quality control in mitochondria: use it, break it, fix it, trash it. F1000prime Rep. 6. 
Kriegstein, A., and Alvarez-Buylla, A. (2009). The Glial Nature of Embryonic and Adult Neural Stem Cells. Annu. 
Rev. Neurosci. 32, 149–184. 
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., 
Buch, A., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of 
Parkinson’s disease. Nature. 
La Manno, G., Gyllborg, D., Codeluppi, S., Nishimura, K., Salto, C., Zeisel, A., Borm, L.E., Stott, S.R.W., Toledo, 
E.M., Villaescusa, J.C., et al. (2016). Molecular Diversity of Midbrain Development in Mouse, Human, and Stem 
Cells. Cell 167, 566–580.e19. 
Lancaster, M.A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L.S., Hurles, M.E., Homfray, T., Penninger, J.M., 
Jackson, A.P., and Knoblich, J.A. (2013). Cerebral organoids model human brain development and microcephaly. 
Nature 501, 373–379. 
Langer, T. (2000). AAA proteases: cellular machines for degrading membrane proteins. Trends Biochem. Sci. 25, 
247–251. 
Langston, J.W. (2006). The parkinson’s complex: Parkinsonism is just the tip of the iceberg. Ann. Neurol. 59, 591–
596. 
Langston, J.W. (2017). The MPTP Story. J. Park. Dis. 7, S11–S19. 
Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of 
meperidine-analog synthesis. Science 219, 979–980. 
Lashuel, H.A., Overk, C.R., Oueslati, A., and Masliah, E. (2012). The many faces of α-synuclein: from structure and 
toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48. 
Lawton, M., Baig, F., Rolinski, M., Ruffman, C., Nithi, K., May, M.T., Ben-Shlomo, Y., and Hu, M.T.M. (2015). 
Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort. J. Park. Dis. 5, 
269–279. 
Le Grand, J.N., Gonzalez-Cano, L., Pavlou, M.A., and Schwamborn, J.C. (2014). Neural stem cells in Parkinson’s 
disease: a role for neurogenesis defects in onset and progression. Cell. Mol. Life Sci. 
Lesage, S., Patin, E., Condroyer, C., Leutenegger, A.L., Lohmann, E., Giladi, N., Bar-Shira, A., Belarbi, S., Hecham, 
N., Pollak, P., et al. (2010). Parkinson’s disease-related LRRK2 G2019S mutation results from independent 
mutational events in humans. Hum. Mol. Genet. 19, 1998–2004. 
Levine, A.J., and Brivanlou, A.H. (2007). Proposal of a model of mammalian neural induction. Dev. Biol. 308, 247–
256. 
Li, J.-Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T., Quinn, N.P., Rehncrona, S., 
Björklund, A., et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-
graft disease propagation. Nat. Med. 14, 501–503. 
Li, M., Rothwell, R., Vermaat, M., Wachsmuth, M., Schröder, R., Laros, J.F.J., van Oven, M., de Bakker, P.I.W., 
Bovenberg, J.A., van Duijn, C.M., et al. (2016). Transmission of human mtDNA heteroplasmy in the Genome of the 
Netherlands families: support for a variable-size bottleneck. Genome Res. 26, 417–426. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXI 
Lin, M.T., and Beal, M.F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. 
Nature 443, 787–795. 
Lin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.-X., Yang, W.-J., Ding, J., et al. 
(2009). Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson’s-
Disease-Related Mutant α-synuclein. Neuron 64, 807–827. 
Liu, G.-H., Qu, J., Suzuki, K., Nivet, E., Li, M., Montserrat, N., Yi, F., Xu, X., Ruiz, S., Zhang, W., et al. (2012). 
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491, 603–607. 
López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The Hallmarks of Aging. Cell 153, 
1194–1217. 
Lorenz, C., Lesimple, P., Bukowiecki, R., Zink, A., Inak, G., Mlody, B., Singh, M., Semtner, M., Mah, N., Auré, K., 
et al. (2017). Human iPSC-Derived Neural Progenitors Are an Effective Drug Discovery Model for Neurological 
mtDNA Disorders. Cell Stem Cell 20, 659–674.e9. 
Luk, K.C., and Lee, V.M.-Y. (2014). Modeling Lewy pathology propagation in Parkinson’s disease. Parkinsonism 
Relat. Disord. 20, S85–S87. 
Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J.Q., and Lee, V.M.-Y. (2012). Pathological -
Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. Science 338, 949–953. 
Lumsden, A., and Graham, A. (1995). Neural patterning: A forward role for hedgehog. Curr. Biol. 5, 1347–1350. 
Lunnon, K., Smith, R., Hannon, E., De Jager, P.L., Srivastava, G., Volta, M., Troakes, C., Al-Sarraj, S., Burrage, J., 
Macdonald, R., et al. (2014). Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. 
Nat. Neurosci. 17, 1164–1170. 
Luzio, J.P., Pryor, P.R., and Bright, N.A. (2007). Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8, 622–
632. 
MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., and Abeliovich, A. (2006). The Familial Parkinsonism 
Gene LRRK2 Regulates Neurite Process Morphology. Neuron 52, 587–593. 
MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B.D., Marder, K.S., Honig, L.S., Clark, 
L.N., Small, S.A., et al. (2013). RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and 
Parkinson’s Disease Risk. Neuron 77, 425–439. 
Makin, S. (2016). Pathology: The prion principle. Nature 538, S13–S16. 
Manzoni, C., Mamais, A., Roosen, D.A., Dihanich, S., Soutar, M.P.M., Plun-Favreau, H., Bandopadhyay, R., Hardy, 
J., Tooze, S.A., Cookson, M.R., et al. (2016). mTOR independent regulation of macroautophagy by Leucine Rich 
Repeat Kinase 2 via Beclin-1. Sci. Rep. 6. 
Marchetto, M.C., and Gage, F.H. (2012). Modeling Brain Disease in a Dish: Really? Cell Stem Cell 10, 642–645. 
Mari, P.-O., Florea, B.I., Persengiev, S.P., Verkaik, N.S., Brüggenwirth, H.T., Modesti, M., Giglia-Mari, G., 
Bezstarosti, K., Demmers, J.A., Luider, T.M., et al. (2006). Dynamic assembly of end-joining complexes requires 
interaction between Ku70/80 and XRCC4. Proc. Natl. Acad. Sci. 103, 18597–18602. 
Mariani, J., Simonini, M.V., Palejev, D., Tomasini, L., Coppola, G., Szekely, A.M., Horvath, T.L., and Vaccarino, 
F.M. (2012). Modeling human cortical development in vitro using induced pluripotent stem cells. Proc. Natl. Acad. 
Sci. 109, 12770–12775. 
Markesbery, W.R., Jicha, G.A., Liu, H., and Schmitt, F.A. (2009). Lewy body pathology in normal elderly subjects. 
J. Neuropathol. Exp. Neurol. 68, 816–822. 
Marras, C., Lohmann, K., Lang, A., and Klein, C. (2012). Fixing the broken system of genetic locus symbols 
Parkinson disease and dystonia as examples. Neurology 78, 1016–1024. 
Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned 
by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. 78, 7634–7638. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXII 
Martin, I., Kim, J.W., Lee, B.D., Kang, H.C., Xu, J.-C., Jia, H., Stankowski, J., Kim, M.-S., Zhong, J., Kumar, M., et 
al. (2014a). Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson’s Disease. 
Cell 157, 472–485. 
Martin, I., Kim, J.W., Dawson, V.L., and Dawson, T.M. (2014b). LRRK2 pathobiology in Parkinson’s disease. J. 
Neurochem. 131, 554–565. 
Martinez-Vicente, M., and Cuervo, A.M. (2007). Autophagy and neurodegeneration: when the cleaning crew goes 
on strike. Lancet Neurol. 6, 352–361. 
Marxreiter, F., Regensburger, M., and Winkler, J. (2013). Adult neurogenesis in Parkinson’s disease. Cell. Mol. Life 
Sci. 70, 459–473. 
Matikainen-Ankney, B.A., Kezunovic, N., Mesias, R.E., Tian, Y., Williams, F.M., Huntley, G.W., and Benson, D.L. 
(2016). Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson’s Disease-Linked 
LRRK2–G2019S Mutation. J. Neurosci. 36, 7128–7141. 
Matsunaga, E., Araki, I., and Nakamura, H. (2000). Pax6 defines the di-mesencephalic boundary by repressing 
En1 and Pax2. Development 127, 2357–2365. 
Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., De Bock, P.-J., 
Morais, V.A., Vilain, S., Haddad, D., et al. (2012). LRRK2 Controls an EndoA Phosphorylation Cycle in Synaptic 
Endocytosis. Neuron 75, 1008–1021. 
Mertens, J., Marchetto, M.C., Bardy, C., and Gage, F.H. (2016). Evaluating cell reprogramming, differentiation and 
conversion technologies in neuroscience. Nat. Rev. Neurosci. 
Mieko Mizutani, C., and Bier, E. (2008). EvoD/Vo: the origins of BMP signalling in the neuroectoderm. Nat. Rev. 
Genet. 9, 663–677. 
Miller, J.D., Ganat, Y.M., Kishinevsky, S., Bowman, R.L., Liu, B., Tu, E.Y., Mandal, P.K., Vera, E., Shim, J., Kriks, 
S., et al. (2013). Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging. Cell Stem Cell 
13, 691–705. 
Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M.D., Klionsky, D.J., Ohsumi, M., and Ohsumi, 
Y. (1998). A protein conjugation system essential for autophagy. Nature 395, 395–398. 
Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., Cowell, R.M., and West, A.B. 
(2012). LRRK2 Inhibition Attenuates Microglial Inflammatory Responses. J. Neurosci. 32, 1602–1611. 
Monzel, A.S., Smits, L.M., Hemmer, K., Hachi, S., Moreno, E.L., van Wuellen, T., Jarazo, J., Walter, J., 
Br?ggemann, I., Boussaad, I., et al. (2017). Derivation of Human Midbrain-Specific Organoids from Neuroepithelial 
Stem?Cells. Stem Cell Rep. 8, 1144–1154. 
Moore, K., McKnight, A.J., Craig, D., and O’Neill, F. (2014). Epigenome-Wide Association Study for Parkinson’s 
Disease. NeuroMolecular Med. 16, 845–855. 
Muguruma, K., Nishiyama, A., Kawakami, H., Hashimoto, K., and Sasai, Y. (2015). Self-Organization of Polarized 
Cerebellar Tissue in 3D Culture of Human Pluripotent Stem Cells. Cell Rep. 10, 537–550. 
Muñoz-Sanjuán, I., and Brivanlou, A.H. (2002). NEURAL INDUCTION, THE DEFAULT MODEL AND EMBRYONIC 
STEM CELLS. Nat. Rev. Neurosci. 3, 271–280. 
Nakamura, H., Sato, T., and Suzuki-Hirano, A. (2008). Isthmus organizer for mesencephalon and metencephalon: 
Isthmus organizer. Dev. Growth Differ. 50, S113–S118. 
Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., Kara, E., Bras, J., 
Sharma, M., et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci 
for Parkinson’s disease. Nat. Genet. 46, 989–993. 
Narendra, D., Tanaka, A., Suen, D.-F., and Youle, R.J. (2008). Parkin is recruited selectively to impaired 
mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXIII 
Neufeld, E.F. (1991). Lysosomal storage diseases. Annu. Rev. Biochem. 60, 257–280. 
Neutzner, A., Youle, R.J., and Karbowski, M. (2007). Outer mitochondrial membrane protein degradation by the 
proteasome. Novartis Found. Symp. 287, 4-14; discussion 14-20. 
Nichols, J., and Smith, A. (2009). Naive and Primed Pluripotent States. Cell Stem Cell 4, 487–492. 
Niehrs, C. (2004). Regionally specific induction by the Spemann–Mangold organizer. Nat. Rev. Genet. 5, 425–434. 
Niu, J., Yu, M., Wang, C., and Xu, Z. (2012). Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via 
Dynamin-like protein: LRRK2 disturbs mitochondrial dynamics via DLP1. J. Neurochem. 122, 650–658. 
Niwa, H. (2007). How is pluripotency determined and maintained? Development 134, 635–646. 
Nixon, R.A. (2006). Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci. 29, 528–
535. 
Nixon, R.A. (2013). The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983–997. 
Nuytemans, K., Theuns, J., Cruts, M., and Van Broeckhoven, C. (2010). Genetic etiology of Parkinson disease 
associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. 
Mutat. 31, 763–780. 
Okabe, S., Forsberg-Nilsson, K., Spiro, A.C., Segal, M., and McKay, R.D.G. (1996). Development of neuronal 
precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech. Dev. 59, 89–102. 
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., 
Tezuka, K., et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 
409–412. 
Oliveira, M.A.P., Balling, R., Smidt, M.P., and Fleming, R.M.T. (2017). Embryonic development of selectively 
vulnerable neurons in Parkinson’s disease. Npj Park. Dis. 3. 
Olsson, M., Nikkhah, G., Bentlage, C., and Bjorklund, A. (1995). Forelimb akinesia in the rat Parkinson model: 
differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 
15, 3863–3875. 
Orenstein, S.J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L.S., Dauer, 
W., Consiglio, A., et al. (2013). Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394–
406. 
Orkin, S.H., and Zon, L.I. (2008). Hematopoiesis: An Evolving Paradigm for Stem Cell Biology. Cell 132, 631–644. 
Paisán-Ruiz, C., Lewis, P.A., and Singleton, A.B. (2013). LRRK2: cause, risk, and mechanism. J. Park. Dis. 3, 85–
103. 
Paisán-Ruı́z, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., van der Brug, M., de Munain, A.L., Aparicio, S., Gil, 
A.M., Khan, N., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s 
disease. Neuron 44, 595–600. 
Pan, T., Kondo, S., Le, W., and Jankovic, J. (2008). The role of autophagy-lysosome pathway in neurodegeneration 
associated with Parkinson’s disease. Brain 131, 1969–1978. 
Parisiadou, L., Xie, C., Cho, H.J., Lin, X., Gu, X.-L., Long, C.-X., Lobbestael, E., Baekelandt, V., Taymans, J.-M., 
Sun, L., et al. (2009). Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement 
of Actin Cytoskeleton in Neuronal Morphogenesis. J. Neurosci. 29, 13971–13980. 
Parisiadou, L., Yu, J., Sgobio, C., Xie, C., Liu, G., Sun, L., Gu, X.-L., Lin, X., Crowley, N.A., Lovinger, D.M., et al. 
(2014). LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. 
Nat. Neurosci. 17, 367–376. 
Parkinson, J. (1817). An Essay on the Shaking Palsy. Whittingham and Rowland. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXIV 
Pasparakis, M., and Vandenabeele, P. (2015). Necroptosis and its role in inflammation. Nature 517, 311–320. 
Perrier, A.L., Tabar, V., Barberi, T., Rubio, M.E., Bruses, J., Topf, N., Harrison, N.L., and Studer, L. (2004). 
Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 101, 
12543–12548. 
Phinney, D.G., Di Giuseppe, M., Njah, J., Sala, E., Shiva, S., St Croix, C.M., Stolz, D.B., Watkins, S.C., Di, Y.P., 
Leikauf, G.D., et al. (2015). Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle 
microRNAs. Nat. Commun. 6, 8472. 
Pissadaki, E.K., and Bolam, J.P. (2013). The energy cost of action potential propagation in dopamine neurons: 
clues to susceptibility in Parkinson’s disease. Front. Comput. Neurosci. 7. 
Plowey, E.D., Cherra, S.J., Liu, Y.-J., and Chu, C.T. (2008). Role of autophagy in G2019S-LRRK2-associated 
neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 105, 1048–1056. 
Plusa, B., and Hadjantonakis, A.-K. (2014). Embryonic stem cell identity grounded in the embryo. Nat. Cell Biol. 16, 
502. 
Polymeropoulos, M.H. (1997). Mutation in the -Synuclein Gene Identified in Families with Parkinson’s Disease. 
Science 276, 2045–2047. 
Prakash, N., and Wurst, W. (2006). Genetic networks controlling the development of midbrain dopaminergic 
neurons: Genetic control of midbrain dopaminergic neuron development. J. Physiol. 575, 403–410. 
Prieto, J., León, M., Ponsoda, X., Sendra, R., Bort, R., Ferrer-Lorente, R., Raya, A., López-García, C., and Torres, 
J. (2016). Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell 
reprogramming. Nat. Commun. 7, 11124. 
Proukakis, C., Houlden, H., and Schapira, A.H. (2013). Somatic alpha-synuclein mutations in Parkinson’s disease: 
Hypothesis and preliminary data: Snca Somatic Mutation Hypothesis. Mov. Disord. 28, 705–712. 
Przedborski, S. (2017). The two-century journey of Parkinson disease research. Nat. Rev. Neurosci. 18, 251–259. 
Qing, H., Zhang, Y., Deng, Y., McGeer, E.G., and McGeer, P.L. (2009). Lrrk2 interaction with α-synuclein in diffuse 
Lewy body disease. Biochem. Biophys. Res. Commun. 390, 1229–1234. 
Raposo, G., and Stoorvogel, W. (2013). Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell Biol. 
200, 373–383. 
Recasens, A., Dehay, B., Bové, J., Carballo-Carbajal, I., Dovero, S., Pérez-Villalba, A., Fernagut, P.-O., Blesa, J., 
Parent, A., Perier, C., et al. (2014). Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology 
and neurodegeneration in mice and monkeys: LB-Induced Pathology. Ann. Neurol. 75, 351–362. 
Reeve, A., Simcox, E., and Turnbull, D. (2014). Ageing and Parkinson’s disease: Why is advancing age the biggest 
risk factor? Ageing Res. Rev. 14, 19–30. 
Reinhardt, P., Schmid, B., Burbulla, L.F., Schöndorf, D.C., Wagner, L., Glatza, M., Höing, S., Hargus, G., Heck, 
S.A., Dhingra, A., et al. (2013a). Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian 
Neurodegeneration to ERK-Dependent Changes in Gene Expression. Cell Stem Cell 12, 354–367. 
Reinhardt, P., Glatza, M., Hemmer, K., Tsytsyura, Y., Thiel, C.S., Höing, S., Moritz, S., Parga, J.A., Wagner, L., 
Bruder, J.M., et al. (2013b). Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors 
for Neurodegenerative Disease Modeling. PLoS ONE 8, e59252. 
Reubinoff, B.E., Itsykson, P., Turetsky, T., Pera, M.F., Reinhartz, E., Itzik, A., and Ben-Hur, T. (2001). Neural 
progenitors from human embryonic stem cells. Nat. Biotechnol. 19, 1134–1140. 
Reynolds, B., and Weiss, S. (1992). Generation of neurons and astrocytes from isolated cells of the adult 
mammalian central nervous system. Science 255, 1707–1710. 
Reynolds, B.A., Tetzlaff, W., and Weiss, S. (1992). A multipotent EGF-responsive striatal embryonic progenitor cell 
produces neurons and astrocytes. J. Neurosci. 12, 4565–4574. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXV 
Rideout, H.J. (2017). Leucine-Rich Repeat kinase 2 (LRRK2). 
Rivero‑Ríos, P., Gómez‑Suaga, P., Fernández, B., Madero‑Pérez, J., Schwab, A.J., Ebert, A.D., and Hilfiker, S. 
(2015). Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson’s disease. 
Biochem. Soc. Trans. 43, 390–395. 
Rochet, J.-C., Conway, K.A., and Lansbury, P.T. (2000). Inhibition of Fibrillization and Accumulation of Prefibrillar 
Oligomers in Mixtures of Human and Mouse α-Synuclein †. Biochemistry (Mosc.) 39, 10619–10626. 
Rolletschek, A., Chang, H., Guan, K., Czyz, J., Meyer, M., and Wobus, A.M. (2001). Differentiation of embryonic 
stem cell-derived dopaminergic neurons is enhanced by survival-promoting factors. Mech. Dev. 105, 93–104. 
Roosen, D.A., and Cookson, M.R. (2016). LRRK2 at the interface of autophagosomes, endosomes and lysosomes. 
Mol. Neurodegener. 11. 
Rossignol, R., Gilkerson, R., Aggeler, R., Yamagata, K., Remington, S.J., and Capaldi, R.A. (2004). Energy 
substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 64, 985–993. 
Rubenstein, J.L., Martinez, S., Shimamura, K., Puelles, L., and others (1994). The embryonic vertebrate forebrain: 
the prosomeric model. Sci.-N. Y. THEN Wash.- 578–578. 
Rubinsztein, D.C., Mariño, G., and Kroemer, G. (2011). Autophagy and Aging. Cell 146, 682–695. 
Ryan, S.D., Dolatabadi, N., Chan, S.F., Zhang, X., Akhtar, M.W., Parker, J., Soldner, F., Sunico, C.R., Nagar, S., 
Talantova, M., et al. (2013). Isogenic Human iPSC Parkinson’s Model Shows Nitrosative Stress-Induced 
Dysfunction in MEF2-PGC1α Transcription. Cell 155, 1351–1364. 
Sakurada, K., Ohshima-Sakurada, M., Palmer, T.D., and Gage, F.H. (1999). Nurr1, an orphan nuclear receptor, is 
a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. 
Development 126, 4017–4026. 
Sanai, N., Nguyen, T., Ihrie, R.A., Mirzadeh, Z., Tsai, H.-H., Wong, M., Gupta, N., Berger, M.S., Huang, E., Garcia-
Verdugo, J.-M., et al. (2011). Corridors of migrating neurons in the human brain and their decline during infancy. 
Nature 478, 382–386. 
Sánchez-Danés, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jiménez-Delgado, S., Caig, C., Mora, S., Di 
Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A., et al. (2012). Disease-specific phenotypes in dopamine neurons 
from human iPS-based models of genetic and sporadic Parkinson’s disease: iPS cell-based model of Parkinson’s 
disease. EMBO Mol. Med. 4, 380–395. 
Sanders, L.H., Laganière, J., Cooper, O., Mak, S.K., Vu, B.J., Huang, Y.A., Paschon, D.E., Vangipuram, M., 
Sundararajan, R., Urnov, F.D., et al. (2014). LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived 
neural cells from Parkinson’s disease patients: Reversal by gene correction. Neurobiol. Dis. 62, 381–386. 
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di Malta, C., Donaudy, F., 
Embrione, V., Polishchuk, R.S., et al. (2009). A Gene Network Regulating Lysosomal Biogenesis and Function. 
Science. 
Sargsyan, A., Cai, J., Fandino, L.B., Labasky, M.E., Forostyan, T., Colosimo, L.K., Thompson, S.J., and Graham, 
T.E. (2015). Rapid parallel measurements of macroautophagy and mitophagy in mammalian cells using a single 
fluorescent biosensor. Sci. Rep. 5, 12397. 
Sarko, D.K., and McKinney, C.E. (2017). Exosomes: Origins and Therapeutic Potential for Neurodegenerative 
Disease. Front. Neurosci. 11. 
Sasai, Y. (2013). Next-Generation Regenerative Medicine: Organogenesis from Stem Cells in 3D Culture. Cell 
Stem Cell 12, 520–530. 
Schaefer, K.A., Wu, W.-H., Colgan, D.F., Tsang, S.H., Bassuk, A.G., and Mahajan, V.B. (2017). Unexpected 
mutations after CRISPR-Cas9 editing in vivo. Nat. Methods 14, 547–548. 
Schapira, A.H.V., Chaudhuri, K.R., and Jenner, P. (2017). Non-motor features of Parkinson disease. Nat. Rev. 
Neurosci. 18, 435–450. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXVI 
Schon, E.A., DiMauro, S., and Hirano, M. (2012). Human mitochondrial DNA: roles of inherited and somatic 
mutations. Nat. Rev. Genet. 13, 878–890. 
Schöndorf, D.C., Aureli, M., McAllister, F.E., Hindley, C.J., Mayer, F., Schmid, B., Sardi, S.P., Valsecchi, M., 
Hoffmann, S., Schwarz, L.K., et al. (2014). iPSC-derived neurons from GBA1-associated Parkinson’s disease 
patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5. 
Searles Nielsen, S., Gallagher, L.G., Lundin, J.I., Longstreth, W.T., Smith-Weller, T., Franklin, G.M., Swanson, 
P.D., and Checkoway, H. (2012). Environmental tobacco smoke and Parkinson’s disease. Mov. Disord. 27, 293–
297. 
Settembre, C., Fraldi, A., Medina, D.L., and Ballabio, A. (2013). Signals from the lysosome: a control centre for 
cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 14, 283–296. 
Shulman, J.M., De Jager, P.L., and Feany, M.B. (2011). Parkinson’s Disease: Genetics and Pathogenesis. Annu. 
Rev. Pathol. Mech. Dis. 6, 193–222. 
Sidransky, E., and Lopez, G. (2012). The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986–
998. 
Sierra, M., González-Aramburu, I., Sánchez-Juan, P., Sánchez-Quintana, C., Polo, J.M., Berciano, J., Combarros, 
O., and Infante, J. (2011). High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson’s 
disease patients in Cantabria (Spain). Mov. Disord. 26, 2343–2346. 
Simeone, A., Acampora, D., Gulisano, M., Stornaiuolo, A., and Boncinelli, E. (1992). Nested expression domains 
of four homeobox genes in developing rostral brain. Nature 358, 687–690. 
Skibinski, G., Nakamura, K., Cookson, M.R., and Finkbeiner, S. (2014). Mutant LRRK2 Toxicity in Neurons 
Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies. J. Neurosci. 34, 418–433. 
Smirnova, E., Griparic, L., Shurland, D.-L., and Van Der Bliek, A.M. (2001). Dynamin-related protein Drp1 is required 
for mitochondrial division in mammalian cells. Mol. Biol. Cell 12, 2245–2256. 
Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M., and Ross, C.A. 
(2005). Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal 
degeneration. Proc. Natl. Acad. Sci. U. S. A. 102, 18676–18681. 
Soldner, F., Stelzer, Y., Shivalila, C.S., Abraham, B.J., Latourelle, J.C., Barrasa, M.I., Goldmann, J., Myers, R.H., 
Young, R.A., and Jaenisch, R. (2016). Parkinson-associated risk variant in distal enhancer of α-synuclein modulates 
target gene expression. Nature 533, 95–99. 
Soubannier, V., McLelland, G.-L., Zunino, R., Braschi, E., Rippstein, P., Fon, E.A., and McBride, H.M. (2012a). A 
Vesicular Transport Pathway Shuttles Cargo from Mitochondria to Lysosomes. Curr. Biol. 22, 135–141. 
Soubannier, V., Rippstein, P., Kaufman, B.A., Shoubridge, E.A., and McBride, H.M. (2012b). Reconstitution of 
Mitochondria Derived Vesicle Formation Demonstrates Selective Enrichment of Oxidized Cargo. PLoS ONE 7, 
e52830. 
Spalding, K.L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H.B., Boström, E., Westerlund, I., 
Vial, C., Buchholz, B.A., et al. (2013). Dynamics of Hippocampal Neurogenesis in Adult Humans. Cell 153, 1219–
1227. 
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein 
in Lewy bodies. Nature 388, 839–840. 
Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). α-Synuclein in filamentous 
inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. 95, 
6469–6473. 
Stafa, K., Tsika, E., Moser, R., Musso, A., Glauser, L., Jones, A., Biskup, S., Xiong, Y., Bandopadhyay, R., Dawson, 
V.L., et al. (2014). Functional interaction of Parkinson’s disease-associated LRRK2 with members of the dynamin 
GTPase superfamily. Hum. Mol. Genet. 23, 2055–2077. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXVII 
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., 
et al. (2016). Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab 
GTPases. eLife 5. 
Steinbeck, J.A., and Studer, L. (2015). Moving Stem Cells to the Clinic: Potential and Limitations for Brain Repair. 
Neuron 86, 187–206. 
Stiles, J., and Jernigan, T.L. (2010). The Basics of Brain Development. Neuropsychol. Rev. 20, 327–348. 
Stracker, T.H., and Petrini, J.H.J. (2011). The MRE11 complex: starting from the ends. Nat. Rev. Mol. Cell Biol. 12, 
90–103. 
Studer, L., Vera, E., and Cornacchia, D. (2015). Programming and Reprogramming Cellular Age in the Era of 
Induced Pluripotency. Cell Stem Cell 16, 591–600. 
Su, Y.-C., and Qi, X. (2013). Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal 
damage caused by LRRK2 G2019S mutation. Hum. Mol. Genet. 22, 4545–4561. 
Sugiura, A., McLelland, G.-L., Fon, E.A., and McBride, H.M. (2014). A new pathway for mitochondrial quality control: 
mitochondrial-derived vesicles. EMBO J. 33, 2142–2156. 
Sulzer, D. (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci. 30, 
244–250. 
Sulzer, D., and Surmeier, D.J. (2013). Neuronal vulnerability, pathogenesis, and Parkinson’s disease: Neuronal 
Vulnerability, Pathogenesis, and PD. Mov. Disord. 28, 41–50. 
Sulzer, D., Alcalay, R.N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, 
W.H., Mao, X., et al. (2017). T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature 
546, 656–661. 
Sun, N., Youle, R.J., and Finkel, T. (2016). The Mitochondrial Basis of Aging. Mol. Cell 61, 654–666. 
Surmeier, D.J., Guzman, J.N., and Sanchez-Padilla, J. (2010). Calcium, cellular aging, and selective neuronal 
vulnerability in Parkinson’s disease. Cell Calcium 47, 175–182. 
Surmeier, D.J., Obeso, J.A., and Halliday, G.M. (2017). Selective neuronal vulnerability in Parkinson disease. Nat. 
Rev. Neurosci. 18, 101–113. 
Sweet, E.S., Saunier-Rebori, B., Yue, Z., and Blitzer, R.D. (2015). The Parkinson’s Disease-Associated Mutation 
LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus. J. Neurosci. 35, 11190–11195. 
Swistowski, A., Peng, J., Liu, Q., Mali, P., Rao, M.S., Cheng, L., and Zeng, X. (2010). Efficient Generation of 
Functional Dopaminergic Neurons from Human Induced Pluripotent Stem Cells Under Defined Conditions. STEM 
CELLS 28, 1893–1904. 
Takahashi, K., and Yamanaka, S. (2006). Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult 
Fibroblast Cultures by Defined Factors. Cell 126, 663–676. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction 
of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 131, 861–872. 
Takeshige, K., Baba, M., Tsuboi, S., Noda, T., and Ohsumi, Y. (1992). Autophagy in yeast demonstrated with 
proteinase-deficient mutants and conditions for its induction. J. Cell Biol. 119, 301–311. 
Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G.B., and Kondo, S. (2005). Synergistic 
augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein 
kinase B inhibitors. Cancer Res. 65, 3336–3346. 
Tanida, I., Minematsu-Ikeguchi, N., Ueno, T., and Kominami, E. (2005). Lysosomal turnover, but not a cellular level, 
of endogenous LC3 is a marker for autophagy. Autophagy 1, 84–91. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXVIII 
Taylor, R.W., and Turnbull, D.M. (2005). Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 6, 389–
402. 
Thenganatt, M.A., and Jankovic, J. (2014). Parkinson Disease Subtypes. JAMA Neurol. 71, 499. 
Theunissen, T.W., Powell, B.E., Wang, H., Mitalipova, M., Faddah, D.A., Reddy, J., Fan, Z.P., Maetzel, D., Ganz, 
K., Shi, L., et al. (2014). Systematic Identification of Culture Conditions for Induction and Maintenance of Naive 
Human Pluripotency. Cell Stem Cell 15, 471–487. 
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. 
(1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147. 
Thornton, C., and Hagberg, H. (2015). Role of mitochondria in apoptotic and necroptotic cell death in the developing 
brain. Clin. Chim. Acta 451, 35–38. 
Turrens, J.F. (2003). Mitochondrial formation of reactive oxygen species. J. Physiol. 552, 335–344. 
Vasquez, K.M., Marburger, K., Intody, Z., and Wilson, J.H. (2001). Manipulating the mammalian genome by 
homologous recombination. Proc. Natl. Acad. Sci. 98, 8403–8410. 
Wakabayashi, K., and Takahashi, H. (2008). Neuropathology of Autonomic Nervous System in Parkinson’s 
Disease. Eur. Neurol. 38, 2–7. 
Wallings, R., Manzoni, C., and Bandopadhyay, R. (2015). Cellular processes associated with LRRK2 function and 
dysfunction. FEBS J. n/a-n/a. 
Walton, N.M., Shin, R., Tajinda, K., Heusner, C.L., Kogan, J.H., Miyake, S., Chen, Q., Tamura, K., and Matsumoto, 
M. (2012). Adult Neurogenesis Transiently Generates Oxidative Stress. PLoS ONE 7, e35264. 
Wang, X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922–2933. 
Wang, C., Liu, F., Liu, Y.-Y., Zhao, C.-H., You, Y., Wang, L., Zhang, J., Wei, B., Ma, T., Zhang, Q., et al. (2011). 
Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult 
human brain. Cell Res. 21, 1534–1550. 
Wang, X., Yan, M.H., Fujioka, H., Liu, J., Wilson-Delfosse, A., Chen, S.G., Perry, G., Casadesus, G., and Zhu, X. 
(2012). LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. 
Genet. 21, 1931–1944. 
Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., Qiu, Z., Chang, T., Huang, H., Lin, R.-J., and Yee, J.-K. (2015). 
Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral 
vectors. Nat. Biotechnol. 33, 175–178. 
Weinberger, L., Ayyash, M., Novershtern, N., and Hanna, J.H. (2016). Dynamic stem cell states: naive to primed 
pluripotency in rodents and humans. Nat. Rev. Mol. Cell Biol. 17, 155–169. 
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, B.E., and Jaenisch, R. 
(2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448, 318–324. 
West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.-L., Dawson, 
V.L., et al. (2007). Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase 
activities to neuronal toxicity. Hum. Mol. Genet. 16, 223–232. 
Wilkinson, D.G., Bhatt, S., Cook, M., Boncinelli, E., and Krumlauf, R. (1989). Segmental expression of Hox-2 
homoeobox-containing genes in the developing mouse hindbrain. Nature 341, 405–409. 
Wilson, S.W., and Houart, C. (2004). Early steps in the development of the forebrain. Dev. Cell 6, 167–181. 
Winklhofer, K.F., and Haass, C. (2010). Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. Acta 
BBA - Mol. Basis Dis. 1802, 29–44. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXIX 
Winner, B., Melrose, H.L., Zhao, C., Hinkle, K.M., Yue, M., Kent, C., Braithwaite, A.T., Ogholikhan, S., Aigner, R., 
and Winkler, J. (2011a). Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol. 
Dis. 41, 706–716. 
Winner, B., Kohl, Z., and Gage, F.H. (2011b). Neurodegenerative disease and adult neurogenesis: 
Neurodegenerative disease and adult neurogenesis. Eur. J. Neurosci. 33, 1139–1151. 
Winslow, A.R., Chen, C.-W., Corrochano, S., Acevedo-Arozena, A., Gordon, D.E., Peden, A.A., Lichtenberg, M., 
Menzies, F.M., Ravikumar, B., Imarisio, S., et al. (2010). α-Synuclein impairs macroautophagy: implications for 
Parkinson’s disease. J. Cell Biol. 190, 1023–1037. 
Wong, Y.C., and Krainc, D. (2016). Lysosomal trafficking defects link Parkinson’s disease with Gaucher’s disease: 
Lysosomes in Parkinson’s & Gaucher’s Diseases. Mov. Disord. 31, 1610–1618. 
Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K., Morrison, A., Lwin, A., Colegial, 
C., Allman, J.M., et al. (2004). Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. 
Genet. Metab. 82, 192–207. 
Woodbury, M.E., and Ikezu, T. (2014). Fibroblast Growth Factor-2 Signaling in Neurogenesis and 
Neurodegeneration. J. Neuroimmune Pharmacol. 9, 92–101. 
Wurst, W., and Bally-Cuif, L. (2001). Neural plate patterning: upstream and downstream of the isthmic organizer. 
Nat. Rev. Neurosci. 2, 99. 
Xiao, L., Ohayon, D., McKenzie, I.A., Sinclair-Wilson, A., Wright, J.L., Fudge, A.D., Emery, B., Li, H., and 
Richardson, W.D. (2016). Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill 
learning. Nat. Neurosci. 19, 1210–1217. 
Yagi, M., Kishigami, S., Tanaka, A., Semi, K., Mizutani, E., Wakayama, S., Wakayama, T., Yamamoto, T., and 
Yamada, Y. (2017). Derivation of ground-state female ES cells maintaining gamete-derived DNA methylation. 
Nature. 
Yan, J., Studer, L., and McKay, R.D. (2001). Ascorbic acid increases the yield of dopaminergic neurons derived 
from basic fibroblast growth factor expanded mesencephalic precursors. J. Neurochem. 76, 307–311. 
Yeung, M.S.Y., Zdunek, S., Bergmann, O., Bernard, S., Salehpour, M., Alkass, K., Perl, S., Tisdale, J., Possnert, 
G., Brundin, L., et al. (2014). Dynamics of Oligodendrocyte Generation and Myelination in the Human Brain. Cell 
159, 766–774. 
Yin, H., Kauffman, K.J., and Anderson, D.G. (2017). Delivery technologies for genome editing. Nat. Rev. Drug 
Discov. 16, 387–399. 
Youle, R.J., and Narendra, D.P. (2011). Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9–14. 
Youle, R.J., and Van Der Bliek, A.M. (2012). Mitochondrial fission, fusion, and stress. Science 337, 1062–1065. 
Young, A., Assey, K.S., Sturkie, C.D., West, F.D., Machacek, D.W., and Stice, S.L. (2010). Glial cell line-derived 
neurotrophic factor enhances in vitro differentiation of mid-/hindbrain neural progenitor cells to dopaminergic-like 
neurons: Dopaminergic Differentiation. J. Neurosci. Res. 88, 3222–3232. 
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., 
Ruotti, V., Stewart, R., et al. (2007). Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. 
Science 318, 1917–1920. 
Zavodszky, E., Seaman, M.N.J., Moreau, K., Jimenez-Sanchez, M., Breusegem, S.Y., Harbour, M.E., and 
Rubinsztein, D.C. (2014). Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex 
association and inhibits autophagy. Nat. Commun. 5. 
Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F.A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., and 
Sarna, T. (2008). Neuromelanin can protect against iron mediated oxidative damage in system modeling iron 
overload of brain aging and Parkinson’s disease. J. Neurochem. 
Zechel, S., Meinhardt, A., Unsicker, K., and von Bohlen und Halbach, O. (2010). Expression of leucine-rich-repeat-
kinase 2 (LRRK2) during embryonic development. Int. J. Dev. Neurosci. 28, 391–399. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXX 
Zhang, F.-R., Huang, W., Chen, S.-M., Sun, L.-D., Liu, H., Li, Y., Cui, Y., Yan, X.-X., Yang, H.-T., Yang, R.-D., et 
al. (2009). Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609–2618. 
Zhang, S.-C., Wernig, M., Duncan, I.D., Brüstle, O., and Thomson, J.A. (2001). In vitro differentiation of 
transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19, 1129–1133. 
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., 
Calne, D.B., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic 
pathology. Neuron 44, 601–607. 
Zou, Y., Liu, J., Tian, Z., Lu, D., and Zhou, Y. (2015). Systematic review of the prevalence and incidence of 
Parkinson’s disease in the People’s Republic of China. Neuropsychiatr. Dis. Treat. 1467. 
Zwaka, T.P. (2017). Stem cells: The cost of perpetual youth. Nature. 
 
Abeliovich, A., and Gitler, A.D. (2016). Defects in trafficking bridge Parkinson’s disease pathology and genetics. 
Nature 539, 207–216. 
Abeliovich, A., and Hammond, R. (2007). Midbrain dopamine neuron differentiation: Factors and fates. Dev. Biol. 
304, 447–454. 
Abou-Sleiman, P.M., Muqit, M.M.K., and Wood, N.W. (2006). Expanding insights of mitochondrial dysfunction in 
Parkinson’s disease. Nat. Rev. Neurosci. 7, 207–219. 
Adams, J. (2004). The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349–360. 
Alegre-Abarrategui, J., Ansorge, O., Esiri, M., and Wade-Martins, R. (2008). LRRK2 is a component of granular 
alpha-synuclein pathology in the brainstem of Parkinson’s disease. Neuropathol. Appl. Neurobiol. 34, 272–283. 
Alegre-Abarrategui, J., Christian, H., Lufino, M.M.P., Mutihac, R., Venda, L.L., Ansorge, O., and Wade-Martins, R. 
(2009). LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human 
genomic reporter cellular model. Hum. Mol. Genet. 18, 4022–4034. 
Altman, J. (1963). Autoradiographic investigation of cell proliferation in the brains of rats and cats. Anat. Rec. 145, 
573–591. 
Alvarez-Buylla, A., García-Verdugo, J.M., and Tramontin, A.D. (2001). A unified hypothesis on the lineage of neural 
stem cells. Nat. Rev. Neurosci. 2, 287–293. 
Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., Caccavello, R.J., Barbour, R., Huang, J., 
Kling, K., Lee, M., et al. (2006). Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein 
in Familial and Sporadic Lewy Body Disease. J. Biol. Chem. 281, 29739–29752. 
Antony, P.M.A., Diederich, N.J., and Balling, R. (2011). Parkinson’s disease mouse models in translational 
research. Mamm. Genome 22, 401–419. 
Antony, P.M.A., Diederich, N.J., Krüger, R., and Balling, R. (2013). The hallmarks of Parkinson’s disease. FEBS J. 
280, 5981–5993. 
Arenas, E., Denham, M., and Villaescusa, J.C. (2015). How to make a midbrain dopaminergic neuron. Development 
142, 1918–1936. 
Arnold, S.J., and Robertson, E.J. (2009). Making a commitment: cell lineage allocation and axis patterning in the 
early mouse embryo. Nat. Rev. Mol. Cell Biol. 10, 91–103. 
Bae, B.-I., Jayaraman, D., and Walsh, C.A. (2015). Genetic Changes Shaping the Human Brain. Dev. Cell 32, 423–
434. 
Bahnassawy, L. ’a, Nicklas, S., Palm, T., Menzl, I., Birzele, F., Gillardon, F., and Schwamborn, J.C. (2013). The 
Parkinson’s Disease-Associated LRRK2 Mutation R1441G Inhibits Neuronal Differentiation of Neural Stem Cells. 
Stem Cells Dev. 22, 2487–2496. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXI 
Bakken, T.E., Miller, J.A., Ding, S.-L., Sunkin, S.M., Smith, K.A., Ng, L., Szafer, A., Dalley, R.A., Royall, J.J., Lemon, 
T., et al. (2016). A comprehensive transcriptional map of primate brain development. Nature 535, 367–375. 
Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., Brant, S.R., Silverberg, M.S., Taylor, 
K.D., Barmada, M.M., et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for 
Crohn’s disease. Nat. Genet. 40, 955–962. 
Beal, M.F. (2001). Experimental models of Parkinson’s disease. Nat. Rev. Neurosci. 2, 325–334. 
Beal, M.F. (2010). Parkinson’s disease: a model dilemma. Nature 466, S8–S10. 
Bear, M.F., Connors, B.W., and Paradiso, M.A. (2016). Neurowissenschaften: ein grundlegendes Lehrbuch für 
Biologie, Medizin und Psychologie (Berlin Heidelberg: Springer Spektrum). 
Beckervordersandforth, R., Ebert, B., Schäffner, I., Moss, J., Fiebig, C., Shin, J., Moore, D.L., Ghosh, L., Trinchero, 
M.F., Stockburger, C., et al. (2017). Role of Mitochondrial Metabolism in the Control of Early Lineage Progression 
and Aging Phenotypes in Adult Hippocampal Neurogenesis. Neuron 93, 560–573.e6. 
Bejarano, E., and Cuervo, A.M. (2010). Chaperone-Mediated Autophagy. Proc. Am. Thorac. Soc. 7, 29–39. 
Bento, C.F., Ashkenazi, A., Jimenez-Sanchez, M., and Rubinsztein, D.C. (2016). The Parkinson’s disease-
associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat. Commun. 7, 11803. 
Berardelli, A., Wenning, G.K., Antonini, A., Berg, D., Bloem, B.R., Bonifati, V., Brooks, D., Burn, D.J., Colosimo, C., 
Fanciulli, A., et al. (2013). EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur. J. 
Neurol. 20, 16–34. 
Berg, D. (2005). Type and frequency of mutations in the LRRK2 gene in familiar and sporadic Parkinson’s disease. 
Brain. 
Berwick, D.C., and Harvey, K. (2012). LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and 
membrane-localized LRP6. Hum. Mol. Genet. 21, 4966–4979. 
Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.-W., Savitt, J.M., 
Waldvogel, H.J., et al. (2006). Localization of LRRK2 to membranous and vesicular structures in mammalian brain. 
Ann. Neurol. 60, 557–569. 
Björklund, L.M., Sánchez-Pernaute, R., Chung, S., Andersson, T., Chen, I.Y.C., McNaught, K.S.P., Brownell, A.-L., 
Jenkins, B.G., Wahlestedt, C., Kim, K.-S., et al. (2002). Embryonic stem cells develop into functional dopaminergic 
neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. 99, 2344–2349. 
Blesa, J., and Przedborski, S. (2014). Parkinson’s disease: animal models and dopaminergic cell vulnerability. 
Front. Neuroanat. 8. 
Braak, E., Sandmann-Keil, D., Rüb, U., Gai, W.P., de Vos, R.A., Steur, E.N., Arai, K., and Braak, H. (2001). alpha-
synuclein immunopositive Parkinson’s disease-related inclusion bodies in lower brain stem nuclei. Acta 
Neuropathol. (Berl.) 101, 195–201. 
Braak, H., Del Tredici, K., Rüb, U., De Vos, R.A., Steur, E.N.J., and Braak, E. (2003). Staging of brain pathology 
related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211. 
Brás, J., Guerreiro, R., and Hardy, J. (2015). SnapShot: Genetics of Parkinson’s Disease. Cell 160, 570–570.e1. 
Bucci, C., Thomsen, P., Nicoziani, P., McCarthy, J., and van Deurs, B. (2000). Rab7: a key to lysosome biogenesis. 
Mol. Biol. Cell 11, 467–480. 
Büchi, J., Prost, M., Eichenberger, H., and Lieberherr, R. (1952). Synthese und analgetische Wirkung einiger 1-
Methyl-4-phenyl-piperidin-(4)-alkylsulfone. 1. Mitteilung. Helv. Chim. Acta 35, 1527–1536. 
Bugalho, P., Lampreia, T., Miguel, R., Mendonça, M.D., Caetano, A., and Barbosa, R. (2016). Non-Motor symptoms 
in Portuguese Parkinson’s Disease patients: correlation and impact on Quality of Life and Activities of Daily Living. 
Sci. Rep. 6. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXII 
Burchiel, K.J., Anderson, V.C., Favre, J., and Hammerstad, J.P. (1999). Comparison of pallidal and subthalamic 
nucleus deep brain stimulation for advanced Parkinson’s disease: results of a randomized, blinded pilot study. 
Neurosurgery 45, 1375-1382; discussion 1382-1384. 
Burke, R.E., Dauer, W.T., and Vonsattel, J.P.G. (2008). A critical evaluation of the Braak staging scheme for 
Parkinson’s disease. Ann. Neurol. 64, 485–491. 
Calne, D.B. (1989). Is“ Parkinson’s disease” one disease? J. Neurol. Neurosurg. Psychiatry 52, 18–21. 
Calvo, S.E., and Mootha, V.K. (2010). The Mitochondrial Proteome and Human Disease. Annu. Rev. Genomics 
Hum. Genet. 11, 25–44. 
Carroll, D. (2016). A Perspective on the State of Genome Editing. Mol. Ther. 24, 412–413. 
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, M., and Studer, L. (2009). Highly 
efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 
275–280. 
Chen, H., Ge, H., Wu, G., Cheng, B., Lu, Y., and Jiang, C. (2016). Autophagy Prevents Oxidative Stress-Induced 
Loss of Self-Renewal Capacity and Stemness in Human Tendon Stem Cells by Reducing ROS Accumulation. Cell. 
Physiol. Biochem. 39, 2227–2238. 
Chen, H., Kwong, J.C., Copes, R., Tu, K., Villeneuve, P.J., van Donkelaar, A., Hystad, P., Martin, R.V., Murray, 
B.J., Jessiman, B., et al. (2017a). Living near major roads and the incidence of dementia, Parkinson’s disease, and 
multiple sclerosis: a population-based cohort study. The Lancet 389, 718–726. 
Chen, Z.-C., Zhang, W., Chua, L.-L., Chai, C., Li, R., Lin, L., Cao, Z., Angeles, D.C., Stanton, L.W., Peng, J.-H., et 
al. (2017b). Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and 
neurotoxicity in Parkinson’s disease. Sci. Signal. 10, eaam6790. 
Chin, M.H., Mason, M.J., Xie, W., Volinia, S., Singer, M., Peterson, C., Ambartsumyan, G., Aimiuwu, O., Richter, 
L., Zhang, J., et al. (2009). Induced Pluripotent Stem Cells and Embryonic Stem Cells Are Distinguished by Gene 
Expression Signatures. Cell Stem Cell 5, 111–123. 
Chinopoulos, C., and Adam-Vizi, V. (2010). Mitochondria as ATP consumers in cellular pathology. Biochim. 
Biophys. Acta BBA - Mol. Basis Dis. 1802, 221–227. 
Choi, J., Huebner, A.J., Clement, K., Walsh, R.M., Savol, A., Lin, K., Gu, H., Di Stefano, B., Brumbaugh, J., Kim, 
S.-Y., et al. (2017). Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells. 
Nature. 
Conti, L., and Cattaneo, E. (2010). Neural stem cell systems: physiological players or in vitro entities? Nat. Rev. 
Neurosci. 
Cook, D.A., Kannarkat, G.T., Cintron, A.F., Butkovich, L.M., Fraser, K.B., Chang, J., Grigoryan, N., Factor, S.A., 
West, A.B., Boss, J.M., et al. (2017). LRRK2 levels in immune cells are increased in Parkinson’s disease. Npj Park. 
Dis. 3. 
Cookson, M.R. (2010). The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease. Nat. Rev. Neurosci. 
11, 791–797. 
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M., McLean, J.R., Carrillo-Reid, 
L., Xie, Z., Osborn, T., et al. (2012). Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells 
from Patients with Familial Parkinson’s Disease. Sci. Transl. Med. 4, 141ra90-141ra90. 
Coxhead, J., Kurzawa-Akanbi, M., Hussain, R., Pyle, A., Chinnery, P., and Hudson, G. (2016). Somatic mtDNA 
variation is an important component of Parkinson’s disease. Neurobiol. Aging 38, 217.e1-217.e6. 
Crossley, P.H., Martinez, S., and Martin, G.R. (1996). Midbrain development induced by FGF8 in the chick embryo. 
Nature 380, 66–68. 
Crotzer, V.L., and Blum, J.S. (2005). Autophagy and intracellular surveillance: modulating MHC class II antigen 
presentation with stress. Proc. Natl. Acad. Sci. 102, 7779–7780. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXIII 
Cuervo, A.M. (2004). Impaired Degradation of Mutant -Synuclein by Chaperone-Mediated Autophagy. Science 305, 
1292–1295. 
Cuervo, A.M., and Dice, J.F. (1996). A receptor for the selective uptake and degradation of proteins by lysosomes. 
Science 273, 501–503. 
Cuervo, A.M., and Dice, J.F. (2000). Regulation of lamp2a levels in the lysosomal membrane. Traffic 1, 570–583. 
Curtis, M.A., Faull, R.L.M., and Eriksson, P.S. (2007). The effect of neurodegenerative diseases on the 
subventricular zone. Nat. Rev. Neurosci. 8, 712–723. 
Dauer, W., and Przedborski, S. (2003). Parkinson’s disease: mechanisms and models. Neuron 39, 889–909. 
Davis, C. -h. O., Kim, K.-Y., Bushong, E.A., Mills, E.A., Boassa, D., Shih, T., Kinebuchi, M., Phan, S., Zhou, Y., 
Bihlmeyer, N.A., et al. (2014). Transcellular degradation of axonal mitochondria. Proc. Natl. Acad. Sci. 111, 9633–
9638. 
De Jager, P.L., Srivastava, G., Lunnon, K., Burgess, J., Schalkwyk, L.C., Yu, L., Eaton, M.L., Keenan, B.T., Ernst, 
J., McCabe, C., et al. (2014). Alzheimer’s disease: early alterations in brain DNA methylation at ANK1, BIN1, 
RHBDF2 and other loci. Nat. Neurosci. 17, 1156–1163. 
De Lau, L.M., and Breteler, M.M. (2006). Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525–535. 
Deas, E., Wood, N.W., and Plun-Favreau, H. (2011). Mitophagy and Parkinson’s disease: The PINK1–parkin link. 
Biochim. Biophys. Acta BBA - Mol. Cell Res. 1813, 623–633. 
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., and Bjorklund, A. (2013). TFEB-mediated 
autophagy rescues midbrain dopamine neurons from -synuclein toxicity. Proc. Natl. Acad. Sci. 110, E1817–E1826. 
Dehé, P.-M., and Gaillard, P.-H.L. (2017). Control of structure-specific endonucleases to maintain genome stability. 
Nat. Rev. Mol. Cell Biol. 18, 315–330. 
Dias, V., Junn, E., and Mouradian, M.M. (2013). The role of oxidative stress in Parkinson’s disease. J. Park. Dis. 3, 
461–491. 
Ding, Q., Regan, S.N., Xia, Y., Oostrom, L.A., Cowan, C.A., and Musunuru, K. (2013). Enhanced Efficiency of 
Human Pluripotent Stem Cell Genome Editing through Replacing TALENs with CRISPRs. Cell Stem Cell 12, 393–
394. 
Dodson, M.W., Leung, L.K., Lone, M., Lizzio, M.A., and Guo, M. (2014). Novel ethyl methanesulfonate (EMS)-
induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and 
autophagy in vivo. Dis. Model. Mech. 7, 1351–1363. 
Doi, D., Samata, B., Katsukawa, M., Kikuchi, T., Morizane, A., Ono, Y., Sekiguchi, K., Nakagawa, M., Parmar, M., 
and Takahashi, J. (2014). Isolation of Human Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors by 
Cell Sorting for Successful Transplantation. Stem Cell Rep. 2, 337–350. 
Dorey, K., and Amaya, E. (2010). FGF signalling: diverse roles during early vertebrate embryogenesis. 
Development 137, 3731–3742. 
Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., Marshall, F.J., 
Ravina, B.M., Schifitto, G., Siderowf, A., et al. (2007). Projected number of people with Parkinson disease in the 
most populous nations, 2005 through 2030. Neurology 68, 384–386. 
Drechsel, D.A., and Patel, M. (2008). Role of reactive oxygen species in the neurotoxicity of environmental agents 
implicated in Parkinson’s disease. Free Radic. Biol. Med. 44, 1873–1886. 
van Duinen, S.G., Lammers, G.-J., Maat-Schieman, M.L., and Roos, R.A. (1999). Numerous and widespread α-
synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol. (Berl.) 97, 533–539. 
Eriksson, P.S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D.A., and Gage, F.H. 
(1998). Neurogenesis in the adult human hippocampus. Nat. Med. 4, 1313–1317. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXIV 
Evans, M.J., and Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 
292, 154–156. 
Exner, N., Lutz, A.K., Haass, C., and Winklhofer, K.F. (2012). Mitochondrial dysfunction in Parkinson’s disease: 
molecular mechanisms and pathophysiological consequences. EMBO J. 31, 3038–3062. 
Fang, D., Qing, Y., Yan, S., Chen, D., and Yan, S.S. (2016). Development and Dynamic Regulation of Mitochondrial 
Network in Human Midbrain Dopaminergic Neurons Differentiated from iPSCs. Stem Cell Rep. 7, 678–692. 
Fares, M.-B., Maco, B., Oueslati, A., Rockenstein, E., Ninkina, N., Buchman, V.L., Masliah, E., and Lashuel, H.A. 
(2016). Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson’s disease. Proc. Natl. Acad. 
Sci. 113, E912–E921. 
Feany, M.B., and Bender, W.W. (2000). A Drosophila model of Parkinson’s disease. Nature 404, 394–398. 
Figdor, M.C., and Stern, C.D. (1993). Segmental organization of embryonic diencephalon. Nature 363, 630–634. 
Finkel, T., and Holbrook, N.J. (2000). Oxidants, oxidative stress and the biology of ageing. Nature 408, 239–247. 
Fitzmaurice, A.G., Rhodes, S.L., Cockburn, M., Ritz, B., and Bronstein, J.M. (2014). Aldehyde dehydrogenase 
variation enhances effect of pesticides associated with Parkinson disease. Neurology 82, 419–426. 
Forno, L.S. (1996). Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55, 259–272. 
Fraser, S., Keynes, R., and Lumsden, A. (1990). Segmentation in the chick embryo hindbrain is defined by cell 
lineage restrictions. Nature 344, 431–435. 
Frost, B., and Diamond, M.I. (2010). Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 
11, 155–159. 
Fuentealba, L.C., Rompani, S.B., Parraguez, J.I., Obernier, K., Romero, R., Cepko, C.L., and Alvarez-Buylla, A. 
(2015). Embryonic Origin of Postnatal Neural Stem Cells. Cell 161, 1644–1655. 
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S., Shen, J., Takio, K., and 
Iwatsubo, T. (2002). [alpha]-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160. 
Füllgrabe, J., Klionsky, D.J., and Joseph, B. (2014). The return of the nucleus: transcriptional and epigenetic control 
of autophagy. Nat. Rev. Mol. Cell Biol. 15, 65–74. 
Funayama, M., Hasegawa, K., Kowa, H., Saito, M., Tsuji, S., and Obata, F. (2002). A new locus for Parkinson’s 
disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51, 296–301. 
Gafni, O., Weinberger, L., Mansour, A.A., Manor, Y.S., Chomsky, E., Ben-Yosef, D., Kalma, Y., Viukov, S., Maza, 
I., Zviran, A., et al. (2013). Derivation of novel human ground state naive pluripotent stem cells. Nature 504, 282–
286. 
Gage, F.H. (2000). Mammalian Neural Stem Cells. Science 287, 1433–1438. 
Gage, F.H. (2008). Adult neurogenesis. Cold Spring Harb. Lab. Press. 
Gage, F.H., Coates, P.W., Palmer, T.D., Kuhn, H.G., Fisher, L.J., Suhonen, J.O., Peterson, D.A., Suhr, S.T., and 
Ray, J. (1995). Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain. Proc. 
Natl. Acad. Sci. 92, 11879–11883. 
Gaig, C., Marti, M.J., Ezquerra, M., Rey, M.J., Cardozo, A., and Tolosa, E. (2007). G2019S LRRK2 mutation causing 
Parkinson’s disease without Lewy bodies. J. Neurol. Neurosurg. Psychiatry 78, 626–628. 
Gaj, T., Gersbach, C.A., and Barbas, C.F. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome 
engineering. Trends Biotechnol. 31, 397–405. 
Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O., and Olson, L. (2006). LRRK2 expression linked 
to dopamine-innervated areas. Ann. Neurol. 59, 714–719. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXV 
Gammill, L.S., and Bronner-Fraser, M. (2003). Neural crest specification: migrating into genomics. Nat. Rev. 
Neurosci. 4, 795–805. 
García-Prat, L., Martínez-Vicente, M., Perdiguero, E., Ortet, L., Rodríguez-Ubreva, J., Rebollo, E., Ruiz-Bonilla, V., 
Gutarra, S., Ballestar, E., Serrano, A.L., et al. (2016). Autophagy maintains stemness by preventing senescence. 
Nature 529, 37–42. 
Garcia-Reitboeck, P., Anichtchik, O., Dalley, J.W., Ninkina, N., Tofaris, G.K., Buchman, V.L., and Spillantini, M.G. 
(2013). Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. 
Exp. Neurol. 248, 541–545. 
Gardet, A., Benita, Y., Li, C., Sands, B.E., Ballester, I., Stevens, C., Korzenik, J.R., Rioux, J.D., Daly, M.J., Xavier, 
R.J., et al. (2010). LRRK2 Is Involved in the IFN- Response and Host Response to Pathogens. J. Immunol. 185, 
5577–5585. 
Gasser, T. (2009a). Mendelian forms of Parkinson’s disease. Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1792, 
587–596. 
Gasser, T. (2009b). Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev. Mol. 
Med. 11. 
Gasser, T. (2011). Genetic basis of Parkinson’s disease: inheritance, penetrance, and expression. Appl. Clin. 
Genet. 67. 
Gehrke, S., Imai, Y., Sokol, N., and Lu, B. (2010). Pathogenic LRRK2 negatively regulates microRNA-mediated 
translational repression. Nature 466, 637–641. 
Geisler, S., Holmström, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J., and Springer, W. (2010). 
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119–131. 
Gemma, C., Vila, J., Bachstetter, A., and Bickford, P.C. (2007). Oxidative Stress and the Aging Brain: From Theory 
to Prevention. In Brain Aging: Models, Methods, and Mechanisms, D.R. Riddle, ed. (Boca Raton (FL): CRC 
Press/Taylor & Francis), p. 
Germain, P.-L., and Testa, G. (2017). Taming Human Genetic Variability: Transcriptomic Meta-Analysis Guides the 
Experimental Design and Interpretation of iPSC-Based Disease Modeling. Stem Cell Rep. 8, 1784–1796. 
Giasson, B.I., Covy, J.P., Bonini, N.M., Hurtig, H.I., Farrer, M.J., Trojanowski, J.Q., and Van Deerlin, V.M. (2006). 
Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315–322. 
Gibb, W.R., and Lees, A.J. (1991). Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia 
nigra, and differential cell death in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 54, 388–396. 
Gibson, T.J., Seiler, M., and Veitia, R.A. (2013). The transience of transient overexpression. Nat. Methods 10, 715–
721. 
Gilsbach, B.K., and Kortholt, A. (2014). Structural biology of the LRRK2 GTPase and kinase domains: implications 
for regulation. Front. Mol. Neurosci. 7. 
Goedert, M., Spillantini, M.G., Del Tredici, K., and Braak, H. (2012). 100 years of Lewy pathology. Nat. Rev. Neurol. 
9, 13–24. 
Gomez-Suaga, P., Luzon-Toro, B., Churamani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P.G., Churchill, 
G.C., and Hilfiker, S. (2012). Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent 
pathway involving NAADP. Hum. Mol. Genet. 21, 511–525. 
Götz, M., and Huttner, W.B. (2005). The cell biology of neurogenesis. Nat. Rev. Mol. Cell Biol. 6, 777–788. 
Grace, A.A. (2016). Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. 
Nat. Rev. Neurosci. 17, 524–532. 
Graf, T., and Enver, T. (2009). Forcing cells to change lineages. Nature 462, 587–594. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXVI 
Graham, D.G. (1978). Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic 
quinones. Mol. Pharmacol. 14, 633–643. 
Groiss, S.J., Wojtecki, L., Südmeyer, M., and Schnitzler, A. (2009). Deep brain stimulation in Parkinson’s disease. 
Ther. Adv. Neurol. Disord. 2, 379–391. 
Guaitoli, G., Raimondi, F., Gilsbach, B.K., Gómez-Llorente, Y., Deyaert, E., Renzi, F., Li, X., Schaffner, A., Jagtap, 
P.K.A., Boldt, K., et al. (2016). Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact 
architecture involving distant interdomain contacts. Proc. Natl. Acad. Sci. 113, E4357–E4366. 
Guerreiro, P.S., Huang, Y., Gysbers, A., Cheng, D., Gai, W.P., Outeiro, T.F., and Halliday, G.M. (2013). LRRK2 
interactions with α-synuclein in Parkinson’s disease brains and in cell models. J. Mol. Med. 91, 513–522. 
Guzman, J.N., Sanchez-Padilla, J., Chan, C.S., and Surmeier, D.J. (2009). Robust Pacemaking in Substantia Nigra 
Dopaminergic Neurons. J. Neurosci. 29, 11011–11019. 
Hakimi, M., Selvanantham, T., Swinton, E., Padmore, R.F., Tong, Y., Kabbach, G., Venderova, K., Girardin, S.E., 
Bulman, D.E., Scherzer, C.R., et al. (2011). Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue 
immune cells and upregulated following recognition of microbial structures. J. Neural Transm. 118, 795–808. 
Han, D.W., Tapia, N., Hermann, A., Hemmer, K., Höing, S., Araúzo-Bravo, M.J., Zaehres, H., Wu, G., Frank, S., 
Moritz, S., et al. (2012). Direct Reprogramming of Fibroblasts into Neural Stem Cells by Defined Factors. Cell Stem 
Cell 10, 465–472. 
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M.M., Hofstetter, R., 
Klauber, M., et al. (1990). The Lewy body variant of Alzheimer’s disease: A clinical and pathologic entity. Neurology 
40, 1–1. 
Harrington, A.J., Hamamichi, S., Caldwell, G.A., and Caldwell, K.A. (2010). C. elegans as a model organism to 
investigate molecular pathways involved with Parkinson’s disease. Dev. Dyn. NA-NA. 
He, C., and Klionsky, D.J. (2009). Regulation Mechanisms and Signaling Pathways of Autophagy. Annu. Rev. 
Genet. 43, 67–93. 
Henchcliffe, C., and Beal, M.F. (2008). Mitochondrial biology and oxidative stress in Parkinson disease 
pathogenesis. Nat. Clin. Pract. Neurol. 4, 600–609. 
Hernandez, D.G., Reed, X., and Singleton, A.B. (2016). Genetics in Parkinson disease: Mendelian versus non-
Mendelian inheritance. J. Neurochem. 139, 59–74. 
Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., 
Danner, S., et al. (2011). LRRK2 protein levels are determined by kinase function and are crucial for kidney and 
lung homeostasis in mice. Hum. Mol. Genet. 20, 4209–4223. 
Hockemeyer, D., Soldner, F., Beard, C., Gao, Q., Mitalipova, M., DeKelver, R.C., Katibah, G.E., Amora, R., 
Boydston, E.A., Zeitler, B., et al. (2009). Efficient targeting of expressed and silent genes in human ESCs and iPSCs 
using zinc-finger nucleases. Nat. Biotechnol. 27, 851–857. 
Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., Cassady, J.P., Cost, G.J., Zhang, L., Santiago, Y., Miller, 
J.C., et al. (2011). Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731–
734. 
Höglinger, G.U., Rizk, P., Muriel, M.P., Duyckaerts, C., Oertel, W.H., Caille, I., and Hirsch, E.C. (2004). Dopamine 
depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 7, 726–735. 
Huisman, E., Uylings, H.B.M., and Hoogland, P.V. (2004). A 100% increase of dopaminergic cells in the olfactory 
bulb may explain hyposmia in Parkinson’s disease. Mov. Disord. 19, 687–692. 
Hyttinen, J.M.T., Niittykoski, M., Salminen, A., and Kaarniranta, K. (2013). Maturation of autophagosomes and 
endosomes: A key role for Rab7. Biochim. Biophys. Acta BBA - Mol. Cell Res. 1833, 503–510. 
Imai, Y., Gehrke, S., Wang, H.-Q., Takahashi, R., Hasegawa, K., Oota, E., and Lu, B. (2008). Phosphorylation of 
4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432–2443. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXVII 
Imai, Y., Kobayashi, Y., Inoshita, T., Meng, H., Arano, T., Uemura, K., Asano, T., Yoshimi, K., Zhang, C.-L., 
Matsumoto, G., et al. (2015). The Parkinson’s Disease-Associated Protein Kinase LRRK2 Modulates Notch 
Signaling through the Endosomal Pathway. PLOS Genet. 11, e1005503. 
Ishihara, L., Warren, L., Gibson, R., Amouri, R., Lesage, S., Dürr, A., Tazir, M., Wszolek, Z.K., Uitti, R.J., Nichols, 
W.C., et al. (2006). Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 
2 G2019S Mutations. Arch. Neurol. 63, 1250. 
Ito, K., and Suda, T. (2014). Metabolic requirements for the maintenance of self-renewing stem cells. Nat. Rev. Mol. 
Cell Biol. 15, 243–256. 
Jacobs, S., Lie, D.C., DeCicco, K.L., Shi, Y., DeLuca, L.M., Gage, F.H., and Evans, R.M. (2006). Retinoic acid is 
required early during adult neurogenesis in the dentate gyrus. Proc. Natl. Acad. Sci. U. S. A. 103, 3902–3907. 
Jager, W.D.H., and Bethlem, J. (1960). The distribution of Lewy bodies in the central and autonomic nervous 
systems in idiopathic paralysis agitans. J. Neurol. Neurosurg. Psychiatry 23, 283. 
Jagmag, S.A., Tripathi, N., Shukla, S.D., Maiti, S., and Khurana, S. (2016). Evaluation of Models of Parkinson’s 
Disease. Front. Neurosci. 9. 
Jaleel, M., Nichols, R.J., Deak, M., Campbell, D.G., Gillardon, F., Knebel, A., and Alessi, D.R. (2007). LRRK2 
phosphorylates moesin at threonine-558: characterization of how Parkinson’s disease mutants affect kinase activity. 
Biochem. J. 405, 307–317. 
Jellinger, K.A. (2009). A critical evaluation of current staging of α-synuclein pathology in Lewy body disorders. 
Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1792, 730–740. 
Jenner, P. (2003). Oxidative stress in Parkinson’s disease. Ann. Neurol. 53, S26–S38. 
Jin, S.M., and Youle, R.J. (2012). PINK1- and Parkin-mediated mitophagy at a glance. J. Cell Sci. 125, 795–799. 
Johnston, I.G., Burgstaller, J.P., Havlicek, V., Kolbe, T., Rülicke, T., Brem, G., Poulton, J., and Jones, N.S. (2015). 
Stochastic modelling, Bayesian inference, and new in vivo measurements elucidate the debated mtDNA bottleneck 
mechanism. Elife 4, e07464. 
Jones, R. (2010). The roles of PINK1 and Parkin in Parkinson’s disease. PLoS Biol. 8, e1000299. 
Jung, C.H., Ro, S.-H., Cao, J., Otto, N.M., and Kim, D.-H. (2010). mTOR regulation of autophagy. FEBS Lett. 584, 
1287–1295. 
Kamel, F., and Hoppin, J.A. (2004). Association of Pesticide Exposure with Neurologic Dysfunction and Disease. 
Environ. Health Perspect. 112, 950–958. 
Kang, R., Zeh, H.J., Lotze, M.T., and Tang, D. (2011). The Beclin 1 network regulates autophagy and apoptosis. 
Cell Death Differ. 18, 571–580. 
Kanninen, K.M., Bister, N., Koistinaho, J., and Malm, T. (2016). Exosomes as new diagnostic tools in CNS diseases. 
Biochim. Biophys. Acta BBA - Mol. Basis Dis. 1862, 403–410. 
Kelava, I., and Lancaster, M.A. (2016). Stem Cell Models of Human Brain Development. Cell Stem Cell 18, 736–
748. 
Khurana, V., and Lindquist, S. (2010). Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with 
baker’s yeast? Nat. Rev. Neurosci. 11, 436–449. 
Kim, H.-J., and Jeon, B.S. (2014). Hypothesis: Somatic Mosaicism and Parkinson Disease. Exp. Neurobiol. 23, 
271. 
Kim, B., Yang, M.-S., Choi, D., Kim, J.-H., Kim, H.-S., Seol, W., Choi, S., Jou, I., Kim, E.-Y., and Joe, E. (2012). 
Impaired Inflammatory Responses in Murine Lrrk2-Knockdown Brain Microglia. PLoS ONE 7, e34693. 
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M.J., Ji, H., Ehrlich, L.I.R., et al. (2010). 
Epigenetic memory in induced pluripotent stem cells. Nature 467, 285–290. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXVIII 
Kirkeby, A., Nolbrant, S., Tiklova, K., Heuer, A., Kee, N., Cardoso, T., Ottosson, D.R., Lelos, M.J., Rifes, P., Dunnett, 
S.B., et al. (2017). Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of 
hESC-Based Therapy for Parkinson’s Disease. Cell Stem Cell 20, 135–148. 
Klein, C., and Westenberger, A. (2012). Genetics of Parkinson’s Disease. Cold Spring Harb. Perspect. Med. 2, 
a008888–a008888. 
Klionsky, D.J. (2007). Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. 
Rev. Mol. Cell Biol. 8, 931–937. 
Klionsky, D.J., Abdalla, F.C., Abeliovich, H., Abraham, R.T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, 
M., Agostinis, P., Aguirre-Ghiso, J.A., et al. (2012). Guidelines for the use and interpretation of assays for monitoring 
autophagy. Autophagy 8, 445–544. 
Koller, W.C. (1992). When does Parkinson’s disease begin? Neurology 42, 27-31; discussion 41-48. 
Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., and Olanow, C.W. (2008). Lewy body–like pathology in long-
term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 14, 504–506. 
Kornmann, B. (2014). Quality control in mitochondria: use it, break it, fix it, trash it. F1000prime Rep. 6. 
Kriegstein, A., and Alvarez-Buylla, A. (2009). The Glial Nature of Embryonic and Adult Neural Stem Cells. Annu. 
Rev. Neurosci. 32, 149–184. 
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y.M., Wakeman, D.R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., 
Buch, A., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of 
Parkinson’s disease. Nature. 
La Manno, G., Gyllborg, D., Codeluppi, S., Nishimura, K., Salto, C., Zeisel, A., Borm, L.E., Stott, S.R.W., Toledo, 
E.M., Villaescusa, J.C., et al. (2016). Molecular Diversity of Midbrain Development in Mouse, Human, and Stem 
Cells. Cell 167, 566–580.e19. 
Lancaster, M.A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L.S., Hurles, M.E., Homfray, T., Penninger, J.M., 
Jackson, A.P., and Knoblich, J.A. (2013). Cerebral organoids model human brain development and microcephaly. 
Nature 501, 373–379. 
Langer, T. (2000). AAA proteases: cellular machines for degrading membrane proteins. Trends Biochem. Sci. 25, 
247–251. 
Langston, J.W. (2006). The parkinson’s complex: Parkinsonism is just the tip of the iceberg. Ann. Neurol. 59, 591–
596. 
Langston, J.W. (2017). The MPTP Story. J. Park. Dis. 7, S11–S19. 
Langston, J.W., Ballard, P., Tetrud, J.W., and Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of 
meperidine-analog synthesis. Science 219, 979–980. 
Lashuel, H.A., Overk, C.R., Oueslati, A., and Masliah, E. (2012). The many faces of α-synuclein: from structure and 
toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48. 
Lawton, M., Baig, F., Rolinski, M., Ruffman, C., Nithi, K., May, M.T., Ben-Shlomo, Y., and Hu, M.T.M. (2015). 
Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort. J. Park. Dis. 5, 
269–279. 
Le Grand, J.N., Gonzalez-Cano, L., Pavlou, M.A., and Schwamborn, J.C. (2014). Neural stem cells in Parkinson’s 
disease: a role for neurogenesis defects in onset and progression. Cell. Mol. Life Sci. 
Lesage, S., Patin, E., Condroyer, C., Leutenegger, A.L., Lohmann, E., Giladi, N., Bar-Shira, A., Belarbi, S., Hecham, 
N., Pollak, P., et al. (2010). Parkinson’s disease-related LRRK2 G2019S mutation results from independent 
mutational events in humans. Hum. Mol. Genet. 19, 1998–2004. 
Levine, A.J., and Brivanlou, A.H. (2007). Proposal of a model of mammalian neural induction. Dev. Biol. 308, 247–
256. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XXXIX 
Li, J.-Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T., Quinn, N.P., Rehncrona, S., 
Björklund, A., et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-
graft disease propagation. Nat. Med. 14, 501–503. 
Li, M., Rothwell, R., Vermaat, M., Wachsmuth, M., Schröder, R., Laros, J.F.J., van Oven, M., de Bakker, P.I.W., 
Bovenberg, J.A., van Duijn, C.M., et al. (2016). Transmission of human mtDNA heteroplasmy in the Genome of the 
Netherlands families: support for a variable-size bottleneck. Genome Res. 26, 417–426. 
Lin, M.T., and Beal, M.F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. 
Nature 443, 787–795. 
Lin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.-X., Yang, W.-J., Ding, J., et al. 
(2009). Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson’s-
Disease-Related Mutant α-synuclein. Neuron 64, 807–827. 
Liu, G.-H., Qu, J., Suzuki, K., Nivet, E., Li, M., Montserrat, N., Yi, F., Xu, X., Ruiz, S., Zhang, W., et al. (2012). 
Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491, 603–607. 
López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The Hallmarks of Aging. Cell 153, 
1194–1217. 
Lorenz, C., Lesimple, P., Bukowiecki, R., Zink, A., Inak, G., Mlody, B., Singh, M., Semtner, M., Mah, N., Auré, K., 
et al. (2017). Human iPSC-Derived Neural Progenitors Are an Effective Drug Discovery Model for Neurological 
mtDNA Disorders. Cell Stem Cell 20, 659–674.e9. 
Luk, K.C., and Lee, V.M.-Y. (2014). Modeling Lewy pathology propagation in Parkinson’s disease. Parkinsonism 
Relat. Disord. 20, S85–S87. 
Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J.Q., and Lee, V.M.-Y. (2012). Pathological -
Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice. Science 338, 949–953. 
Lumsden, A., and Graham, A. (1995). Neural patterning: A forward role for hedgehog. Curr. Biol. 5, 1347–1350. 
Lunnon, K., Smith, R., Hannon, E., De Jager, P.L., Srivastava, G., Volta, M., Troakes, C., Al-Sarraj, S., Burrage, J., 
Macdonald, R., et al. (2014). Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. 
Nat. Neurosci. 17, 1164–1170. 
Luzio, J.P., Pryor, P.R., and Bright, N.A. (2007). Lysosomes: fusion and function. Nat. Rev. Mol. Cell Biol. 8, 622–
632. 
MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K., and Abeliovich, A. (2006). The Familial Parkinsonism 
Gene LRRK2 Regulates Neurite Process Morphology. Neuron 52, 587–593. 
MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., McCabe, B.D., Marder, K.S., Honig, L.S., Clark, 
L.N., Small, S.A., et al. (2013). RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and 
Parkinson’s Disease Risk. Neuron 77, 425–439. 
Makin, S. (2016). Pathology: The prion principle. Nature 538, S13–S16. 
Manzoni, C., Mamais, A., Roosen, D.A., Dihanich, S., Soutar, M.P.M., Plun-Favreau, H., Bandopadhyay, R., Hardy, 
J., Tooze, S.A., Cookson, M.R., et al. (2016). mTOR independent regulation of macroautophagy by Leucine Rich 
Repeat Kinase 2 via Beclin-1. Sci. Rep. 6. 
Marchetto, M.C., and Gage, F.H. (2012). Modeling Brain Disease in a Dish: Really? Cell Stem Cell 10, 642–645. 
Mari, P.-O., Florea, B.I., Persengiev, S.P., Verkaik, N.S., Brüggenwirth, H.T., Modesti, M., Giglia-Mari, G., 
Bezstarosti, K., Demmers, J.A., Luider, T.M., et al. (2006). Dynamic assembly of end-joining complexes requires 
interaction between Ku70/80 and XRCC4. Proc. Natl. Acad. Sci. 103, 18597–18602. 
Mariani, J., Simonini, M.V., Palejev, D., Tomasini, L., Coppola, G., Szekely, A.M., Horvath, T.L., and Vaccarino, 
F.M. (2012). Modeling human cortical development in vitro using induced pluripotent stem cells. Proc. Natl. Acad. 
Sci. 109, 12770–12775. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XL 
Markesbery, W.R., Jicha, G.A., Liu, H., and Schmitt, F.A. (2009). Lewy body pathology in normal elderly subjects. 
J. Neuropathol. Exp. Neurol. 68, 816–822. 
Marras, C., Lohmann, K., Lang, A., and Klein, C. (2012). Fixing the broken system of genetic locus symbols 
Parkinson disease and dystonia as examples. Neurology 78, 1016–1024. 
Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned 
by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. 78, 7634–7638. 
Martin, I., Kim, J.W., Lee, B.D., Kang, H.C., Xu, J.-C., Jia, H., Stankowski, J., Kim, M.-S., Zhong, J., Kumar, M., et 
al. (2014a). Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson’s Disease. 
Cell 157, 472–485. 
Martin, I., Kim, J.W., Dawson, V.L., and Dawson, T.M. (2014b). LRRK2 pathobiology in Parkinson’s disease. J. 
Neurochem. 131, 554–565. 
Martinez-Vicente, M., and Cuervo, A.M. (2007). Autophagy and neurodegeneration: when the cleaning crew goes 
on strike. Lancet Neurol. 6, 352–361. 
Marxreiter, F., Regensburger, M., and Winkler, J. (2013). Adult neurogenesis in Parkinson’s disease. Cell. Mol. Life 
Sci. 70, 459–473. 
Matikainen-Ankney, B.A., Kezunovic, N., Mesias, R.E., Tian, Y., Williams, F.M., Huntley, G.W., and Benson, D.L. 
(2016). Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson’s Disease-Linked 
LRRK2–G2019S Mutation. J. Neurosci. 36, 7128–7141. 
Matsunaga, E., Araki, I., and Nakamura, H. (2000). Pax6 defines the di-mesencephalic boundary by repressing 
En1 and Pax2. Development 127, 2357–2365. 
Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., De Bock, P.-J., 
Morais, V.A., Vilain, S., Haddad, D., et al. (2012). LRRK2 Controls an EndoA Phosphorylation Cycle in Synaptic 
Endocytosis. Neuron 75, 1008–1021. 
Mertens, J., Marchetto, M.C., Bardy, C., and Gage, F.H. (2016). Evaluating cell reprogramming, differentiation and 
conversion technologies in neuroscience. Nat. Rev. Neurosci. 
Mieko Mizutani, C., and Bier, E. (2008). EvoD/Vo: the origins of BMP signalling in the neuroectoderm. Nat. Rev. 
Genet. 9, 663–677. 
Miller, J.D., Ganat, Y.M., Kishinevsky, S., Bowman, R.L., Liu, B., Tu, E.Y., Mandal, P.K., Vera, E., Shim, J., Kriks, 
S., et al. (2013). Human iPSC-Based Modeling of Late-Onset Disease via Progerin-Induced Aging. Cell Stem Cell 
13, 691–705. 
Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M.D., Klionsky, D.J., Ohsumi, M., and Ohsumi, 
Y. (1998). A protein conjugation system essential for autophagy. Nature 395, 395–398. 
Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., Cowell, R.M., and West, A.B. 
(2012). LRRK2 Inhibition Attenuates Microglial Inflammatory Responses. J. Neurosci. 32, 1602–1611. 
Monzel, A.S., Smits, L.M., Hemmer, K., Hachi, S., Moreno, E.L., van Wuellen, T., Jarazo, J., Walter, J., 
Br?ggemann, I., Boussaad, I., et al. (2017). Derivation of Human Midbrain-Specific Organoids from Neuroepithelial 
Stem?Cells. Stem Cell Rep. 8, 1144–1154. 
Moore, K., McKnight, A.J., Craig, D., and O’Neill, F. (2014). Epigenome-Wide Association Study for Parkinson’s 
Disease. NeuroMolecular Med. 16, 845–855. 
Muguruma, K., Nishiyama, A., Kawakami, H., Hashimoto, K., and Sasai, Y. (2015). Self-Organization of Polarized 
Cerebellar Tissue in 3D Culture of Human Pluripotent Stem Cells. Cell Rep. 10, 537–550. 
Muñoz-Sanjuán, I., and Brivanlou, A.H. (2002). NEURAL INDUCTION, THE DEFAULT MODEL AND EMBRYONIC 
STEM CELLS. Nat. Rev. Neurosci. 3, 271–280. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLI 
Nakamura, H., Sato, T., and Suzuki-Hirano, A. (2008). Isthmus organizer for mesencephalon and metencephalon: 
Isthmus organizer. Dev. Growth Differ. 50, S113–S118. 
Nalls, M.A., Pankratz, N., Lill, C.M., Do, C.B., Hernandez, D.G., Saad, M., DeStefano, A.L., Kara, E., Bras, J., 
Sharma, M., et al. (2014). Large-scale meta-analysis of genome-wide association data identifies six new risk loci 
for Parkinson’s disease. Nat. Genet. 46, 989–993. 
Narendra, D., Tanaka, A., Suen, D.-F., and Youle, R.J. (2008). Parkin is recruited selectively to impaired 
mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803. 
Neufeld, E.F. (1991). Lysosomal storage diseases. Annu. Rev. Biochem. 60, 257–280. 
Neutzner, A., Youle, R.J., and Karbowski, M. (2007). Outer mitochondrial membrane protein degradation by the 
proteasome. Novartis Found. Symp. 287, 4-14; discussion 14-20. 
Nichols, J., and Smith, A. (2009). Naive and Primed Pluripotent States. Cell Stem Cell 4, 487–492. 
Niehrs, C. (2004). Regionally specific induction by the Spemann–Mangold organizer. Nat. Rev. Genet. 5, 425–434. 
Niu, J., Yu, M., Wang, C., and Xu, Z. (2012). Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via 
Dynamin-like protein: LRRK2 disturbs mitochondrial dynamics via DLP1. J. Neurochem. 122, 650–658. 
Niwa, H. (2007). How is pluripotency determined and maintained? Development 134, 635–646. 
Nixon, R.A. (2006). Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci. 29, 528–
535. 
Nixon, R.A. (2013). The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983–997. 
Nuytemans, K., Theuns, J., Cruts, M., and Van Broeckhoven, C. (2010). Genetic etiology of Parkinson disease 
associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. 
Mutat. 31, 763–780. 
Okabe, S., Forsberg-Nilsson, K., Spiro, A.C., Segal, M., and McKay, R.D.G. (1996). Development of neuronal 
precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech. Dev. 59, 89–102. 
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., 
Tezuka, K., et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat. Methods 8, 
409–412. 
Oliveira, M.A.P., Balling, R., Smidt, M.P., and Fleming, R.M.T. (2017). Embryonic development of selectively 
vulnerable neurons in Parkinson’s disease. Npj Park. Dis. 3. 
Olsson, M., Nikkhah, G., Bentlage, C., and Bjorklund, A. (1995). Forelimb akinesia in the rat Parkinson model: 
differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 
15, 3863–3875. 
Orenstein, S.J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L.S., Dauer, 
W., Consiglio, A., et al. (2013). Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394–
406. 
Orkin, S.H., and Zon, L.I. (2008). Hematopoiesis: An Evolving Paradigm for Stem Cell Biology. Cell 132, 631–644. 
Paisán-Ruiz, C., Lewis, P.A., and Singleton, A.B. (2013). LRRK2: cause, risk, and mechanism. J. Park. Dis. 3, 85–
103. 
Paisán-Ruı́z, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., van der Brug, M., de Munain, A.L., Aparicio, S., Gil, 
A.M., Khan, N., et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s 
disease. Neuron 44, 595–600. 
Pan, T., Kondo, S., Le, W., and Jankovic, J. (2008). The role of autophagy-lysosome pathway in neurodegeneration 
associated with Parkinson’s disease. Brain 131, 1969–1978. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLII 
Parisiadou, L., Xie, C., Cho, H.J., Lin, X., Gu, X.-L., Long, C.-X., Lobbestael, E., Baekelandt, V., Taymans, J.-M., 
Sun, L., et al. (2009). Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement 
of Actin Cytoskeleton in Neuronal Morphogenesis. J. Neurosci. 29, 13971–13980. 
Parisiadou, L., Yu, J., Sgobio, C., Xie, C., Liu, G., Sun, L., Gu, X.-L., Lin, X., Crowley, N.A., Lovinger, D.M., et al. 
(2014). LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. 
Nat. Neurosci. 17, 367–376. 
Parkinson, J. (1817). An Essay on the Shaking Palsy. Whittingham and Rowland. 
Pasparakis, M., and Vandenabeele, P. (2015). Necroptosis and its role in inflammation. Nature 517, 311–320. 
Perrier, A.L., Tabar, V., Barberi, T., Rubio, M.E., Bruses, J., Topf, N., Harrison, N.L., and Studer, L. (2004). 
Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 101, 
12543–12548. 
Phinney, D.G., Di Giuseppe, M., Njah, J., Sala, E., Shiva, S., St Croix, C.M., Stolz, D.B., Watkins, S.C., Di, Y.P., 
Leikauf, G.D., et al. (2015). Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle 
microRNAs. Nat. Commun. 6, 8472. 
Pissadaki, E.K., and Bolam, J.P. (2013). The energy cost of action potential propagation in dopamine neurons: 
clues to susceptibility in Parkinson’s disease. Front. Comput. Neurosci. 7. 
Plowey, E.D., Cherra, S.J., Liu, Y.-J., and Chu, C.T. (2008). Role of autophagy in G2019S-LRRK2-associated 
neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 105, 1048–1056. 
Plusa, B., and Hadjantonakis, A.-K. (2014). Embryonic stem cell identity grounded in the embryo. Nat. Cell Biol. 16, 
502. 
Polymeropoulos, M.H. (1997). Mutation in the -Synuclein Gene Identified in Families with Parkinson’s Disease. 
Science 276, 2045–2047. 
Prakash, N., and Wurst, W. (2006). Genetic networks controlling the development of midbrain dopaminergic 
neurons: Genetic control of midbrain dopaminergic neuron development. J. Physiol. 575, 403–410. 
Prieto, J., León, M., Ponsoda, X., Sendra, R., Bort, R., Ferrer-Lorente, R., Raya, A., López-García, C., and Torres, 
J. (2016). Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell 
reprogramming. Nat. Commun. 7, 11124. 
Proukakis, C., Houlden, H., and Schapira, A.H. (2013). Somatic alpha-synuclein mutations in Parkinson’s disease: 
Hypothesis and preliminary data: Snca Somatic Mutation Hypothesis. Mov. Disord. 28, 705–712. 
Przedborski, S. (2017). The two-century journey of Parkinson disease research. Nat. Rev. Neurosci. 18, 251–259. 
Qing, H., Zhang, Y., Deng, Y., McGeer, E.G., and McGeer, P.L. (2009). Lrrk2 interaction with α-synuclein in diffuse 
Lewy body disease. Biochem. Biophys. Res. Commun. 390, 1229–1234. 
Raposo, G., and Stoorvogel, W. (2013). Extracellular vesicles: Exosomes, microvesicles, and friends. J. Cell Biol. 
200, 373–383. 
Recasens, A., Dehay, B., Bové, J., Carballo-Carbajal, I., Dovero, S., Pérez-Villalba, A., Fernagut, P.-O., Blesa, J., 
Parent, A., Perier, C., et al. (2014). Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology 
and neurodegeneration in mice and monkeys: LB-Induced Pathology. Ann. Neurol. 75, 351–362. 
Reeve, A., Simcox, E., and Turnbull, D. (2014). Ageing and Parkinson’s disease: Why is advancing age the biggest 
risk factor? Ageing Res. Rev. 14, 19–30. 
Reinhardt, P., Schmid, B., Burbulla, L.F., Schöndorf, D.C., Wagner, L., Glatza, M., Höing, S., Hargus, G., Heck, 
S.A., Dhingra, A., et al. (2013a). Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian 
Neurodegeneration to ERK-Dependent Changes in Gene Expression. Cell Stem Cell 12, 354–367. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLIII 
Reinhardt, P., Glatza, M., Hemmer, K., Tsytsyura, Y., Thiel, C.S., Höing, S., Moritz, S., Parga, J.A., Wagner, L., 
Bruder, J.M., et al. (2013b). Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors 
for Neurodegenerative Disease Modeling. PLoS ONE 8, e59252. 
Reubinoff, B.E., Itsykson, P., Turetsky, T., Pera, M.F., Reinhartz, E., Itzik, A., and Ben-Hur, T. (2001). Neural 
progenitors from human embryonic stem cells. Nat. Biotechnol. 19, 1134–1140. 
Reynolds, B., and Weiss, S. (1992). Generation of neurons and astrocytes from isolated cells of the adult 
mammalian central nervous system. Science 255, 1707–1710. 
Reynolds, B.A., Tetzlaff, W., and Weiss, S. (1992). A multipotent EGF-responsive striatal embryonic progenitor cell 
produces neurons and astrocytes. J. Neurosci. 12, 4565–4574. 
Rideout, H.J. (2017). Leucine-Rich Repeat kinase 2 (LRRK2). 
Rivero‑Ríos, P., Gómez‑Suaga, P., Fernández, B., Madero‑Pérez, J., Schwab, A.J., Ebert, A.D., and Hilfiker, S. 
(2015). Alterations in late endocytic trafficking related to the pathobiology of LRRK2-linked Parkinson’s disease. 
Biochem. Soc. Trans. 43, 390–395. 
Rochet, J.-C., Conway, K.A., and Lansbury, P.T. (2000). Inhibition of Fibrillization and Accumulation of Prefibrillar 
Oligomers in Mixtures of Human and Mouse α-Synuclein †. Biochemistry (Mosc.) 39, 10619–10626. 
Rolletschek, A., Chang, H., Guan, K., Czyz, J., Meyer, M., and Wobus, A.M. (2001). Differentiation of embryonic 
stem cell-derived dopaminergic neurons is enhanced by survival-promoting factors. Mech. Dev. 105, 93–104. 
Roosen, D.A., and Cookson, M.R. (2016). LRRK2 at the interface of autophagosomes, endosomes and lysosomes. 
Mol. Neurodegener. 11. 
Rossignol, R., Gilkerson, R., Aggeler, R., Yamagata, K., Remington, S.J., and Capaldi, R.A. (2004). Energy 
substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 64, 985–993. 
Rubenstein, J.L., Martinez, S., Shimamura, K., Puelles, L., and others (1994). The embryonic vertebrate forebrain: 
the prosomeric model. Sci.-N. Y. THEN Wash.- 578–578. 
Rubinsztein, D.C., Mariño, G., and Kroemer, G. (2011). Autophagy and Aging. Cell 146, 682–695. 
Ryan, S.D., Dolatabadi, N., Chan, S.F., Zhang, X., Akhtar, M.W., Parker, J., Soldner, F., Sunico, C.R., Nagar, S., 
Talantova, M., et al. (2013). Isogenic Human iPSC Parkinson’s Model Shows Nitrosative Stress-Induced 
Dysfunction in MEF2-PGC1α Transcription. Cell 155, 1351–1364. 
Sakurada, K., Ohshima-Sakurada, M., Palmer, T.D., and Gage, F.H. (1999). Nurr1, an orphan nuclear receptor, is 
a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. 
Development 126, 4017–4026. 
Sanai, N., Nguyen, T., Ihrie, R.A., Mirzadeh, Z., Tsai, H.-H., Wong, M., Gupta, N., Berger, M.S., Huang, E., Garcia-
Verdugo, J.-M., et al. (2011). Corridors of migrating neurons in the human brain and their decline during infancy. 
Nature 478, 382–386. 
Sánchez-Danés, A., Richaud-Patin, Y., Carballo-Carbajal, I., Jiménez-Delgado, S., Caig, C., Mora, S., Di 
Guglielmo, C., Ezquerra, M., Patel, B., Giralt, A., et al. (2012). Disease-specific phenotypes in dopamine neurons 
from human iPS-based models of genetic and sporadic Parkinson’s disease: iPS cell-based model of Parkinson’s 
disease. EMBO Mol. Med. 4, 380–395. 
Sanders, L.H., Laganière, J., Cooper, O., Mak, S.K., Vu, B.J., Huang, Y.A., Paschon, D.E., Vangipuram, M., 
Sundararajan, R., Urnov, F.D., et al. (2014). LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived 
neural cells from Parkinson’s disease patients: Reversal by gene correction. Neurobiol. Dis. 62, 381–386. 
Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di Malta, C., Donaudy, F., 
Embrione, V., Polishchuk, R.S., et al. (2009). A Gene Network Regulating Lysosomal Biogenesis and Function. 
Science. 
Sargsyan, A., Cai, J., Fandino, L.B., Labasky, M.E., Forostyan, T., Colosimo, L.K., Thompson, S.J., and Graham, 
T.E. (2015). Rapid parallel measurements of macroautophagy and mitophagy in mammalian cells using a single 
fluorescent biosensor. Sci. Rep. 5, 12397. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLIV 
Sarko, D.K., and McKinney, C.E. (2017). Exosomes: Origins and Therapeutic Potential for Neurodegenerative 
Disease. Front. Neurosci. 11. 
Sasai, Y. (2013). Next-Generation Regenerative Medicine: Organogenesis from Stem Cells in 3D Culture. Cell 
Stem Cell 12, 520–530. 
Schaefer, K.A., Wu, W.-H., Colgan, D.F., Tsang, S.H., Bassuk, A.G., and Mahajan, V.B. (2017). Unexpected 
mutations after CRISPR-Cas9 editing in vivo. Nat. Methods 14, 547–548. 
Schapira, A.H.V., Chaudhuri, K.R., and Jenner, P. (2017). Non-motor features of Parkinson disease. Nat. Rev. 
Neurosci. 18, 435–450. 
Schon, E.A., DiMauro, S., and Hirano, M. (2012). Human mitochondrial DNA: roles of inherited and somatic 
mutations. Nat. Rev. Genet. 13, 878–890. 
Schöndorf, D.C., Aureli, M., McAllister, F.E., Hindley, C.J., Mayer, F., Schmid, B., Sardi, S.P., Valsecchi, M., 
Hoffmann, S., Schwarz, L.K., et al. (2014). iPSC-derived neurons from GBA1-associated Parkinson’s disease 
patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 5. 
Searles Nielsen, S., Gallagher, L.G., Lundin, J.I., Longstreth, W.T., Smith-Weller, T., Franklin, G.M., Swanson, 
P.D., and Checkoway, H. (2012). Environmental tobacco smoke and Parkinson’s disease. Mov. Disord. 27, 293–
297. 
Settembre, C., Fraldi, A., Medina, D.L., and Ballabio, A. (2013). Signals from the lysosome: a control centre for 
cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 14, 283–296. 
Shulman, J.M., De Jager, P.L., and Feany, M.B. (2011). Parkinson’s Disease: Genetics and Pathogenesis. Annu. 
Rev. Pathol. Mech. Dis. 6, 193–222. 
Sidransky, E., and Lopez, G. (2012). The link between the GBA gene and parkinsonism. Lancet Neurol. 11, 986–
998. 
Sierra, M., González-Aramburu, I., Sánchez-Juan, P., Sánchez-Quintana, C., Polo, J.M., Berciano, J., Combarros, 
O., and Infante, J. (2011). High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson’s 
disease patients in Cantabria (Spain). Mov. Disord. 26, 2343–2346. 
Simeone, A., Acampora, D., Gulisano, M., Stornaiuolo, A., and Boncinelli, E. (1992). Nested expression domains 
of four homeobox genes in developing rostral brain. Nature 358, 687–690. 
Skibinski, G., Nakamura, K., Cookson, M.R., and Finkbeiner, S. (2014). Mutant LRRK2 Toxicity in Neurons 
Depends on LRRK2 Levels and Synuclein But Not Kinase Activity or Inclusion Bodies. J. Neurosci. 34, 418–433. 
Smirnova, E., Griparic, L., Shurland, D.-L., and Van Der Bliek, A.M. (2001). Dynamin-related protein Drp1 is required 
for mitochondrial division in mammalian cells. Mol. Biol. Cell 12, 2245–2256. 
Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M., and Ross, C.A. 
(2005). Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal 
degeneration. Proc. Natl. Acad. Sci. U. S. A. 102, 18676–18681. 
Soldner, F., Stelzer, Y., Shivalila, C.S., Abraham, B.J., Latourelle, J.C., Barrasa, M.I., Goldmann, J., Myers, R.H., 
Young, R.A., and Jaenisch, R. (2016). Parkinson-associated risk variant in distal enhancer of α-synuclein modulates 
target gene expression. Nature 533, 95–99. 
Soubannier, V., McLelland, G.-L., Zunino, R., Braschi, E., Rippstein, P., Fon, E.A., and McBride, H.M. (2012a). A 
Vesicular Transport Pathway Shuttles Cargo from Mitochondria to Lysosomes. Curr. Biol. 22, 135–141. 
Soubannier, V., Rippstein, P., Kaufman, B.A., Shoubridge, E.A., and McBride, H.M. (2012b). Reconstitution of 
Mitochondria Derived Vesicle Formation Demonstrates Selective Enrichment of Oxidized Cargo. PLoS ONE 7, 
e52830. 
Spalding, K.L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H.B., Boström, E., Westerlund, I., 
Vial, C., Buchholz, B.A., et al. (2013). Dynamics of Hippocampal Neurogenesis in Adult Humans. Cell 153, 1219–
1227. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLV 
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein 
in Lewy bodies. Nature 388, 839–840. 
Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). α-Synuclein in filamentous 
inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. 95, 
6469–6473. 
Stafa, K., Tsika, E., Moser, R., Musso, A., Glauser, L., Jones, A., Biskup, S., Xiong, Y., Bandopadhyay, R., Dawson, 
V.L., et al. (2014). Functional interaction of Parkinson’s disease-associated LRRK2 with members of the dynamin 
GTPase superfamily. Hum. Mol. Genet. 23, 2055–2077. 
Steger, M., Tonelli, F., Ito, G., Davies, P., Trost, M., Vetter, M., Wachter, S., Lorentzen, E., Duddy, G., Wilson, S., 
et al. (2016). Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab 
GTPases. eLife 5. 
Steinbeck, J.A., and Studer, L. (2015). Moving Stem Cells to the Clinic: Potential and Limitations for Brain Repair. 
Neuron 86, 187–206. 
Stiles, J., and Jernigan, T.L. (2010). The Basics of Brain Development. Neuropsychol. Rev. 20, 327–348. 
Stracker, T.H., and Petrini, J.H.J. (2011). The MRE11 complex: starting from the ends. Nat. Rev. Mol. Cell Biol. 12, 
90–103. 
Studer, L., Vera, E., and Cornacchia, D. (2015). Programming and Reprogramming Cellular Age in the Era of 
Induced Pluripotency. Cell Stem Cell 16, 591–600. 
Su, Y.-C., and Qi, X. (2013). Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal 
damage caused by LRRK2 G2019S mutation. Hum. Mol. Genet. 22, 4545–4561. 
Sugiura, A., McLelland, G.-L., Fon, E.A., and McBride, H.M. (2014). A new pathway for mitochondrial quality control: 
mitochondrial-derived vesicles. EMBO J. 33, 2142–2156. 
Sulzer, D. (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci. 30, 
244–250. 
Sulzer, D., and Surmeier, D.J. (2013). Neuronal vulnerability, pathogenesis, and Parkinson’s disease: Neuronal 
Vulnerability, Pathogenesis, and PD. Mov. Disord. 28, 41–50. 
Sulzer, D., Alcalay, R.N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, 
W.H., Mao, X., et al. (2017). T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature 
546, 656–661. 
Sun, N., Youle, R.J., and Finkel, T. (2016). The Mitochondrial Basis of Aging. Mol. Cell 61, 654–666. 
Surmeier, D.J., Guzman, J.N., and Sanchez-Padilla, J. (2010). Calcium, cellular aging, and selective neuronal 
vulnerability in Parkinson’s disease. Cell Calcium 47, 175–182. 
Surmeier, D.J., Obeso, J.A., and Halliday, G.M. (2017). Selective neuronal vulnerability in Parkinson disease. Nat. 
Rev. Neurosci. 18, 101–113. 
Sweet, E.S., Saunier-Rebori, B., Yue, Z., and Blitzer, R.D. (2015). The Parkinson’s Disease-Associated Mutation 
LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus. J. Neurosci. 35, 11190–11195. 
Swistowski, A., Peng, J., Liu, Q., Mali, P., Rao, M.S., Cheng, L., and Zeng, X. (2010). Efficient Generation of 
Functional Dopaminergic Neurons from Human Induced Pluripotent Stem Cells Under Defined Conditions. STEM 
CELLS 28, 1893–1904. 
Takahashi, K., and Yamanaka, S. (2006). Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult 
Fibroblast Cultures by Defined Factors. Cell 126, 663–676. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction 
of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 131, 861–872. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLVI 
Takeshige, K., Baba, M., Tsuboi, S., Noda, T., and Ohsumi, Y. (1992). Autophagy in yeast demonstrated with 
proteinase-deficient mutants and conditions for its induction. J. Cell Biol. 119, 301–311. 
Takeuchi, H., Kondo, Y., Fujiwara, K., Kanzawa, T., Aoki, H., Mills, G.B., and Kondo, S. (2005). Synergistic 
augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein 
kinase B inhibitors. Cancer Res. 65, 3336–3346. 
Tanida, I., Minematsu-Ikeguchi, N., Ueno, T., and Kominami, E. (2005). Lysosomal turnover, but not a cellular level, 
of endogenous LC3 is a marker for autophagy. Autophagy 1, 84–91. 
Taylor, R.W., and Turnbull, D.M. (2005). Mitochondrial DNA mutations in human disease. Nat. Rev. Genet. 6, 389–
402. 
Thenganatt, M.A., and Jankovic, J. (2014). Parkinson Disease Subtypes. JAMA Neurol. 71, 499. 
Theunissen, T.W., Powell, B.E., Wang, H., Mitalipova, M., Faddah, D.A., Reddy, J., Fan, Z.P., Maetzel, D., Ganz, 
K., Shi, L., et al. (2014). Systematic Identification of Culture Conditions for Induction and Maintenance of Naive 
Human Pluripotency. Cell Stem Cell 15, 471–487. 
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., Marshall, V.S., and Jones, J.M. 
(1998). Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147. 
Thornton, C., and Hagberg, H. (2015). Role of mitochondria in apoptotic and necroptotic cell death in the developing 
brain. Clin. Chim. Acta 451, 35–38. 
Turrens, J.F. (2003). Mitochondrial formation of reactive oxygen species. J. Physiol. 552, 335–344. 
Vasquez, K.M., Marburger, K., Intody, Z., and Wilson, J.H. (2001). Manipulating the mammalian genome by 
homologous recombination. Proc. Natl. Acad. Sci. 98, 8403–8410. 
Wakabayashi, K., and Takahashi, H. (2008). Neuropathology of Autonomic Nervous System in Parkinson’s 
Disease. Eur. Neurol. 38, 2–7. 
Wallings, R., Manzoni, C., and Bandopadhyay, R. (2015). Cellular processes associated with LRRK2 function and 
dysfunction. FEBS J. n/a-n/a. 
Walton, N.M., Shin, R., Tajinda, K., Heusner, C.L., Kogan, J.H., Miyake, S., Chen, Q., Tamura, K., and Matsumoto, 
M. (2012). Adult Neurogenesis Transiently Generates Oxidative Stress. PLoS ONE 7, e35264. 
Wang, X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922–2933. 
Wang, C., Liu, F., Liu, Y.-Y., Zhao, C.-H., You, Y., Wang, L., Zhang, J., Wei, B., Ma, T., Zhang, Q., et al. (2011). 
Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult 
human brain. Cell Res. 21, 1534–1550. 
Wang, X., Yan, M.H., Fujioka, H., Liu, J., Wilson-Delfosse, A., Chen, S.G., Perry, G., Casadesus, G., and Zhu, X. 
(2012). LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. 
Genet. 21, 1931–1944. 
Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., Qiu, Z., Chang, T., Huang, H., Lin, R.-J., and Yee, J.-K. (2015). 
Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral 
vectors. Nat. Biotechnol. 33, 175–178. 
Weinberger, L., Ayyash, M., Novershtern, N., and Hanna, J.H. (2016). Dynamic stem cell states: naive to primed 
pluripotency in rodents and humans. Nat. Rev. Mol. Cell Biol. 17, 155–169. 
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, B.E., and Jaenisch, R. 
(2007). In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448, 318–324. 
West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.-L., Dawson, 
V.L., et al. (2007). Parkinson’s disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase 
activities to neuronal toxicity. Hum. Mol. Genet. 16, 223–232. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLVII 
Wilkinson, D.G., Bhatt, S., Cook, M., Boncinelli, E., and Krumlauf, R. (1989). Segmental expression of Hox-2 
homoeobox-containing genes in the developing mouse hindbrain. Nature 341, 405–409. 
Wilson, S.W., and Houart, C. (2004). Early steps in the development of the forebrain. Dev. Cell 6, 167–181. 
Winklhofer, K.F., and Haass, C. (2010). Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. Acta 
BBA - Mol. Basis Dis. 1802, 29–44. 
Winner, B., Melrose, H.L., Zhao, C., Hinkle, K.M., Yue, M., Kent, C., Braithwaite, A.T., Ogholikhan, S., Aigner, R., 
and Winkler, J. (2011a). Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol. 
Dis. 41, 706–716. 
Winner, B., Kohl, Z., and Gage, F.H. (2011b). Neurodegenerative disease and adult neurogenesis: 
Neurodegenerative disease and adult neurogenesis. Eur. J. Neurosci. 33, 1139–1151. 
Winslow, A.R., Chen, C.-W., Corrochano, S., Acevedo-Arozena, A., Gordon, D.E., Peden, A.A., Lichtenberg, M., 
Menzies, F.M., Ravikumar, B., Imarisio, S., et al. (2010). α-Synuclein impairs macroautophagy: implications for 
Parkinson’s disease. J. Cell Biol. 190, 1023–1037. 
Wong, Y.C., and Krainc, D. (2016). Lysosomal trafficking defects link Parkinson’s disease with Gaucher’s disease: 
Lysosomes in Parkinson’s & Gaucher’s Diseases. Mov. Disord. 31, 1610–1618. 
Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K., Morrison, A., Lwin, A., Colegial, 
C., Allman, J.M., et al. (2004). Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol. 
Genet. Metab. 82, 192–207. 
Woodbury, M.E., and Ikezu, T. (2014). Fibroblast Growth Factor-2 Signaling in Neurogenesis and 
Neurodegeneration. J. Neuroimmune Pharmacol. 9, 92–101. 
Wurst, W., and Bally-Cuif, L. (2001). Neural plate patterning: upstream and downstream of the isthmic organizer. 
Nat. Rev. Neurosci. 2, 99. 
Xiao, L., Ohayon, D., McKenzie, I.A., Sinclair-Wilson, A., Wright, J.L., Fudge, A.D., Emery, B., Li, H., and 
Richardson, W.D. (2016). Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill 
learning. Nat. Neurosci. 19, 1210–1217. 
Yagi, M., Kishigami, S., Tanaka, A., Semi, K., Mizutani, E., Wakayama, S., Wakayama, T., Yamamoto, T., and 
Yamada, Y. (2017). Derivation of ground-state female ES cells maintaining gamete-derived DNA methylation. 
Nature. 
Yan, J., Studer, L., and McKay, R.D. (2001). Ascorbic acid increases the yield of dopaminergic neurons derived 
from basic fibroblast growth factor expanded mesencephalic precursors. J. Neurochem. 76, 307–311. 
Yeung, M.S.Y., Zdunek, S., Bergmann, O., Bernard, S., Salehpour, M., Alkass, K., Perl, S., Tisdale, J., Possnert, 
G., Brundin, L., et al. (2014). Dynamics of Oligodendrocyte Generation and Myelination in the Human Brain. Cell 
159, 766–774. 
Yin, H., Kauffman, K.J., and Anderson, D.G. (2017). Delivery technologies for genome editing. Nat. Rev. Drug 
Discov. 16, 387–399. 
Youle, R.J., and Narendra, D.P. (2011). Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 12, 9–14. 
Youle, R.J., and Van Der Bliek, A.M. (2012). Mitochondrial fission, fusion, and stress. Science 337, 1062–1065. 
Young, A., Assey, K.S., Sturkie, C.D., West, F.D., Machacek, D.W., and Stice, S.L. (2010). Glial cell line-derived 
neurotrophic factor enhances in vitro differentiation of mid-/hindbrain neural progenitor cells to dopaminergic-like 
neurons: Dopaminergic Differentiation. J. Neurosci. Res. 88, 3222–3232. 
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., 
Ruotti, V., Stewart, R., et al. (2007). Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. 
Science 318, 1917–1920. 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLVIII 
Zavodszky, E., Seaman, M.N.J., Moreau, K., Jimenez-Sanchez, M., Breusegem, S.Y., Harbour, M.E., and 
Rubinsztein, D.C. (2014). Mutation in VPS35 associated with Parkinson’s disease impairs WASH complex 
association and inhibits autophagy. Nat. Commun. 5. 
Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F.A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., and 
Sarna, T. (2008). Neuromelanin can protect against iron mediated oxidative damage in system modeling iron 
overload of brain aging and Parkinson’s disease. J. Neurochem. 
Zechel, S., Meinhardt, A., Unsicker, K., and von Bohlen und Halbach, O. (2010). Expression of leucine-rich-repeat-
kinase 2 (LRRK2) during embryonic development. Int. J. Dev. Neurosci. 28, 391–399. 
Zhang, F.-R., Huang, W., Chen, S.-M., Sun, L.-D., Liu, H., Li, Y., Cui, Y., Yan, X.-X., Yang, H.-T., Yang, R.-D., et 
al. (2009). Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609–2618. 
Zhang, S.-C., Wernig, M., Duncan, I.D., Brüstle, O., and Thomson, J.A. (2001). In vitro differentiation of 
transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19, 1129–1133. 
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., 
Calne, D.B., et al. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic 
pathology. Neuron 44, 601–607. 
Zou, Y., Liu, J., Tian, Z., Lu, D., and Zhou, Y. (2015). Systematic review of the prevalence and incidence of 
Parkinson’s disease in the People’s Republic of China. Neuropsychiatr. Dis. Treat. 1467. 
Zwaka, T.P. (2017). Stem cells: The cost of perpetual youth. Nature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                Appendix 
 
                                                                                                                                                  XLIX 
Acknowledgement 
PhD is an once-in-a-lifetime opportunity and experience. It is tough at times and may feel like 
an eternity, but it teaches you a lot and I am feeling truly blessed that I have had a chance to 
make this unforgettable experience. My initially quote: ‘I lost my old and found another me in 
this journey of life called Ph.D.’ is a paraphrase, it is rather an advancement on all levels.  
At first, I would like to express my deepest and sincerest gratitude to Dr. Jens C. Schwamborn 
for the chance he gave me, to conduct my Doctor’s studies at his laboratory. I joined the lab, 
in an exciting and challenging expansion phase, while transiting from Muenster (Germany) to 
Luxembourg. This transition thought me a lot about setting up a lab but also about the time it 
costs to ‘just’ move a laboratory. I would like to thank him for his support, trust, supervision, 
and the thrilling topic for this thesis. But also for challenging me, keeping me motivated and 
over all, giving me a lot of freedom to develop own ideas and not being too harsh once I failed 
with those ideas. Further, I would like to thank him for being open for unexpected findings; I 
think this was a key factor for the success of the thesis.  
I wish to express my deepest appreciation and gratitude to my co-supervisors Dr. Rudi Balling 
and Dr. Giuseppe Testa for their constant excellent feedback during the whole study, 
interesting discussions, and fine doses of helpful criticism during our regular meetings. 
Organizing our thesis committee meetings was an interesting challenge. It is a pity that 
Giuseppe was not able to join for the defense at the scheduled date. I sincerely thank Dr. Paul 
Antony for making my thesis in this form possible – doing the image analyses by hand would 
have been impossible for me. Thanks Paul for teaching me so much, I wish I would have had 
more time to get into the image analysis coding. I also extend my sincere thanks to all current 
group members and alumni of the lab, who supported me extremely longanimous throughout 
my studies. The atmosphere you created made the work in the lab a remarkable experience. 
I extend the appreciations to all co-workers of the institute for always being friendly, open, and 
very supportive. 
I want to express my deepest gratitude to my family and friends, for their constant help, 
empathy, and support at hard moments, faith, love and distraction from work. I up most thank 
my beloved girlfriend Natalie for her love, inspiration, patience, and for filling my life with joy 
and happiness. My Ph.D. would have not been possible without the generous support by 
FNR/AFR, Luxembourg National Research Fund, and the Luxemburgish taxpayers. Thank you 
for your trust and support. Last but not least I am thanking JJ and NB for proofreading and the 
‘sci-hub’ initiative for making scientific knowledge freely accessible. 
 
                                                                                                                                Appendix 
 
                                                                                                                                                  L 
Affidavit 
 
I declare that the Ph.D. Thesis “Analysis of neuronal differentiation in genetic forms of 
Parkinson’s disease reveals a neurodevelopmental contribution” has been written 
independently and without any other sources than cited. 
 
Hiermit erkläre ich, dass ich die vorliegende Doktorarbeit “Analysis of neuronal differentiation 
in genetic forms of Parkinson’s disease reveals a neurodevelopmental contribution” 
selbständig angefertigt habe. Es wurden ausschliesslich die angegebenen Quellen und 
Hilfsmittel verwendet. 
 
 
________________________ 
Jonas Walter 
Luxembourg, 11.12.2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
